



THE *MOVEMENT* DISORDER SOCIETY'S

7TH INTERNATIONAL CONGRESS OF PARKINSON'S
DISEASE AND MOVEMENT DISORDERS

**FINAL
PROGRAM**




MIAMI | FLORIDA

November 10-14, 2002


What if you could give your Parkinson's patients an extra 6 hours of "on" time a day – while decreasing their levodopa-induced dyskinesia?

Imagine what they would do.

STN Stimulation (n=40*)
Average Improvement
6.1 Hours*



GPi Stimulation (n=24*)
Average Improvement
6.7 Hours*



Absolute Change in Patient Daily "On" Time at 12 Months*

* Includes only patient data that were fully verified against medical records. Percentages have been rounded to the nearest whole percent. Data on file at Medtronic, Inc.

Activa® Parkinson's Control Therapy: Product technical manual must be reviewed prior to use for detailed disclosure.

Indications: Bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic® Activa® Parkinson's Control Therapy is indicated for adjunctive therapy in reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication.

Contraindications: Contraindications include patients who will be exposed to MRI using a full body radio-frequency (RF) coil or a head transmit coil that extends over the chest area, patients for whom test stimulation is unsuccessful, or patients who are unable to properly operate the neurostimulator. Also, diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) is contraindicated because diathermy's energy can be transferred through the implanted system (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system.

Warnings/ Precautions/Adverse Events: There is a potential risk of tissue damage using stimulation parameter settings of high amplitudes and wide pulse widths. Extreme care should be used with lead implantation in patients with a heightened risk of intracranial hemorrhage. Do not place the lead-extension connector in the soft tissues of the neck. Placement in this location has been associated with an increased incidence of lead fracture. Theft detectors and security screening devices may cause stimulation to switch ON or OFF, and may cause some patients to experience a momentary

increase in perceived stimulation. Although some MRI procedures can be performed safely with an implanted Activa System, clinicians should carefully weigh the decision to use MRI in patients with an implanted Activa System. MRI can cause induced voltages in the neurostimulator and/or lead possibly causing uncomfortable, jolting or shocking levels of stimulation. MRI image quality may be reduced for patients who require the neurostimulator to control tremor, because the tremor may return when the neurostimulator is turned off. Severe burns could result if the neurostimulator case is ruptured or pierced. The Activa System may be affected by or adversely affect medical equipment such as cardiac pacemakers or therapies, cardioverter/ defibrillators, external defibrillators, ultrasonic equipment, electrocautery or radiation therapy. Safety and effectiveness has not been established for patients with neurological disease other than Parkinson's disease, previous surgical ablation procedures, dementia, coagulopathies or moderate to severe depression; or for patients who are pregnant, under 18 years or over 75 years of age. Adverse events related to the therapy, device or procedure can include: stimulation not effective, cognitive disorders, pain, dyskinesia, dystonia, speech disorders including dysarthria, infection, paresthesia, intracranial hemorrhage, electromagnetic interference, cardiovascular events, visual disturbances, sensory disturbances, device migration, paresis/asthenia, abnormal gait, incoordination, headaches, lead repositioning, thinking abnormal, device explant, hemiplegia, lead fracture, seizures, respiratory events and shocking or jolting stimulation.

Rx only

© Medtronic, Inc. 2002

All Rights Reserved Printed in USA

UC200301356EN

ACTIVA®
Parkinson's Control Therapy

To learn more about Activa® Therapy and receive a complimentary "Abstracts-on-Disk" CD from this year's congress, visit Medtronic booth #306.



Medtronic
When Life Depends on Medical Technology

www.brainstimulation.net

Invitation

Dear Colleagues,

On behalf of The *Movement* Disorder Society, we are pleased to welcome you to Miami for the 7th International Congress of Parkinson's Disease and Movement Disorders.

To offer forums for exchange and debate of the most recent research results as well as practical issues in diagnosis and treatment of Parkinson's Disease and other movement Disorders is on of the key missions of The *Movement* Disorder Society. As in past years, the 7th International Congress is a unique opportunity to network and learn from colleagues. The International Congress Organizing Committee has created a groundbreaking scientific program including outstanding plenary and parallel sessions, topic-focused wine and cheese seminars, video dinners, and innovative abstract poster sessions.

On Sunday, November 10, the Congress will begin with Kickoff Seminars, funded through unrestricted educational grants from our industry supporters. To provide a complete educational experience throughout the week, the 7th International Congress offers eight Plenary Sessions, six Parallel Sessions, as well as three Lectureships. Wine and Cheese Seminars and Video Dinners take place in the evening and offer a smaller more interactive atmosphere.

This year, we have a record breaking 1,182 abstracts to be presented as posters. To ensure all Congress Delegates the opportunity to view the latest developments in movement disorders, time is set aside exclusively for poster viewing. In addition to poster presentations, please take time to visit the Exhibit Hall, as companies and organizations from around the world join us in sharing their contributions to the field of movement disorders.

Aside from the professional aspects of the Congress, Miami is a beautiful city with numerous activities to enjoy. In addition to the MDS Welcome Cocktail Reception on the Great Lawn and the Banquet at the Miami Seaquarium, there are many opportunities to tour the Miami Beach area and all the culture it has to offer.

We thank you for joining us at this exceptional event, and we are pleased and honored to have you with us.

Sincerely,



Werner Poewe
President



C. Warren Olanow
President-Elect

Table of Contents

Organization	2
MDS Committees	8
Congress Registration and Venue	10
Congress Information	10
• Continuing Education	
• MDS Committee Meetings	
• MDS History Exhibit	
Faculty	16
Map of Miami	34
Abstract Submission Guidelines	35

*All photos provided by the Greater Miami Convention
& Visitors Bureau, www.TropicoolMiami.com*

Acknowledgments

The International Congress Organizing Committee of The *Movement* Disorder Society's 7th International Congress of Parkinson's Disease and Movement Disorders wishes to acknowledge and thank the following companies for their generous support:

Platinum Level:

ALLERGAN

élan



 **NOVARTIS**

**ORION
PHARMA**


PHARMACIA



Silver Level:

**SCHWARZ
P H A R M A**

Bronze Level:



Patients with Parkinson's disease are...

EQUIPPED FOR LIVING

**The only dopamine agonist
with 5-year clinical data¹**

**REQUIP maintains ADLs with continued therapy
with or without added L-dopa**

- No statistically significant difference in mean change in ADL scores from baseline to end of study with REQUIP, with or without added L-dopa, compared with L-dopa alone^{1,2}
- One third of patients on REQUIP completing the study (29/85) were maintained on REQUIP alone¹

**REQUIP provides a lower risk of dyskinesia
compared with L-dopa**

- Patients on REQUIP, with or without adjunct L-dopa, were almost 4 times less likely to develop dyskinesia than patients on L-dopa alone ($P < 0.0001$)¹

REQUIP has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Hallucinations may occur at any time during treatment. REQUIP may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.

Please see Brief Summary of complete
Prescribing Information on adjacent page.



© 2001 The GlaxoSmithKline Group of Companies. All rights reserved. Printed in USA. 88Y18307 November 2001

References: 1. Rascol O, Brooks DJ, Kilgore AJ, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. *N Engl J Med.* 2000;342:1449-1458
2. Data on file. GlaxoSmithKline.



**STAY
WITH**

REQUIP[®]
ropinirole HCl

**Help patients shape
a functional future**

Patients with Parkinson's disease are...

EQUIPPED FOR LIVING

**The only dopamine agonist
with 5-year clinical data¹**

REQUIP controls PD symptoms in initial monotherapy (5-year study)

- No statistically significant difference in mean change in ADL scores from baseline to end of study in patients on monotherapy with REQUIP compared with patients on L-dopa^{1,2}
- One third of patients on REQUIP completing the study (29/85) were maintained on REQUIP alone¹

Lower risk of dyskinesia in patients on monotherapy with REQUIP compared with L-dopa

- Overall incidence of dyskinesia in patients on monotherapy with REQUIP was 5%, compared to 36% of patients on L-dopa¹

REQUIP has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Hallucinations may occur at any time during treatment. REQUIP may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.

Please see Brief Summary of complete Prescribing Information on adjacent page.



**START
WITH**

REQUIP[®]
ropinirole HCl

**Help patients shape
a functional future**

Organization



The *Movement Disorder Society*

The *Movement Disorder Society* (MDS) is an international not-for-profit organization representing and serving clinicians, other health professionals, researchers, and policy makers in movement disorders. The spectrum of clinical disorders represented by the Society includes but is not limited to:

- Parkinson's disease
- Blepharospasm
- Dysphonia
- Dystonic disorders
- Tremor
- Gait disorders
- Ataxia
- Tics and Tourette syndrome
- Tardive dyskinesia
- Myoclonus
- Spasticity
- Huntington's disease

The *Movement Disorder Society's Mission*

- To bring clinicians the latest developments and practical advice for the diagnosis and treatment of all movement disorders and related neurological matters
- To offer an international forum for sharing new developments in basic and clinical research in movement disorders
- To publish the pre-eminent clinical and research journal devoted to movement disorders, using print, online and video formats
- To create professional liaisons with other regional and subspecialty organizations for unifying the many disciplines represented in the field of movement disorders

MDS Secretariat

The *Movement Disorder Society*
611 E. Wells St.
Milwaukee, WI 53202
USA
Tel: +1-414-276-2145
Fax: +1-414-276-3349
E-mail: congress@movementdisorders.org
info@movementdisorders.org
Internet: www.movementdisorders.org

MDS Officers (2001-2002)

President	Werner Poewe, Austria
President-Elect	C. Warren Olanow, USA
Secretary	Niall P. Quinn, UK
Secretary-Elect	Andres M. Lozano, Canada
Treasurer	Robert E. Burke, USA
Treasurer-Elect	Wolfgang H. Oertel, Germany
Past President	Mark Hallett, USA



Downtown Miami

International Executive Committee (2001-2002)

Francisco Cardoso, Brazil
Cynthia L. Comella, USA
Ann M. Graybiel, USA
Eldad Melamed, Israel
Yoshikuni Mizuno, Japan
John G. Nutt, USA
José A. Obeso, Spain
Olivier Rascol, France
Caroline M. Tanner, USA
Philip D. Thompson, Australia

International Congress Organizing Committee Chair

Chair

William C. Koller, USA

Members

Alfredo Berardelli, Italy
David J. Brooks, UK
Robert E. Burke, USA
Lueder Deecke, Austria
Stanley Fahn,
Mark Hallett, USA
Eldad Melamed, Israel
Niall P. Quinn, UK
Olivier Rascol, France
Miguel S. Rueda, Colombia
Eduardo Tolosa, Spain

Past Presidents

1998-2000	Mark Hallett, USA
1996-1998	Eduardo Tolosa, Spain
1994-1996	Joseph Jankovic, USA
1991-1994	C. David Marsden, UK
1988-1991	Stanley Fahn, USA

MDS Committees, 2001-2002

Archives

Chair: Robert E. Burke, USA

Awards

Chair: Anthony Schapira, UK

Members:

Oscar S. Gershanik, Argentina
José A. Obeso, Spain
Serge Przedborski, USA
Heinz Reichmann, Germany
Matthew B. Stern, USA
Caroline M. Tanner, USA

Bylaws

Chair: Demetrius Maraganore, USA

Members:

Kailash P. Bhatia, UK
Elan Louis, USA
David Riley, USA
Evzen Ruzicka, Czech Republic

Education

Chair: Cynthia L. Comella, USA

Co-Chair: Fabrizio Stocchi, Italy

Members:

Stewart Factor, USA
Joaquim Ferreira, Portugal
Robert Jansek, Australia
Kelly Lyons, USA
Yoshikuni Mizuno, Japan
Kapil D. Sethi, USA

Financial Affairs

Chair: Robert E. Burke (Treasurer), USA

Members:

Mark Hallett (Past President), USA
William C. Koller (Past Treasurer) USA
Wolfgang H. Oertel (Treasurer-Elect), Germany
C. Warren Olanow (President-Elect), USA
Werner Poewe (President), Austria

Industrial Relations

Chair: Olivier Rascol, France

Members:

David J. Brooks, UK
Joseph Jankovic, USA
Karl D. Kiebert, USA
William C. Koller, USA
Wolfgang H. Oertel, Germany
C. Warren Olanow, USA

Journal Oversight

Chair: Mark Hallett, USA

Members:

Rivka Inzelberg, Israel
William C. Koller, USA
Hiroshi Shibasaki, Japan

Liaison

Chair: Christopher G. Goetz, USA

Members:

Regina Katzenschlager, UK
Klaus Leonhard Leenders, The Netherlands
Masahiro Nomoto, Japan
Ivan Rektor, Czech Republic

Membership

Chair: Günther Deuschl, Germany

Members:

Carlo Colosimo, Italy
Roger J. Elble, USA
Nir Giladi, Israel
Horta Wagner, Brazil
Ruyji Kaji, Japan
Elan Louis, USA
Gregor K. Wenning, Austria

Scientific Issues

Chair: David J. Brooks, UK

Members:

Thomas Gasser, Germany
Etienne Hirsch, France
Paul Krack, France
Irene Litvan, USA
Fabrizio Stocchi, Italy

Strategy and Planning

Chair: Eduardo Tolosa (Past-Past President), Spain

Members:

Mark Hallett (Past President), USA
C. Warren Olanow (President-Elect), USA
Werner Poewe (President), Austria

Congress Registration & Venue

Venue

Fontainebleau Hilton Resort & Towers
4441 Collins Avenue
Miami Beach, Florida 33140
USA
Phone: +1 305-538-2000
Fax: +1 305-674-4607

The Fontainebleau Hilton Resort & Towers, located in the South Beach district of Miami, Florida is the headquarters for all scientific sessions, posters and exhibits.

Dates

Sunday, November 10, 2002 through
Thursday, November 14, 2002

Congress Hotels

Best Western Beach Resort
4333 Collins Avenue
Miami Beach, Florida 33140
USA
Phone: +1 305-532-3311
Fax: +1 305-531-5296

The Best Western is located one-half block south of the Fontainebleau Hilton. It can be easily accessed via Miami Beach's oceanfront boardwalk. The Best Western features an outdoor swimming pool, beach access, and a restaurant and lounge. Check-in time is 3:00 pm.

Days Inn Oceanside
4299 Collins Avenue
Miami Beach, Florida 33140
USA
Phone: +1 305-673-1513
Fax: +1 305-538-0727

The Days Inn is located one block south of the Fontainebleau Hilton, easily accessed via Miami Beach's oceanfront boardwalk. The Days Inn offers an outdoor swimming pool, beach access, and restaurant. Check-in time is 3:00 pm.

Four Points Sheraton
4343 Collins Avenue
Miami Beach, Florida 33140
Phone: +1 305-538-1938
Fax: +1 305-538-2025

The Four Points Sheraton is located one-half block south of the Fontainebleau Hilton, easily accessed via Miami Beach's oceanfront boardwalk. The Four Points Sheraton offers an outdoor swimming pool, beach access, and restaurant. Check-in time is 3:00 pm.

Language

The official language of the Congress is English.

Registration Desk

To verify participation, all Congress delegates will be required to provide a signature on the Congress sign-in sheet, upon registration.

Name badges, tickets and registration bags can be collected at the Registration Desk located in the Grand Gallerie, adjacent to the main lobby of the Fontainebleau Hilton, during the following hours:

Saturday, November 9	3:00 pm – 8:30 pm
Sunday, November 10	6:30 am – 7:30 pm
Monday, November 11	6:30 am – 7:30 pm
Tuesday, November 12	6:30 am – 7:30 pm
Wednesday, November 13	6:30 am – 6:00 pm
Thursday, November 14	6:30 am – 12:00 pm

Continuing Medical Education Registration

To verify participation, all Congress delegates will be required to provide a signature on the Congress sign-in sheet. Delegates interested in receiving Continuing Medical Education (CME) for attending the Congress may check the appropriate box indicating interest in CME.

Please note: Delegates requesting CME must sign in at the Congress registration area in the Grand Gallerie, each day to verify participation. Each physician should claim only those hours of credit actually spent in the educational activity.



Ocean Drive

Badges

All Congress attendees will receive a name badge with their registration materials. Badges should be worn at all times as they will be used to control access to all Congress sessions and activities. Individuals will be identified as follows:

- Red** = Delegate
- Yellow** = Exhibitor
- Orange** = Exhibitor Delegate
- Green** = Guest
- Purple** = Press
- Blue** = Staff

Special Accessibility Needs

Delegates requiring special arrangements in order to fully participate in the Congress should contact the MDS Secretariat.

Congress Information

Abstracts-On-Disk™

All abstracts published in the supplement to the MDS journal will also be available on the Abstracts-On-Disk™ funded through an unrestricted educational grant from Medtronic. To obtain a copy, visit the Medtronic Exhibit Booth (306) and exchange the voucher located in your registration bag.

Abstract Volume

All abstracts accepted for poster presentation have been published in an abstract supplement to the MDS Journal, *Movement Disorders*. The supplement is funded through an unrestricted educational grant from Teva Neuroscience and Teva Pharmaceuticals. Each delegate will receive one copy with their registration materials. MDS members will receive an additional copy with their November journal issue.

Business Center

For your convenience, the Fontainebleau Hilton has a Business Center that is located on Level IV in the Versailles Building. The Business Center offers business and office supplies, facsimiles, copy machines, and computer work stations. Hours for the Business Center are 8:00 am – 5:00 pm, Monday through Friday. With a 24-hour notice, the Business Center will remain open after hours.

Child Care Center

For your convenience, the Fontainebleau Hilton offers child care service at Kids Cove, located on the lower level of the Chateau Building. Available seven days a week, from 9:00 am – 5:00 pm, Kids Cove is fully supervised. Please contact the Fontainebleau Hilton for further information.

Continuing Education

Target Audience

The target audience of the 7th International Congress of Parkinson's Disease and Movement Disorders includes clinicians, researchers, post-doctoral fellows and medical school students with an interest in the current research and approaches for the treatment of movement disorders.

Statement of Educational Objectives

Upon completion of this activity, attendees should be able to:

- 1) Describe the pathophysiology and neurobiology of Parkinson's disease and other movement disorders;
- 2) Discuss the surgical treatment options available for Parkinson's disease and other movement disorders;
- 3) Discuss the pharmaceutical treatment options available for Parkinson's disease and other movement disorders.

CME Credit

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and The Movement Disorder Society. The NIH/FAES is accredited by the ACCME to provide continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 34.5 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

CPD Approval

The Congress has been approved for Continuing Professional Development (CPD) by the Royal College of Physicians of London. This activity has been awarded 51 CPD credits for full attendance. Participants should claim only those hours of credit actually spent in the activity.

Congress Evaluations

Please take time to complete the evaluation forms provided for each session you attend. Your input and comments are essential in planning future educational sessions for MDS Congresses. When completed, evaluations may be returned to MDS Staff or dropped in the evaluation collection boxes located in the registration area.

Exhibition

Please allow adequate time in your daily schedule to visit the Exhibit Hall, located in the East Ballroom. The exhibition is an integral component to your Congress experience, offering you the opportunity to speak with representatives of companies that provide services and market products directly related to movement disorders. Delegates may enter the Exhibit Hall at the entrance between the Jade Promenade and Fontainebleau Galerie, or through the West Ballroom during the following hours:

Monday, November 11	8:00 am – 5:00 pm
Tuesday, November 12	8:00 am – 5:00 pm
Wednesday, November 13	8:00 am – 5:00 pm

Internet Café

Internet access will be available to meeting attendees in the Grand Galerie, near the Registration Desk. Please limit your Internet use to 15 minutes so that other attendees can also access the service.



Airboat touring the Everglades

Congress Information

MDS Committee Meetings

Saturday, November 9, 2002

Awards Committee

6:00 pm – 7:30 pm
Location: Imperial I, Level IV

Bylaws Committee

6:00 pm – 7:30 pm
Location: Imperial II, Level IV

Industrial Relations Committee

6:00 pm – 7:30 pm
Location: Imperial III, Level IV

Liaison Committee

6:00 pm – 7:30 pm
Location: Imperial IV, Level IV

Scientific Issues

6:00 pm – 7:30 pm
Location: Pasteur, Level IV

Task Force on Epidemiology

6:00 pm – 7:30 pm
Location: Imperial V, Level IV

Sunday, November 10, 2002

Education Committee

6:00 am – 8:00 am
Location: Imperial II, Level IV

Journal Oversight Committee

6:30 am – 8:00 am
Location: Imperial III, Level IV

Membership Committee

6:00 am – 8:00 am
Location: Imperial IV, Level IV

Task Force for the Development of Rating Scales for Parkinson's Disease

6:00 am – 8:00 am
Location: Imperial V, Level IV

Tuesday, November 12, 2002

Strategy and Planning Committee

7:30 pm – 9:30 pm
Location: To be determined

MDS Exhibit & Information Booth

The *Movement* Disorder Society (MDS) is an international society of professionals committed to research and patient care in the fields of Parkinson's disease and other disorders of movement and motor control.

MDS supports and promotes a wide range of educational programming and other initiatives to advance scientific understanding and standards of care as they pertain to movement disorders. For this, MDS provides forums such as a high ranking journal, scientific symposia and international congresses.

Attendees are invited to take advantage of MDS member benefits by applying to the Society. Learn more about MDS initiatives and speak with a representative at the MDS Exhibit and Information Booth located in the Grand Gallerie across from Registration during the following hours:

Saturday, November 9	3:00 pm – 8:30 pm
Sunday, November 10	8:30 am – 7:30 pm
Monday, November 11	6:30 am – 5:00 pm
Tuesday, November 12	6:30 am – 5:00 pm
Wednesday, November 13	6:30 am – 5:00 pm

MDS History Exhibit

Throughout the Congress there will be an exhibit focusing on the historical background of Movement Disorders. The exhibit will trace the early development of Movement Disorders as a discipline, as well as the development of MDS as a preeminent International Society.

Original books, manuscripts, letters, photographs, medical artifacts and instruments related to the development of movement disorders as a discipline will be displayed in glass cases. The MDS membership has been the primary source of the original artifacts; other loans come from libraries and private collections. Archival films documenting early clinical demonstrations of movement disorders and celebrated neurologists examining movement disorder patients will be shown as well.

The MDS History Exhibit will be displayed in the Fontainebleau Gallerie of the Fontainebleau Hilton. The hours are as follows:

Saturday, November 9	3:00 pm – 8:30 pm
Sunday, November 10	7:00 am – 5:30 pm
Monday, November 11	7:00 am – 5:00 pm
Tuesday, November 12	7:00 am – 5:00 pm
Wednesday, November 13	7:00 am – 5:00 pm

Optional Tour

Tours have been arranged by: PGI

Jennifer George, Operations Manager
1320 South Dixie Highway
Suite 241
Miami, FL 33146, USA
Fax: +1-305-740-9432



Tickets for the Everglades Adventure tour are to be collected at the Concierge Desk in the Grand Gallerie of the Fontainebleau Hilton during regular on-site registration hours. Additional tickets for this tour may be purchased at the Concierge Desk and will be handled on a first-come, first served basis.

Transportation for the Everglades Adventure will depart from the Fontainebleau Hilton main driveway. Please be present at 8:45 am (15 minutes prior to departure).

Congress Information

Optional Tour - *Continued*

Monday, November 11, 2002

Everglades Adventure

9:00 am – 1:00 pm

Experience South Florida's outdoors with a trip to the Everglades. This vast wilderness area is home to an abundance of wildlife and plants unique to North America.

Cost: \$55.00 USD per person

Please note: Tours that have not met the minimum participation have been cancelled by PGI. All pre-registered individuals have been notified and will be issued reimbursement for the cancelled tours.

Individual tours may be arranged through the Concierge Desk at the Fontainebleau Hilton.

Press Room

Conference Room 2, Level IV, Versailles Building

Members of the working media may register without charge for the 7th International Congress in the Press Room. Press must register, provide credentials and wear their press badge for admittance to MDS sessions. Press Conferences related to previously selected newsworthy abstracts, along with additional scientific session highlights will be conducted throughout the Congress. Interview space, computers, telephones and fax services are available for the convenience of media representatives covering the meeting.

Please note: the Press Room will be moving on Thursday, November 14, to Imperial I, located on Level IV of the Versailles Building.

Press Room hours are as follows:

Sunday, November 10	8:00 am – 5:00 pm
Monday, November 11	8:00 am – 5:00 pm
Tuesday, November 12	8:00 am – 5:00 pm
Wednesday, November 13	8:00 am – 5:00 pm
Thursday, November 14	8:00 am – 12:00 pm

Scientific Program

Kickoff Seminars

Kickoff seminars have been organized through unrestricted educational grants from Congress industry supporters and are open to all Congress registrants.


Plenary and Parallel Sessions

Plenary and Parallel Sessions will feature scientific updates presented by international leaders in the field of movement disorders. These general sessions are open to all Congress registrants.

Wine & Cheese Seminars

Late afternoon Wine & Cheese seminars are designed to be informal and interactive. As the title suggests, wine and cheese will be served during the seminars. To encourage discussion, attendance is limited to 50-75 participants per seminar. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Fee: \$50 USD / \$35 USD for junior participants and allied health



Miami Lighthouse

Video Dinner Sessions

Video Dinner Sessions have become a popular segment of the MDS Congress as participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session. Participants may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Fee: \$75 USD / \$50 USD for junior participants and allied health

Abstract Poster Sessions

All accepted abstracts will be presented during poster sessions located in the West Ballroom and Jade Promenade. Poster sessions and times are as follows:

Poster Session 1, 1-168	
Monday, November 11,	7:00 am – 8:30 am
Poster Session 2, 169-338	
Monday, November 11,	12:30 pm – 2:00 pm
Poster Session 3, 339-520	
Tuesday, November 12,	7:00 am – 8:30 am
Poster Session 4, 521-694	
Tuesday, November 12,	12:00 pm – 1:30 pm
Poster Session 5, 695-850	
Wednesday, November 13,	7:00 am – 8:30 am
Poster Session 6, 851-1020	
Wednesday, November 13,	12:00 pm – 1:30 pm
Poster Session 7, 1021-1182	
Thursday, November 14,	7:00 am – 8:30 am

12 Please see pages 36-73 for a complete listing of abstract titles, topics and authors.

Congress Information

Social Events

Sunday, November 10, 2002

Welcome Reception

7:15 pm – 9:00 pm

All Congress attendees are invited to meet friends and colleagues during the traditional Congress Welcome Reception on Sunday evening, November 10th, on the Great Lawn of the Fontainebleau Hilton. Following the Opening Ceremony, guests will be guided to this beautiful outdoor area with local Miami music, where cocktails and hors d'oeuvres will be served.



Killer Whale Show at the Miami Seaquarium

Wednesday, November 13, 2002 **Banquet at the Miami Seaquarium**

Co-Sponsored by the National Parkinson Foundation and the Movement Disorder Society

Partially funded through an unrestricted educational grant from GlaxoSmithKline

6:30 pm – 11:00 pm

The Miami Seaquarium, located adjacent to beautiful Biscayne Bay, will be open exclusively for the MDS Congress banquet on Wednesday evening, November 13th. Guests can stroll through a lush, tropical jungle surrounding mangrove islands and tide pools which are home to native fish, birds and sea turtles. The park contains dozens of aquariums with more than 100 species of marine life, including Atlantic and Caribbean reef fish and endangered Florida manatees.

The evening's itinerary will include cocktails and hors d'oeuvres followed by flipper dolphin and killer whale shows. Dinner will be served at 8:45 pm accompanied by relaxing music.

Informal dress is recommended, including comfortable, rubber-soled shoes.

Transportation to and from the Miami Seaquarium will be provided. Shuttle buses will depart the Fontainebleau Hilton's main driveway beginning at 6:30 pm. Shuttle service will depart the Seaquarium, returning to the Fontainebleau in 20-30 minute intervals, beginning at 9:15 pm and thereafter until 11:00 pm.

Tickets purchased in advance will be enclosed with your registration materials. Additional tickets will be sold in the Grand Gallerie of the Fontainebleau Hilton.

Fee: \$85 USD (\$50 for children, ages 14 and under)

Speaker Ready Room

Conference Room 1, Level IV, Versailles Building

All speakers must check in at the Speaker Ready Room with presentation materials, 24-hours prior to their scheduled presentation. Equipment is available for faculty to review their presentations. Audio visual personnel will be available for assistance.

Please note the Speaker Ready Room will be moving on Thursday, November 14, to Imperial II, located on level IV of the Versailles building. The Speaker Ready Room hours are as follows:

Saturday, November 9	12:00 pm – 8:00 pm
Sunday, November 10	6:30 am – 7:30 pm
Monday, November 11	6:30 am – 7:30 pm
Tuesday, November 12	6:30 am – 7:30 pm
Wednesday, November 13	6:30 am – 6:00 pm
Thursday, November 14	6:30 am – 10:30 am

Transportation

Taxi cabs are easily accessed in the main drive of the Fontainebleau Hilton. A hotel super shuttle is available for travel to and from Miami International Airport (MIA).



13 Downtown Yacht Club

Program at a Glance

November 10 -14, 2002

	Sunday	Monday	Tuesday	Wednesday	Thursday
7:00 a.m.		Poster Session 1	Poster Session 3	Poster Session 5	Poster Session 7
8:00 a.m.	Kickoff Seminar 1	Stanley Fahn Lecture	Plenary Session 4	Parallel Sessions 7A and 7B	Plenary Session 10
9:00 a.m.		Plenary Session 1			
10:00 a.m.	Kickoff Seminar 2		Plenary Session 5	Parallel Sessions 8A and 8B	Plenary Session 11
11:00 a.m.		Plenary Session 2			
Noon			Poster Session 4	Poster Session 6	
1:00 p.m.	Kickoff Seminar 3	Poster Session 2		Junior Award Lectures	
2:00 p.m.	Parallel Kickoff Seminars 4 and 5	Plenary Session 3	Plenary Session 6	Parallel Sessions 9A and 9B	
3:00 p.m.					
4:00 p.m.	Parallel Kickoff Seminars 6 and 7	Wine & Cheese Seminars	MDS Business Meeting	Wine & Cheese Seminars	
5:00 p.m.			David Marsden Lecture		
6:00 p.m.					
7:00 p.m.	Opening Ceremony Welcome Reception	Video Dinner Sessions	Video Dinner Sessions	Congress Banquet at the Miami Seaquarium	
8:00 p.m.					
9:00 p.m.					
10:00 p.m.					
11:00 p.m.					



Elan Ad

Scientific Program

Sunday, November 10

Kickoff Seminar 1 8:00 am - 10:00 am
Location: Fontainebleau Ballroom A/B, Level II

Novel approaches to the treatment of Parkinson's disease: From early disease to late stage fluctuations

Funded through an unrestricted educational grant from Teva Pharmaceuticals and Teva Neuroscience

Co-Chair: Olivier Rascol, France
Co-Chair: Eldad Melamed, Israel

Neuroprotective effects of a novel MAO-B inhibitor: Preclinical studies with rasagiline
Moussa Youdim, Israel

Results of the TEMPO trial - Efficacy and safety of rasagiline as monotherapy 12-month data
Ira Shoulson, USA

Fluctuations in Parkinson's disease - Mechanisms, treatment approaches and unmet needs
Stanley Fahn, USA

Etilevodopa: The molecule, the rationale, preliminary studies which proved the concept
Eldad Melamed, Israel

Pivotal studies with etilevodopa
Werner Poewe, Austria

Kickoff Seminar 2 10:15 am - 11:15 am
Location: Fontainebleau Ballroom C/D, Level II

Non-oral drug delivery in Parkinson's disease

Funded through an unrestricted educational grant from Schwarz Pharma AG

Co-Chair: Wolfgang H. Oertel, Germany
Co-Chair: Niall P. Quinn, United Kingdom

Non-oral drug delivery in Parkinson's disease
Olivier Rascol, France

Rotigotine CDS, the Parkinson's patch: Concept and results
Peter A. LeWitt, USA

Continuous dopaminergic stimulation: A promising and valuable clinical concept
Thomas N. Chase, USA

Break 11:15 am - 12:30 pm
Location: Fontainebleau Gallerie, Level II

Kickoff Seminar 3 12:30 pm - 2:00 pm
Location: Fontainebleau Ballroom A/B, Level II

COMT Inhibition: Enhancing Levodopa therapy in Parkinson's disease

Funded through an unrestricted educational grant from Novartis and Orion Pharma

Co-Chair: Abraham Lieberman, USA
Co-Chair: A. Jon Stoessl, Canada

The importance of levodopa in the treatment of Parkinson's disease
William C. Koller, USA

The benefits of levodopa continuous dopaminergic stimulation
José A. Obeso, Spain

Initiation of levodopa with entacapone prevents dyskinesia - New pre-clinical data from an MPTP model
Peter Jenner, UK

Building a body of evidence for early use of entacapone
C. Warren Olanow, USA

Clinical case studies: New long term data in patients with motor complications; New data in early fluctuators
Ray L. Watts, USA

Kickoff Seminar 4 2:15 pm - 3:45 pm
Location: Fontainebleau Ballroom A/B, Level II

Botulinum neurotoxins: Where are we now?

Funded through an unrestricted educational grant from Allergan

Co-Chair: Alfredo Berardelli, Italy
Co-Chair: Mark Hallett, USA

Understanding the therapeutic window
Roger K. Aoki, USA

Understanding the duration of effect
Oliver W. Dolly, UK

Properties of botulinum toxins in clinical practice
Dirk W. Dressler, Germany

Kickoff Seminar 5 2:15 pm - 3:45 pm
Location: Fontainebleau Ballroom C/D, Level II

Dopamine agonists: State of the art in Parkinson's disease treatment

Funded through an unrestricted educational grant from Pharmacia

Co-Chair: Paolo Barone, Italy
Co-Chair: Yoshikuni Mizuno, Japan

Neuroprotection and neurorescue in Parkinson's disease
Anthony H. V. Schapira, UK

Long term neuroimaging data: The bridge from bench to clinic
Kenneth Marek, USA

Long term benefits of initial treatment with dopamine agonists
Joseph Jankovic, USA

Strategies for 24-hour management of Parkinson's disease
K. Ray Chaudhuri, UK

Sunday, November 10

Kickoff Seminar 6 4:00 pm - 5:30 pm
Location: Fontainebleau Ballroom C/D, Level II

Distinguishing features of botulinum toxins

Funded through an unrestricted educational grant from Élan

*Co-Chair: William C. Koller, USA
Co-Chair: Mark Lew, USA*

Characteristics of botulinum toxins
Paulette S. Setler, USA

Understanding the differences between botulinum toxins
Joseph Arezzo, USA

Important factors influencing the immunogenicity of botulinum toxins
Jeffrey Critchfield, USA

Clinical efficacy of botulinum toxins
*Francesca Mancini, Italy
Mark Lew, USA*

Kickoff Seminar 7 4:00 pm - 5:30 pm
Location: Fontainebleau Ballroom A/B, Level II

Dopamine agonists: Realizing the promise

Funded through an unrestricted educational grant from GlaxoSmithKline

*Co-Chair: Werner Poewe, Austria
Co-Chair: Fabrizio Stocchi, Italy*


The pharmacological rationale for the use of dopamine agonists in Parkinson's disease
C. Warren Olanow, USA

Key clinical goals in modern Parkinson's disease therapy - The contribution of dopamine agonists
Matthew B. Stern, USA

Assessing the impact of ropinirole on disease progression - The REAL-PET study
David J. Brooks, UK



Flamingos



Coral Reefs

Opening Ceremony 6:30 pm - 7:15 pm
Location: Fontainebleau Ballroom, Level II

6:30 pm Welcome, Opening Remarks

Werner Poewe, MD, President, MDS

6:35 pm Perspectives on research efforts treatment and management for Parkinson's disease

Ms. Janet Reno

6:45 pm Education and research Initiatives in Parkinson's disease

*Nathan Slewett, Chairman of the Board,
National Parkinson's Foundation
Co-Chair, of the newly formed,
The Parkinson's Foundation*

6:55 pm Acknowledgement of MDS Honorary Membership
Werner Poewe, MD,

Oleh Hornykiewicz, MD (Austria) will be honored, in recognition of his role in discovering Dopamine deficiency in PD and in introducing L-Dopa replacement therapy.

Stanley Fahn, MD (USA) will be honored in recognition of his role as founder of MDS and international leader in the field of movement disorders.

Gerald Stern, MD (UK) will be honored in recognition of his pioneering work in clinical pharmacology of Parkinson's disease.

7:15 pm Close

Welcome Reception 7:15 pm - 9:00 pm

All congress attendees are invited to meet friends and colleagues during the traditional Congress Welcome Reception on Sunday evening, November 14th, on the Great Lawn of the Fontainebleau Hilton. Following the Opening Ceremony, guests will be guided to this beautiful outdoor area with local Miami music, where cocktails and hors d'oeuvres will be served.

Monday, November 11

Poster Session 1 7:00 am - 8:30 am

Location: West Ballroom and Jade Promenade, Level II

Posters 1-168

Topics: Basic science, genetics, neuropharmacology, Parkinson's disease

Stanley Fahn Lecture 8:30 am - 9:00 am

Location: Fontainebleau Ballroom, Level II

Parkinson's Disease: New insights from functional imaging

David J. Brooks, UK

Plenary Session 1 9:00 am - 10:30 am

Location: Fontainebleau Ballroom, Level II

Alpha synucleinopathies

Chair: Michel Goedert, UK

Co-Chair: Dennis Dickson, USA

Relevance of alpha-synuclein for Lewy body diseases and multiple system atrophy

Michel Goedert, UK

Genetic analysis of alpha-synucleinopathies in Drosophila

Mel Feany, USA

Transgenic mouse models of alpha-synucleinopathies

Eliezer Masliah, USA

Coffee Break 10:30 am - 11:00 am

Location: Exhibit Hall, East Ballroom, Level II

Plenary Session 2 11:00 am - 12:30 pm

Location: Fontainebleau Ballroom, Level II

Genetics of parkinsonism

Chair: Yoshikuni Mizuno, Japan

Co-Chair: Thomas Gasser, Germany

Overview: Clinico-genetic correlation and genetic contributions to sporadic Parkinson's disease

Nicholas Wood, UK

Parkin and neuronal death

Ted M. Dawson, USA

Clinical features of recessive Parkinson's disease

Vincenzo Bonifati, Italy

Poster Session 2 12:30 pm - 2:00 pm

Location: West Ballroom and Jade Promenade, Level II

Posters 169-338

Topics: Parkinson's disease

Plenary Session 3 2:00 pm - 3:30 pm

Location: Fontainebleau Ballroom, Level II

Medical therapies in Parkinson's disease: Evidence-based medicine

Chair: Werner Poewe, Austria

Co-Chair: Cristina Sampaio, Portugal

Evidence-based treatment of Parkinson's disease – Possibilities and limitations

Cristina Sampaio, Portugal

Cost effectiveness of dopamine agonist therapy in early Parkinson's disease

Richard Dodel, Germany

Medical and surgical management of motor complications in Parkinson's disease

Christopher G. Goetz, USA

Management of mental dysfunction in Parkinson's disease – An evidence-based approach

Werner Poewe, Austria

Break 3:30 pm - 4:00 pm

Location: Exhibit Hall, East Ballroom Level II

Wine & Cheese Seminars

Late afternoon Wine & Cheese seminars are designed to be informal and interactive. To encourage discussion, attendance is limited to 50-75 participants per seminar. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Wine & Cheese Seminar 1 4:00 pm - 5:30 pm

Location: Pasteur, Level IV

Autonomic nervous system dysfunction in neurodegenerative disease

Pietro Cortelli, Italy

Horacio Kaufmann, USA

Wine & Cheese Seminar 2 4:00 pm - 5:30 pm

Location: Imperial III, Level IV

Advances in stiff person syndrome

Philip D. Thompson, Australia

Hans Michael Meinck, Germany

Wine & Cheese Seminar 3 4:00 pm - 5:30 pm

Location: Champagne, Level I

Treatment options in tremor disorders

Roger J. Eible, USA

Peter George Bain, UK

Monday, November 11

Wine & Cheese Seminar 4 4:00 pm - 5:30 pm

Location: Lafayette, Level IV

Management of levodopa - induced hallucinations/ behavioral disturbance

*E.Ch. Wolters, The Netherlands
Joseph H. Friedman, USA*

Wine & Cheese Seminar 5 4:00 pm - 5:30 pm

Location: Voltaire, Level IV

Patient selection/monitoring for surgery in Parkinson's disease

*Jerrold Lee Vitek, USA
Marcelo Merello, Argentina*

Wine & Cheese Seminar 6 4:00 pm - 5:30 pm

Location: Burgundy, Level I

Update on Huntington's disease

*Justo De Yebenes, Spain
Gillian P. Bates, UK*

Wine & Cheese Seminar 7 4:00 pm - 5:30 pm

Location: Bordeaux, Level I

How to evaluate clinical trials in movement disorders

*Mario Zappia, Italy
Joaquim Ferreira, Portugal*

Wine & Cheese Seminar 8 4:00 pm - 5:30 pm

Location: LeMans, Level I

Restless leg syndrome and sleep problems in Parkinson's disease

*Cynthia L. Comella, USA
Birgit Hogl, Austria*

Wine & Cheese Seminar 9 4:00 pm - 5:30 pm

Location: Imperial II, Level IV

Diagnosis and management of motor complications

*Marie Vidailhet, France
Jan Petter Larsen, Norway*

Wine & Cheese Seminar 10 4:00 pm - 5:30 pm

Location: Brittany, Level I

Parkinsonism – PSP, MSA, CBGD: Clinical update

*Gregor K. Wenning, Austria
Irene Litvan, USA*

Wine & Cheese Seminar 21 4:00 pm - 5:30 pm

Location: Voltaire, Imperial IV

Gene therapy for Parkinson's disease

*Maria G. Castro, USA
Jeffrey H. Kordower, USA*

Video Dinner Sessions

Video Dinner sessions have become a popular segment of the MDS Congress as Participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session and may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Video Dinner 7:00 pm - 10:00 pm

Location: Burgundy, Level I

Tremor

*Günther Deuschl, Germany
William C. Koller, USA*

Video Dinner 2 7:00 pm - 10:00 pm

Location: LeMans, Level I

Dystonia

*Alberto Albanese, Italy
Joseph Jankovic, USA*

Video Dinner 3 7:00 pm - 10:00 pm

Location: Bordeaux, Level I

Myoclonus

*José A. Obeso, Spain
Peter Brown, UK*

Video Dinner 4 7:00 pm - 10:00 pm

Location: Brittany, Level I

Atypical Parkinsonism

*Niall P. Quinn, UK
Jean Hubble, USA*

Video Dinner 5 7:00 pm - 10:00 pm

Location: Champagne, Level I

Unusual movement disorders

*Rajesh Pahwa, USA
Oscar S. Gershanik, Argentina*

Tuesday, November 12

Poster Session 3 7:00 am - 8:30 am

Location: West Ballroom and Jade Promenade, Level II

Posters 339-520

Topics: Parkinson's disease

Plenary Session 4 8:30 am - 10:00 am

Location: Fontainebleau Ballroom, Level II

Tauopathies

*Chair: Zbigniew K. Wszolek, USA
Co-Chair: Timothy Lynch, Ireland*

Familial tauopathies – Clinical considerations
Zbigniew K. Wszolek, USA

Neuropsychological and behavioral aspects of tauopathies
David Neary, UK

Molecular genetic dissection of tauopathies
Peter Heutink, The Netherlands

Pathology of tauopathies
Bernardino Ghetti, USA

Coffee Break 10:00 am - 10:30 am

Location: Exhibit Hall, East Ballroom, Level II

Plenary Session 5 10:30 am - Noon pm

Location: Fontainebleau Ballroom, Level II

Clinical and basic aspects of dystonia

*Chair: Stanley Fahn, USA
Co-Chair: Giovanni Abbruzzese, Italy*

Clinical and genetic heterogeneity of dystonia
Susan B. Bressman, USA

The genetics and its biochemical implications in myoclonus-dystonia
Thomas Gasser, Germany

Deep brain stimulation in the treatment of dystonia
Phillippe Coubes, France

Poster Session 4 Noon - 1:30 pm

Location: West Ballroom and Jade Promenade, Level II

Posters 521-694

Topics: Neuroimaging, surgical therapy, transplantation

Plenary Session 6 2:00 pm - 3:30 pm

Location: Fontainebleau Ballroom, Level II

Neuroimaging update

*Chair: David J. Brooks, UK
Co-Chair: Klaus Leonhard Leenders, The Netherlands*

Understanding complications of Parkinson's disease
A. Jon Stoessl, Canada

Huntington's disease
Klaus Leonhard Leenders, The Netherlands

Dystonia
David Eidelberg, USA

Break 3:30 pm - 4:00 pm

Location: Exhibit Hall, East Ballroom, Level II

MDS Business Meeting 4:00 pm - 5:00 pm

Location: Fontainebleau Ballroom, Level II

David Marsden Lecture 5:00 pm - 5:30 pm

Location: Fontainebleau Ballroom, Level II

Impact of inherited Parkinson's disease on the understanding of nigral neurodegeneration
Yoshikuni Mizuno, Japan

Video Dinner Sessions

Video Dinner sessions have become a popular segment of the MDS Congress as Participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session and may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Video Dinner 6 7:00 pm - 10:00 pm

Location: Burgundy, Level I

Drug-induced movement disorders

*Philippe Damier, France
Amos D. Korczyn, Israel*

Video Dinner 7 7:00 pm - 10:00 pm

Location: Brittany, Level I

Paroxysmal movement disorders

*Kailash P. Bhatia, UK
Kapil D. Sethi, USA*

Tuesday, November 12

Video Dinner 8 7:00 pm - 10:00 pm

Location: Le Mans, Level I

Psychogenic movement disorders

*Anthony E. Lang, Canada
John G. L. Morris, Australia*

Video Dinner 9 7:00 pm - 10:00 pm

Location: Champagne, Level I

Gait disorders

*John G. Nutt, USA
Nir Giladi, Israel*

Video Dinner 10 7:00 pm - 10:00 pm

Location: Bordeaux, Level I

Tourette's syndrome

*Francisco Cardoso, Brazil
Andrew J. Lees, UK*



MOCA



Seaport

Poster Session 5 7:00 am - 8:30 am

Location: West Ballroom and Jade Promenade, Level II

Posters 695-850

Topics: Non-motor aspects of movement disorders, clinical, parkinsonism

Parallel Session 7A 8:30 am - 10:00 am

Location: Fontainebleau Ballroom A/B, Level II

Trinucleotide repeat diseases

*Chair: Anne B. Young, USA
Co-Chair: Thomas Klockgether, Germany*

Friedreich's ataxia
Michel Koenig, France

Spinocerebellar ataxias
Ullrich Wuellner, Germany

Huntington's disease
Jang-Ho John Cha, USA

Parallel Session 7B 8:30 am - 10:00 am

Location: Fontainebleau Ballroom C/D, Level II

Mental changes in Parkinson's disease

*Chair: Bruno Dubois, France
Co-Chair: Ramon Leiguarda, Argentina*

The non-motor functions of the basal ganglia from anatomy to behavior
Peter L. Strick, USA

Is Parkinson's disease with dementia and DLB the same disease?

*Yes: Andrew J. Lees, UK
No: Charles Duyckaerts, France*

Does deep brain stimulation affect cognition/behavior?

*Yes: Jean Saint-Cyr, Canada
No: Pierre Pollak, France*

Coffee Break 10:00 am - 10:30 am

Location: Exhibit Hall, East Ballroom, Level II

Parallel Session 8A 10:30 am - Noon

Location: Fontainebleau Ballroom A/B, Level II

Neurophysiology of movement disorders

*Chair: Alfredo Berardelli, Italy
Co-Chair: Reiner Benecke, Germany*

The role of non-corticospinal system
John C. Rothwell, UK

Changes in the excitability of cortical motor areas
Alfredo Berardelli, Italy

Rhythmic activity in basal ganglia and in motor cortex
Peter Brown, UK

Cerebellar control of movement
Mark Hallett, USA

Wednesday, November 13

Parallel Session 8B 10:30 am - Noon
Location: Fontainebleau Ballroom C/D, Level II

Public health issues and epidemiology in Parkinson's disease

Chair: Eduardo Tolosa, Spain
Co-Chair: Ali Rajput, Canada

Risk factors for Parkinson's disease: An epidemiological approach

Caroline M. Tanner, USA

Impact of co-morbidities on Parkinson's disease

Mark Guttman, Canada

Quality of life determinants in Parkinson's disease

Anette Schrag, UK

Poster Session 6 Noon - 1:30 pm
Location: West Ballroom and Jade Promenade, Level II

Posters 851-1020

Topics: Clinical electrophysiology, dystonia

Junior Awards Lectures 1:30 pm - 2:00 pm
Location: Fontainebleau Ballroom C/D, Level II

Basic science award

Is the rhythm of physiologic tremor involved in cortical motor planning?

Jan H. Raethjen, Kiel, Germany

Clinical science award

Staged lesions through implanted deep brain stimulating electrodes: A new surgical procedure for treating tremor or dyskinesia

Sylvia Raoul, Nantes, France

Parallel Session 9A 2:00 pm - 3:30 pm
Location: Fontainebleau Ballroom A/B, Level II

Sleep disorders in movement disorders

Chair: Wayne A. Hening, USA
Co-Chair: Claudia M. Trenkwalder, Germany

The spectrum of motor disorders of sleep

Pasquale Montagna, Italy

Restless legs syndrome and periodic limb movements:

The most common motor sleep disturbances

Claudia M. Trenkwalder, Germany

REM sleep behavior disorder: A condition of sleep/state motor dysregulation linked to Lewy body diseases

Cynthia L. Comella, USA

Daytime sleepiness in Parkinson's disease: A problem of multiple etiologies?

David Rye, USA

Parallel Session 9B 2:00 pm - 3:30 pm
Location: Fontainebleau Ballroom C/D, Level II

Update on mechanisms of neurodegeneration

Chair: Robert E. Burke, USA
Co-Chair: Eldad Melamed, Israel

An update on mechanisms of MPTP toxicity

Serge Przedborski, USA

Rotenone-induced dopamine neuron death in a rodent model

John Timothy Greenamyre, USA

Mechanisms of programmed cell death in dopamine neurons

Jorg B. Schulz, Germany

Break 3:30 pm - 4:00 pm
Location: Exhibit Hall, East Ballroom, Level II

Wine & Cheese Seminars

Late afternoon Wine & Cheese seminars are designed to be informal and interactive. To encourage discussion, attendance is limited to 50-75 participants per seminar. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Wine & Cheese Seminar 11 4:00 pm - 5:30 pm
Location: Voltaire, Level IV

Gene therapy for Parkinson's disease

Maria G. Castro, USA

Wine & Cheese Seminar 12 4:00 pm - 5:30 pm
Location: LeMans, Level I

Ataxias

S.H. Subramony, USA
Alessandro Filla, Italy

Wine & Cheese Seminar 13 4:00 pm - 5:30 pm
Location: Imperial II, Level IV

Occupational cramps

Alberto Priori, Italy
Steven Frucht, USA

Wine & Cheese Seminar 14 4:00 pm - 5:30 pm
Location: Pasteur, Level IV

Neurodegeneration with iron accumulation; DRPLA

Susan J. Hayflick, USA
Shoji K. C. Tsuji, Japan

Wine & Cheese Seminar 15 4:00 pm - 5:30 pm
Location: Imperial III, Level IV

Wednesday, November 12

Recent advances of Wilson's disease; dopa-responsive dystonia

*Yoshiaki Furukawa, Canada
Federico Micheli, Argentina*

Wine & Cheese Seminar 16 4:00 pm - 5:30 pm

Location: Champagne, Level I

Dementia with Lewy bodies

*I.G. McKeith, UK
Glenda M. Halliday, Australia*

Wine & Cheese Seminar 17 4:00 pm - 5:30 pm

Location: Brittany, Level I

Systemic diseases that cause movement disorders

*Fernando Alarcon, Ecuador
Santiago Gimenez-Roldan, Spain*

Wine & Cheese Seminar 18 4:00 pm - 5:30 pm

Location: Burgundy, Level I

Pediatric movement disorders

*Harvey S. Singer, USA
Robert A. H. Surtees, UK*

Wine & Cheese Seminar 19 4:00 pm - 5:30 pm

Location: Bordeaux, Level I



Miami Beach and Harbor

Thursday, November 14

Poster Session 7 7:00 am - 8:30 am

Location: West Ballroom and Jade Promenade, Level II

Posters 1021-1182

Topics: Ataxia, chorea, drug-induced movement disorders, myoclonus, spasticity, stereotypies, tics, tremor

Plenary Session 10 8:30 am - 10:00 am

Location: Fontainebleau Ballroom, Level II

Clinical trials in movement disorders

*Chair: Olivier Rascol, France
Co-Chair: Miguel Rueda S., Colombia*

The ELLDOPA study

Stanley Fahn, USA

Effects of coenzyme Q10 in early Parkinson's disease:

The QE2 study

Cliff Shults, USA

"N=1" trials – A possible solution to assess interventions in movement disorders

Joaquim Ferreira, Portugal

Update on clinical trials in Huntington's disease

Karl D. Kieburtz, USA

Break 10:00 am - 10:30 am

Location: Fontainebleau Galerie

Plenary Session 11 10:30 am - Noon

Location: Fontainebleau Ballroom, Level II

Surgical treatment of movement disorders

*Chair: Andres M. Lozano, Canada
Co-Chair: Alim L. Benabid, France*

Targeting Parkinson's disease: The role of surgery

Alim L. Benabid, France

What neurorecording in surgery has taught us about movement disorders

Andres M. Lozano, Canada

Transplantation for Parkinson's disease – Pros, cons and where do we go from here?

C. Warren Olanow, USA

Faculty

Abbruzzese, Giovanni
Genova, Italy
PL05

Alarcon, Fernando
Quito, Ecuador
WC17

Albanese, Alberto
Milano, Italy
V02

Aoki, Roger K.
Irvine, CA, USA
KS04

Arezzo, Joseph
Bronx, NY, USA
KS06

Bain, Peter George
Richmond, Surrey, UK
WC03

Barone, Paolo
Napoli, Italy
KS05

Bates, Gillian P.
London, UK
WC06

Benabid, Alim L.
Grenoble, France
PL11

Benecke, Reiner
Rostock, Germany
PL08A

Berardelli, Alfredo
Roma, Italy
KS04, PL08A

Bhatia, Kailash P.
London, UK
V07

Bonifati, Vincenzo
Rotterdam, The Netherlands
PL02

Bressman, Susan B.
New York, NY, USA
PL05

Brooks, David J.
London, UK
KS07, PL06,
Fahn Lectureship

Brown, Peter
London, UK
PL08A, V03

Burke, Robert E.
New York, NY, USA
PL09B

Cardoso, Francisco
Belo Horizonte, Brazil
V10

Castro, Maria G.
Los Angeles, CA, USA
WC11, WC21

Cha, Jang-Ho John
Charlestown, MA, USA
PL07A

Chase, Thomas N.
Bethesda, MD, USA
KS02

Chaudhuri, K. Ray
London, UK
KS05

Chen, Robert
Toronto, ON, Canada
WC19

Comella, Cynthia L.
Chicago, IL, USA
PL09A, WC08

Cortelli, Pietro
Bologna, Italy
WC01

Coubes, Philippe
Montpellier, France
PL05

Critchfield, Jeffrey
San Francisco, CA, USA
KS06

Curra, Antonio
Venafrò, Italy
WC19

Damier, Philippe
Nantes, France
V06

Dawson, Ted M.
Baltimore, MD, USA
PL02

De Yebenes, Justo
Madrid, Spain
WC06

Deuschl, Günther
Kiel, Germany
V01

Dickson, Dennis
Jacksonville, FL, USA
PL01

Dodel, Richard
Marburg, Germany
PL03

Dolly, Oliver W.
London, UK
KS04

Dressler, Dirk W.
Rostock, Germany
KS04

Dubois, Bruno
Paris, France
PL07B

Duyckaerts, Charles
Paris, France
PL07B

Eidelberg, David
Manhasset, NY, USA
PL06

Eible, Roger J.
Springfield, IL, USA
WC03

Fahn, Stanley
New York, NY, USA
KS01, PL05, PL10

Feany, Mel
Boston, MA, USA
PL01

Ferreira, Joaquim
Dois Portos, Portugal
PL10, WC07

Filla, Alessandro
Napoli, Italy
WC12

Friedman, Joseph H.
Pawtucket, RI, USA
WC04

Frucht, Steven
New York, NY, USA
WC13

Furukawa, Yoshiaki
Toronto, ON, Canada
WC15

Gasser, Thomas
München, Germany
PL02, PL05

Gershanik, Oscar S.
Buenos Aires, Argentina
V05

Ghetti, Bernardino
Indianapolis, IN, USA
PL04

Giladi, Nir
Tel Aviv, Israel
V09

Gimenez-Roldan, Santiago
Madrid, Spain
WC17

Goedert, Michel
Cambridge, UK
PL01

Goetz, Christopher G.
Chicago, IL, USA
PL03

Greenamyre, John Timothy
Atlanta, GA, USA
PL09B

Guttman, Mark
Markham, ON, Canada
PL08B

Hallett, Mark
Bethesda, MD, USA
KS04, PL08A

Halliday, Glenda M.
Randwick, Australia
WC16

Hayflick, Susan J.
Portland, OR, USA
WC14

Hening, Wayne A.
New York City, NY, USA
PL09A

Heutink, Peter
Rotterdam, Netherlands
PL04

Hoggl, Birgit
Innsbruck, Austria
WC08

Hubble, Jean
East Hanover, NJ, USA
V04

Jankovic, Joseph
Houston, TX, USA
KS05, V02

Jenner, Peter
London, UK
KS03

Kaufmann, Horacio
New York, NY, USA
WC01

Kiebertz, Karl D.
Rochester, NY, USA
PL10

Klockgether, Thomas
Bonn, Germany
PL07A

Koenig, Michel
Strasbourg, France
PL07A

Koller, William C.
New York, NY, USA
KS03, KS06, V01

Korczyński, Amos D.
Ramat-Aviv, Israel
V06

Kordower, Jeffrey H.
Chicago, IL, USA
WC21

Lang, Anthony
Toronto, ON, Canada
V08

Larsen, Jan Petter
Stavanger, Norway
WC09

Faculty

Leenders, Klaus Leonhard
Groningen, Netherlands
PL06

Lees, Andrew J.
London, UK
PL07B, V10

Leiguarda, Ramon
Buenos Aires, Argentina
PL07B

Lew, Mark
Los Angeles, CA, USA
KS06

LeWitt, Peter A.
Southfield, MI, USA
KS02

Lieberman, Abraham
Miami, FL, USA
KS03

Litvan, Irene
Bethesda, MD, USA
WC10

Lozano, Andres M.
Toronto, ON, Canada
PL11

Ludlow, Christy L.
Bethesda, MD, USA
WC20

Lynch, Timothy
Dublin, Ireland
PL04

Mancini, Francesca
Pavia, Italy
KS06

Marek, Kenneth
New Haven, CT, USA
KS05

Masliah, Eliezer
La Jolla, CA, USA
PL01

McKeith, I.G.
Newcastle Upon Tyne, UK
WC16

Meinck, Hans Michael
Heidelberg, Germany
WC02

Melamed, Eldad
Petah Tiqva, Israel
KS01, PL09B

Merello, Marcelo
Buenos Aires, Argentina
WC05

Micheli, Federico
Buenos Aires, Argentina
WC15

Mizuno, Yoshikuni
Tokyo, Japan
KS05, PL02
Marsden Lectureship

Montagna, Pasquale
Bologna, Italy
PL09A

Morris, John G.L.
Sydney, Australia
V08

Neary, David
Manchester, UK
PL04

Nutt, John G.
Portland, OR, USA
V09

Obeso, José A.
Pamplona, Spain
KS03, V03

Oertel, Wolfgang H.
Marburg, Hessen, Germany
KS02

Olanow, C. Warren
New York, NY, USA
KS03, KS07, PL11

Pahwa, Rajesh
Kansas City, KS, USA
V05

Poewe, Werner
Innsbruck, Austria
KS01, KS07, PL03

Pollak, Pierre
Grenoble, France
PL07B

Priori, Alberto
Milano, Italy
WC13

Przedborski, Serge
New York, NY, USA
PL09B

Quinn, Niall P.
London, UK
KS02, V04

Rajput, Ali
Saskatoon, SK, Canada
PL08B

Ramig, Lorraine
Denver, CO, USA
WC20

Rascol, Olivier
Toulouse, France
KS01, KS02, PL10

Rothwell, John C.
London, UK
PL08A

Rueda S., Miguel
Bogota, Colombia
PL10

Rye, David
Atlanta, GA, USA
PL09A

Saint-Cyr, Jean
Toronto, ON, Canada
PL07B

Sampaio, Cristina
Lisboa, Portugal
PL03

Schapira, Anthony H.V.
London, UK
KS05

Schrag, Anette
London, UK
PL08B

Schulz, Jorg B.
Tuebingen, Germany
PL09B

Sethi, Kapil D.
Augusta, GA, USA
V07

Setler, Paulette
Burlingame, CA, USA
KS06

Shoulson, Ira
Rochester, NY, USA
KS01

Shults, Cliff
San Diego, CA, USA
PL10

Singer, Harvey S.
Baltimore, MD, USA
WC18

Stern, Matthew B.
Philadelphia, PA, USA
KS07

Stocchi, Fabrizio
Roma, Italy
KS07

Stoessl, A. Jon
Vancouver, BC, Canada
KS03, PL06

Strick, Peter L.
Pittsburg, PA, USA
PL07B

Subramony, S.H.
Jackson, MS, USA
WC12

Surtees, Robert A. H.
London, UK
WC18

Tanner, Caroline M.
Sunnyvale, CA, USA
PL08B

Thompson, Philip D.
Adelaide, Australia
WC02

Tolosa, Eduardo
Barcelona, Spain
PL08B

Trenkwalder, Claudia M.
Goettingen, Germany
PL09A

Tsuji, Shoji K.C.
Niigata, Japan
WC14

Vidailhet, Marie
Paris, France
WC09

Vitek, Jerrold Lee
Marietta, GA, USA
WC05

Watts, Ray L.
Atlanta, GA, USA
KS03

Wenning, Gregor K.
Innsbruck, Austria
WC10

Wolters, E.Ch.
Amsterdam, Netherlands
WC04

Wood, Nicholas
London, UK
PL02

Wszolek, Zbigniew K.
Jacksonville, FL, USA
PL04

Wuellner, Ullrich
Bonn, Germany
PL07A

Youdim, Moussa
Haifa, Israel
KS01

Young, Anne B.
Boston, MA, USA
PL07A

Zappia, Mario
Catanzaro, Italy
WC07

Key

- KS = Kickoff Seminar
- PL = Plenary or Parallel Session
- V = Video Dinner Session
- WC = Wine & Cheese Seminar

Exhibitor Information

General Information and Exhibit Hall Hours

Please allow adequate time in your daily schedule to visit the Exhibit Hall, located in the East Ballroom. The exhibition is an integral component to your Congress experience, representatives of companies providing services or marketing products directly related to movement disorders. Delegates may enter the Exhibit Hall at the entrance between the Jade Promenade and Fontainebleau Gallerie or through the West Ballroom during the following hours:

Monday, November 11	8:00 am – 5:00 pm
Tuesday, November 12	8:00 am – 5:00 pm
Wednesday, November 13	8:00 am – 5:00 pm

Exhibitor Registration

Exhibitors may register at the Exhibitor Registration Desk, located in the Grand Gallerie of the Fontainebleau Hilton during the following hours:

Saturday, November 9	3:00 pm – 8:30 pm
Sunday, November 10	6:30 am – 7:30 pm
Monday, November 11	6:30 am – 7:30 pm
Tuesday, November 12	6:30 am – 7:30 pm
Wednesday, November 13	6:30 am – 6:00 pm

Exhibitor Badge Policy

Exhibit booth personnel must show an official MDS exhibitor name badge in order to gain access to the Exhibit Hall during installation, show, or dismantlement hours. Badges should be worn at all times as security guards will monitor Exhibit Hall entrances for proper identification. Exhibitors will be identified as follows:

Exhibitor Badge (Yellow) - Allows admittance to the Exhibit Hall area only.

Exhibitor Delegate Badge (Orange) - Allows the delegate to enter the Exhibit Hall as an exhibitor and attend scientific sessions including poster presentations (access to Wine and Cheese Seminars and Video Dinners at an additional cost).

Endorsement Disclaimer

Products and services displayed in the Exhibit Hall or advertised in the program occur by contractual business arrangements between the MDS and participating companies and organizations. These arrangements do not constitute nor imply an endorsement by the MDS of these products and services.

Exhibitor Directory

XV International Congress of Parkinson's Disease

Department of Foreign Relations
Chinese Medical Association
42 Dongsi Xidajie
Beijing, China, 100710
E-mail: xvicpd@chinamed.com.cn
Website: www.chinamed.com.cn/xvicpd

Booth Number: 14

The XV International Congress on Parkinson's Disease will be held May 30 - June 3, 2003, in Beijing, China. At the Congress, the latest information in combating Parkinson's disease will be shared, as well as the application of the traditional Chinese medicine in the treatment of Parkinson's disease.

Allergan

2525 Dupont Drive
Irvine, CA, 92612-1599, USA
Website: www.allergan.com

Booth Number: 200

Allergan is the manufacturer of BOTOX®, Botulinum Toxin Type-A, Purified Neurotoxin Complex. There are presently a number of BOTOX® clinical trials underway for a wide variety of uses. Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide.

Amarin Pharmaceuticals, Inc.

2 Belvedere Place
Suite #330
Mill Valley, CA 94941, USA
Website: www.amarinpharma.com

Booth Number: 412

Amarin Pharmaceuticals is a fully integrated specialty pharmaceutical company, focused on the development and marketing of novel neurological and pain disorder treatments that target unmet medical needs. Amarin Pharmaceuticals currently markets Permax (r) (pergolide mesylate), a dopamine agonist for the treatment of Parkinson's Disease.

American Parkinson Disease Association, Inc.

1250 Hylan Boulevard
Suite 4B
Staten Island, NY 10305, USA
E-mail: info@apdaparkinson.org
Website: www.apdaparkinson.org

Booth Number: 9

The American Parkinson Disease Association, Inc. (APDA) provides educational, referral and support programs for medical professionals, patients, their families and the public through regional symposia, educational literature and video tapes. APDA has 64 Chapters and more than 800 support groups; funds 54 Information & Referral Centers and sponsors research on Parkinson's disease by funding Advanced Centers for Parkinson's Research, fellowships and research grants.

Exhibitor Directory

American Society for Experimental NeuroTherapeutics

611 E. Wells Street
Milwaukee, WI 53202, USA
E-mail: info@asent.org
Website: www.asent.org

Booth Number: 5

The American Society for Experimental NeuroTherapeutics (ASENT) brings together leaders in government, academia and industry engaged in the field of neurotherapeutics to advance the knowledge of these scientists in advances in experimental neurotherapeutics. ASENT's 5th Annual Meeting will be held from March 13-15, 2003 at the Capital Hilton in Washington, DC.

The Bachmann-Strauss Dystonia & Parkinson Foundation, Inc.

Mount Sinai Medical Center
One Gustave Levy PLace, Box 1490
New York, NY 10029, USA
E-mail: bachmann.strauss@mssn.edu
Website: www.dystonia-parkinsons.org

Booth Number: 3

The major goal of the Bachmann-Strauss Dystonia & Parkinson Foundation is to find a cure for Dystonia and Parkinson diseases. We strive to achieve this goal by: raising awareness of Dystonia and Parkinson's disease in the general public and the medical community, raising funds to support research, and sponsoring educational symposia for patients and families.

Benign Essential Blepharospasm Research Foundation, Inc.

P.O. Box 12468
637 North 7th Street, Suite 102
Beaumont, TX 77726-2468, USA
E-mail: bebrf@ih2000.net
Website: www.blepharospasm.org

Booth Number: 4

The Benign Essential Blepharospasm Research Foundation founded in 1981, is the only organization dedicated solely to finding the cause and cure for Blepharospasm, Meige and related disorders. BEBRF, a volunteer directed, nonprofit organization, has support groups nationwide, promotes awareness and research, distributes educational material to patients and physicians and serves as a referral clearing house.

Bertek Pharmaceuticals, Inc.

Marketing
P.O. Box 14149
RTP, NC 27709-4149, USA
Research Triangle Park
Website: www.bertek.com

Booth Number: 406

Phenytek's 153 300mg Capsules contain the active ingredient extended phenytoin sodium and has proven equal to Dilantin[®] Kapseals[®] in bioequivalence studies. Specially patented technology has allowed scientists to put 300mg of extended phenytoin sodium into one capsule to allow convenient dosing options. Phenytek is also available in 200mg Capsules.

Biotene-Laclede, Inc.

2030 East University Drive
Rancho Dominguez, CA 90220, USA
E-mail: help@laclede.com
Website: www.laclede.com

Booth Number: 118

Biotene & Oralbalance Dry Mouth Products – Over the counter dry mouth care products contain natural antibacterial salivary enzymes that help reduce oral irritations due to dry mouth caused by anti-Parkinson's medications. Biotene dry mouth toothpaste, alcohol-free mouthwash, sugar-free chewing gum and Oralbalance moisturizing gel saliva substitute.

Cambridge Laboratories

Deltic House
King Fisher Way
Silverlink Business Park
Wallsend, Tyne & Wear NE28 9NX
United Kingdom
E-mail: marketing@camb-labs.com
Website: www.camb-labs.com

Booth Number: 117

Cambridge Laboratories is a specialist pharmaceutical company that develops and markets niche pharmaceutical products to hospitals and consultants worldwide. The company's lead product is xenazine 25 which is indicated for the treatment of organic hyperkinetic movement disorders and tardive dyskinesia.

Cleveland Medical Devices

11000 Cedar Avenue
Suite 130
Cleveland, OH 44106, USA
E-mail: sales@clevemed.com
Website: www.clevemed.com

Booth Number: 120

Cleveland Medical Devices' line of lightweight physiological monitors include two wireless 8-channel programmable devices, The BioRadio[®] 110 and the Crystal Monitor[®], and a wireless 2-channel miniature device, the BioRadio Jr., which by eliminating restricting wires, allows continuous EEG, EMG, EOG, and PSG (polysomnograph) monitoring of patients.

Dystonia Medical Research Foundation

One East Wacker Drive #2430
Chicago, IL 60601, USA
E-mail: dystonia@dystonia-foundation.org
Website: www.dystonia-foundation.org

Booth Number: 7

The Dystonia Medical Research Foundation has a 3-fold mission: to advance research into the cause of, and cure for dystonia. To date, 356 grants totaling over \$17 million have been awarded. The second goal is to create public and physician awareness of dystonia, and the third goal is to sponsor educational and support programs.

Exhibitor Directory

Eastern Medical Publishers

173 NW 81 Way
Coral Springs, FL 33071, USA
Website: www.empbooks.com

Booth Number: 219

Eastern Medical Publishers represents several of the leading publishers in the industry.

Élan

5880 Pacific Center
San Diego, CA 92121, USA
Website: www.elan.com

Booth Number: 110

Élan is focused on the discovery, development, manufacturing, selling and marketing of novel therapeutic products in neurology, pain management and autoimmune diseases. Élan products include MYOBLOC, registered in the United States, and NEUROBLOC, registered in Europe.

European Dystonia Federation

69 East King Street
Helensburgh, Argyll&Bute G84 7RE
United Kingdom
Website: www.dystonia-europe.org

Booth Number: 10

The aim of the European Dystonia Federation is to support and coordinate the work of its member groups. The group tends to sponsor those activities or events of an international nature organized by its member groups in their own countries. It also works to establish worthwhile relations with other organizations with similar aims, with governmental and other agencies, and with neurological and other specialists of the international medical community.

European Federation of Neurological Societies

Alser Strasse 4
Vienna, 10900
Austria
E-mail: headoffice@efns.org
Website: www.efns.org

Booth Number: 8

The aim of the European Federation of Neurological Societies (EFNS) is to advance the development of the neurological sciences in Europe. Thirty-eight European national neurological associations are registered members of the EFNS. The EFNS welcomes individual members from all over the world.

FHC, Inc. (Frederick Haer Co., Inc.)

9 Main Street
Bowdoinham, Maine 04008
Email: fhcinc@fh-co.com
Website: www.fh-co.com

Booth Number: 318

FHC's microTargeting[®] products are used for intraoperative micro- and macro-electrode recording, micro- and macro-stimulation, and data analysis in functional neurosurgery for the treatment of movement disorders. MicroTargeting[®] devices include FDA cleared and CE marked mono and bipolar microelectrodes, microdrive systems, and the new microTargeting[®] Platform. The microTargeting[®] Platform mounts on implanted fiducial markers creating a frameless stereotactic system. Benefits of the microTargeting[®] Platform include reduced operating room set-up and times, unique dual targeting capabilities, as well as increased patient comfort and mobility.

GlaxoSmithKline

F2129, COC Building
5 Moore Drive
Research Triangle Park
RTP, NC 27709, USA
Website: www.gsk.com

Booth Number: 206

GlaxoSmithKline is a world leading research-based pharmaceutical company dedicated to improving the quality of life of patients. GlaxoSmithKline continues to strive to provide solutions to many of the problems encountered within the complex field of neurological medicine.

IM Systems

1055 Taylor Avenue
Suite 300
Baltimore, MD 21286, USA
E-mail: mail@imsystems.net
Website: www.imsystems.net

Booth Number: 115

IM Systems' miniature DigiTrac monitor records the frequency and amplitude of movements, and provides PC download for graphical plots and FFT analysis. The monitor also measures a patient's real-time tremor in the clinical setting. This wrist-worn unit is completely ambulatory and ideally suited for use in both the clinical and home environments.

Exhibitor Directory

Image-Guided Neurologics

2290 W. Eau Gallie Boulevard
Melbourne, FL 32937, USA
Website: www.igneurologics.com

Booth Number: 218

Image-Guided Neurologics (IGN) is a leading innovator in the development of precision access, navigation, and delivery products for the less invasive treatment of neurological disease. Focused on expanding the applications for frameless stereotaxy, IGN is guiding the way to a new era where neurosurgeons will have real-time guidance and navigation capabilities right in the operating room – where accurate, less-invasive technologies will enable patients to recover faster and more fully than ever before.

In-Step Mobility Products, Inc.

In-Step Mobility Products, Inc.
8040 N. Ridgeway Avenue
Skokie, Illinois 60076
E-mail: jmiller@ustep.com
Website: www.ustep.com

Booth Number: 220

PRODUCT FEATURING: U-Step Walking Stabilizer with Laser Module The U-Step is an advanced rolling walker that address the needs of those with neurological conditions. Unique design offers greater stability and control than other walkers. The U-Step is beneficial to those with: Parkinsonism, Multiple Sclerosis, ALS, Stroke, PSP, MSA, etc. The Laser Module can be added to reduce freezing common with Parkinson's disease and other Movement Disorders. Medicare approved.

International Tremor Foundation

7046 West 105th Street
Overland Park, KS 66212-1803, USA
E-mail: staff@essentialtremor.org
Website: www.essentialtremor.org

Booth Number: 1

The International Tremor Foundation provides information, services and support to individuals and families affected by essential tremor. The organization supports research to determine the causes, treatment and cures for essential tremor.



Downtown Miami

John Wiley & Sons, Inc.

111 River Street
Hoboken, NJ 07030, USA
Website: www.wiley.com

Booth Number: 116

Founded in 1807, John Wiley & Sons, Inc. is an independent, global publisher of print and electronic products. Wiley specializes in scientific and technical books, journals, textbooks and educational materials for colleges and universities, as well as professional and consumer books and subscription services. Wiley's Internet Site can be accessed at <http://www.wiley.com>.

Lippincott Williams Wilkins

21525 Laguna Drive
Boca Raton, FL 33433, USA
Website: www.lww.com

Booth Number: 121

LWW is a premier medical publisher in movement disorders and all other areas of neurology. This year, we are pleased to announce the NEW fourth edition on the popular title, "Parkinson's Disease and Movement Disorders," edited by Joseph Jankovic and Eduardo Tolosa. Also newly available in the Advances in Neurology series is the proceedings from the XIVth World Congress on Parkinson's Disease.

MEDSYS Technologies

7777 Bonhomme Avenue
Suite 1700
Clayton, MO 63105, USA
Website: www.medsystechnologies.com

Booth Number: 221

MEDSYS Technologies provides innovative technology solutions for neurology and movement disorders. Products include: MARS, a clinical records database system made specifically for neurology; and PiqûrePerfect, a state of the art system for tracking the delivery of neurotoxin treatment.

Medtronic Neurological

710 Medtronic Parkway NE
LN 370
Minneapolis, MN 55432-5604, USA
Website: www.medtronic.com

Booth Number: 306

Medtronic Neurological's Activa® Therapy is a reversible and adjustable treatment for some of the most disabling symptoms of Parkinson's disease and essential tremor. It uses an implanted neurostimulation system, akin to a pacemaker, to relieve symptoms when medication alone fails to provide adequate benefit or consistently causes intolerable side effects.

Exhibitor Directory

Muhammad Ali Parkinson Research Center

500 W. Thomas Road
Suite 720
Phoenix, AZ 85013, USA
E-mail: maprc@chw.edu
Website: www.aliproject.com

Booth Number: 11

The Muhammad Ali Parkinson Research Center at Barrow Neurological Institute has developed a clinical database called the Ali Project. Using information technology, the Ali Project links Parkinson's centers around the country in order to gather, store, and share information about Parkinson's disease. The Ali Project also provides an educational e-learning tool for Parkinson's patients that covers the topics of speech, swallowing, and deep-brain stimulation. The Ali Project hopes that collecting core data about Parkinson's disease will aid researchers in treating and potentially curing the disease.

Myoclonus Research Foundation

200 Old Palisade Road
Suite 17D
Fort Lee, NJ 07024, USA
E-mail: research@myoclonus.com
Website: www.myoclonus.com

Booth Number: 2

The Myoclonus Research Foundation is a public foundation supporting research in Myoclonus, investigating its basic mechanisms and developing new therapies. This research may also help provide clues to other types of movement and neurological disorders such as Epilepsy, Parkinson's disease and Alzheimer's disease.

National Parkinson Foundation, Inc.

Bob Hope Parkinson Research Center
1501 NW 9th Avenue
Bob Hope Road
Miami, Florida 33136-1494
E-mail: mailbox@parkinson.org
Website: www.parkinson.org

Booth Number: 320

The National Parkinson Foundation's mission is to find the cause and cure for Parkinson's disease and related neurodegenerative disorders through research; to educate general medical practitioners to detect the early warning signs of Parkinson's disease; to educate patients, their caregivers and the general public; to provide diagnostic and therapeutic services; to improve the quality of life for both patients and their caregivers.

Nicolet Biomedical

5225 Verona Road
Building 2
Madison, WI 53711, USA
E-mail: info@nicoletbiomedical.com
Website: www.viasyshealthcare.com

Booth Number: 215

Nicolet Biomedical features the MicroGuide, a multi-channel, microelectrode recording (MER) device used for functional neurosurgery procedures for optimal target localization in the treatment of movement disorders, mainly Parkinson's disease, during deep brain stimulator (DBS) implantation, pallidotomy, thalamotomy, and other similar neurosurgical procedures.

Novartis Pharmaceuticals Corporation

One Health Plaza
East Hanover, NJ 07936, USA
Website: www.novartis.com

Booth Number: 100

Novartis Pharmaceuticals Corporation is dedicated to discovering, developing, manufacturing, and marketing prescription drugs that help meet unmet medical needs and provide better options to treat your patients. The Novartis Neuroscience Business Unit is committed to using new skills to improve health and well being through innovative products and services in the treatment of neurodegenerative and neuropsychiatric diseases. Please visit our exhibit area where, in conjunction with Orion Pharma, professional sales representatives will be able to discuss Comtan® (entacapone), answer questions and supply scientific information.

Orion Pharma

P.O. Box 65
Espoo, 02101
Finland
Website: www.orionpharma.com

Booth Number: 100

Orion Pharma is the pharmaceutical division of the Orion Group, one of the leading companies in the healthcare sector in the Nordic area of Europe. Orion Pharma's continued expansion and success is built upon the research and development of its own new innovative drugs in four core therapy areas: CNS therapies, Cardiology and Critical Care, Hormonal therapies, and Respiratory therapies. Orion's leading product in the CNS therapy area is the Parkinson's disease drug Comtess® (entacapone). Entacapone, a COMT enzyme inhibitor, is Orion Pharma's patented molecule discovery, which Orion Pharma developed through multinational clinical trials. Entacapone is available globally as Comtess® and Xoutav®. Please visit our exhibition area.

Exhibitor Directory

Parkinson Foundation of the National Capital Area

7913 Westpark Drive
Suite 101
McLean, VA 22102, USA
E-mail: info@parkinsonfoundation.org
Website: www.parkinsonfoundation.org

Booth Number: 15

The Parkinson Foundation of the National Capital Area (PFNCA), a nonprofit organization serving the Washington, DC, Metropolitan Area, provides services and support for people with Parkinson's disease to improve quality of life and supports research into the cause and cure for Parkinson's disease.

Safe Dose Pharmacy

8770 Guion Road
Suite G
Indianapolis, IN 46268, USA
E-mail: info@safedose.com
Website: www.safedose.com

Booth Number: 314

Pharmacy providing medication management solutions.

Schwarz Pharma AG

Alfred-Nobel-Strasse 10
Monheim, 40789
Germany
Website: www.schwarzpharma.com

Booth Number: 212

Rotigotine CDS, the Parkinson Patch, is the unique formulation designed to test the hypothesis that constant dopaminergic stimulation is beneficial in the treatment of Parkinson's disease. It is applied as a patch once-a-day and replaced by a new patch the next day. Phase III studies in both early and late-stage PD patients are underway.

SDS/MSA Support Group

2004 Howard Lane
Austin, TX 78728, USA
E-mail: don.summers@shy-drager.com
Website: www.shy-drager.com

Booth Number: 13

The mission of the Shy Drager Syndrome/Multiple System Atrophy Support Group (SDS/MSA) is to gather information from each group of people involved (Patients, Caregivers, Family Members, and Physicians) and disseminate that information to all. The SDS/MSA Support Group is an information center and a "Helping Hand" for affected people. Through various programs, including regional patient/caregiver support group meetings, support of local groups, the toll free help line, newsletters and web site, the

Parkinson Study Group/Huntington Study Group

1351 Mount Hope Avenue
Suite 220
Rochester, NY 14620, USA
Website: www.parkinson-study-group.org,
www.huntington-study-group.org

Booth Number: 12

The Parkinson Study Group (PSG) and the Huntington Study Group (HSG) are democratically governed, non-profit, academic consortiums of physicians and other health care providers experienced in the care of Parkinson/Huntington patients and dedicated to the clinical research of Parkinson's/Huntington's disease. The PSG currently has 84 research sites in North America. The HSG has 60 research sites in North America, Europe and Australia. For information on the clinical trials associated with these study groups go to their websites which are located at www.Parkinson-Study-Group.org and www.Huntington-Study-Group.org.

Pharmacia Corporation

100 Route 206 North
MS-041
Peapack, NJ 07977, USA
Website: www.pharmacia.com

Booth Numbers: 300 & 400

Pharmacia Corporation is a global, innovation-driven pharmaceutical and health care company. Our products, services and employees demonstrate the company's commitment to improve wellness and quality of life for people around the world. Stop by our international booth to discuss Cabaser (cabergoline tablets). We look forward to your questions and comments.

Radionics

Department of Marketing
22 Terry Avenue
Burlington, MA 01803, USA
E-mail: info@radionics.com
Website: www.radionics.com

Booth Number: 113

The NeuroPlan System provides the ability to fully support deep brain stimulator implantation. With the AccuDrive and REK, implantation is supported through one system. With this simplified approach the surgeon is able to place a deep brain stimulator with accuracy and confidence.

Exhibitor Directory

Restless Legs Syndrome Foundation

819 Second Street SW
Rochester, MN 55902, USA
E-mail: rlsfoundation@rls.org
Website: www.rls.org

Booth Number: 312

The Restless Legs Syndrome Foundation is a nonprofit organization dedicated to increasing universal awareness, developing effective treatments, and finding a definitive cure for Restless Legs Syndrome (RLS). The organization provides information about RLS, develops local support groups, publishes a quarterly newsletter, and funds research for the study of RLS. SDS/MSA's Support Group can reach many people in need. The support group also works closely with physicians who are newly involved with the disease and/or treating the patients as well as those who are involved in the essential research to discover a cause, modes of treatment, and hopefully a cure. Information about the disease and tips on explaining it to the patient will be provided through several modes, including the web site, links to the American Autonomic Society, access to a referral base of experienced physicians, and educational meetings. By sharing information, resources, and support the SDS/MSA Support Group will create a "Circle of Hope" for those affected by SDS/MSA.

SHS North America

P.O. Box 117
Gaithersburg, MD 20884, USA
E-mail: guestbook@shsna.com
Website: www.shsna.com

Booth Number: 111

SHS North America, International Leader in Clinical Nutrition, invites you to visit our booth to learn more about new medical foods for the nutritional management of intractable epilepsy and tardive dyskinesia. Our representatives will be happy to inform you about the latest clinical trials conducted in this field.

Society for Progressive Supranuclear Palsy, Inc.

1838 Greene Tree Road
Suite 515
Baltimore, MD 21208-6391, USA
E-mail: spsp@psp.org
Website: www.psp.org

Booth Number: 6

The Society for Progressive Supranuclear Palsy (PSP) exists to promote and fund research in finding the cause and cure of PSP, a terminal neurological disease. The society is a nonprofit organization 501(c)3 that provides information, education, support and advocacy for persons diagnosed with PSP, families, physicians and allied health professionals.

W.B. Saunders/Mosby

10810 SW 14th Court
Davie, FL 33324, USA
Website: www.us.elsevierhealth.com

Booth Number: 119

Medical publisher

WE MOVE

204 W. 84th Street
3rd Floor
New York, NY 10024, USA
E-mail: wemove@wemove.org
Website: www.wemove.org

Booth Number: 213


WE MOVE provides movement disorder information and educational materials to physicians, patients, the media and the public. Visit WE MOVE to learn about its comprehensive website www.wemove.org; CME courses and teaching slide sets; E-MOVE-the research news service; rating scales; grant information and more.



Bayside

Floor Plan & Meeting Space

Versailles Building, Level I / Versailles Building, Level IV



MEETING SPACE

Versailles Building, Level I

- Brittany
- Burgundy
- Bordeaux
- Champagne
- Le Mans
- Monaco


Versailles Building, Level IV

- Club Atlantic
- Conference Room 1
- Conference Room 2
- Conference Room 3
- Conference Room 4
- Conference Room 5
- Conference Room 6
- Conference Room 7
- Imperial I
- Imperial II
- Imperial III
- Imperial IV
- Imperial V
- Lafayette
- Pasteur
- Voltaire


Versailles Building, Level II

- East Ballroom
- Fontainebleau Ballroom
- Fontainebleau Gallerie
- Grand Gallerie
- Jade Promenade
- West Ballroom

Versaille Building, Level II



Map of Miami



Poster Sessions

Poster Session 1- Monday, November 11

7:00 am - 8:30 am

Poster numbers 1-168

Basic Science, Genetics, Neuropharmacology, Parkinson's Disease

- P1 A "single toxin-double lesion" rat model of striatonigral degeneration by intrastratial 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis**
I. Ghorayeb, P.O. Fernagut, L. Hervier, B. Labattu, B. Bioulac, F. Tison
- P2 A clinino-pathological analysis of subjects with a-synuclein pathology**
L. Parkkinen, H. Soinenen, J. Autere, I. Alafuzoff
- P3 A combined simultaneous MPTP + 3 nitropropionic acid (3-NP) systemic mouse model of striatonigral degeneration**
P.O. Fernagut, E.N. Diguët, B. Bioulac, F. Tison
- P4 Activity-dependent plasticity in the basal ganglia**
B.E. Fisher, C. Meshul, K. Nixon, G.M. Petzinger, M.W. Jakowec
- P5 Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with L-dopa**
M. Kuoppamaki, G. Al-Barghouthy, M. Jackson, L. Smith, B.-Y. Zeng, N. Quinn
- P6 Bone marrow stromal cell as potential cellular therapy for treatment of Parkinson's Disease**
K. Yang, X. Yuan, J. Sun, Y. Long, E.C. Lai
- P7 Cartography of the limbic territory of the subthalamic nucleus of monkeys: A potential target for Deep Brain Stimulation**
C. Karachi, J. Yelnik, C. Jan, K. MacCairn, L. Tremblay, C. Francois
- P8 Case report of motor evoked potentials from the subthalamic nucleus (STN) DBS electrodes**
E.B. Montgomery, Jr., K.B. Baker, W. Bingaman, A. Rezai, H.O. Luders
- P9 Comparing region specific mRNA expression profiles in Progressive Supranuclear Palsy**
P. Rizzu, V. Bonifati, R. Ravid, A.H. Rajput, P. Heutink
- P10 D3 receptors contribute to the neuroprotective properties of D3/D2 agonists against MPP-induced neurotoxicity but not DA-induced toxicity in SH-SY5Y cells**
J.N. Joyce, S.P. Presgraves, S. Borwege, M.J. Millan
- P11 Dissection of tau isoform composition of tauopathy lesions using novel isoform-specific monoclonal antibodies**
R. de Silva, T. Lashley, G. Gibb, D. Hanger, T. Revesz, A. Lees
- P12 Does extraneuronal melanin maintain neurodegeneration in Parkinson Disease?**
H. Wilms, P. Rosenstiel, J. Sievers, G. Deuschl, L. Zecca, R. Lucius
- P13 Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic MPTP + 3-nitropropionic acid primate model of striatonigral degeneration**
I. Ghorayeb, P.O. Fernagut, N. Stefanova, G.K. Wenning, B. Bioulac, F. Tison
- P14 Effects of levodopa and apomorphine on the neuronal activity of the subthalamic nucleus (STN) in rats with moderate and severe Parkinsonism: relevance of the degree of dopaminergic denervation**
J.A. Ruiz Ortega, S. Gomez Urquijo, L. Ugedo, G. Linasazoro
- P15 Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein**
K. Obi, A. Suzuki, T. Urabe, M. Onodera, H. Mochizuki, Y. Mizuno
- P16 Functional characterization of novel target genes in neurodegeneration**
B. Bingham, S. Naureckiene, S. Kotnis, L. Ma, R. Shen, L.W. Chiang
- P17 Glutamatergic and dopaminergic neuroplasticity in the basal ganglia of the MPTP-lesioned mouse**
M.W. Jakowec, C. Meshul, T. McNeill, K. Nixon, G.M. Petzinger
- P18 Increased Alzheimer pathology in Parkinson's Disease is associated with chronic antimuscarinic drug treatment**
E.K. Perry, D.J. Burn, L. Kilford, A.J. Lees, R.H. Perry
- P19 Is there neurogenesis in the substantia nigra of adult mice?**
A. Hartmann, G. Hoeglinger, G. Kempermann, F. LaChapelle, W.H. Oertel, E.C. Hirsch
- P20 LEC rat model of Wilson Disease does not show nigrostriatal degeneration at age 20 weeks**
T.B. Ahn, B.S. Jeon
- P21 Magnesium sulphate potentiates the antiparkinsonian levodopa effect and has antidyskinetic effect in MPTP-lesioned monkeys**
C. Chassain, A. Eschalier, F. Durif
- P22 Methamphetamine induces neuronal inclusions reminiscent of Lewy bodies**
F. Fornai, M. Gesi, P. Lenzi, M. Ferrucci, G. Lazzeri, S. Ruggieri
- P23 Minocycline attenuates bilirubin-induced neurotoxicity in both cultured cerebellar granule neurons and the Gunn Rat**
S. Lin, Z. Ma, R.C. Dodel, W.H. Oertel, M.R. Farlow, Y. Du
- P24 Minocycline blocks 6-hydroxydopamine -induced neurotoxicity and free radical production in rat cerebellar granule neurons**
Y. Du, S. Lin, X. Wei, R.C. Dodel, W.H. Oertel, M.R. Farlow
- P25 Motor temporal patterns and stereotypies but not rotational behavior can better explain motor response complications in Parkinson's Disease**
M.A. Delfino, A.V. Stefano, J.E. Ferrario, I.R. Taravini, G.M. Murer, O.S. Gershanik
- P26 MPP+ and 6-OHDA neurotoxicity to dopaminergic neurons is ameliorated by NSAIDs**
P. Werner, E. Carrasco, A. Di Rocco, M.D. Yahr
- P27 MPTP systemic toxicity in the non-human primate (Saimiri sciureus)**
G.M. Petzinger, K. Nixon, B.E. Fisher, G.C. Kanel, V. Jackson-Lewis, M.W. Jakowec
- P28 Neurochemical markers and microarrays in postmortem Tourette Syndrome putamen and brain area 9**
O. Lee, C.R. Loiselle, K.G. Becker, N.G. Kwak, A.M. Comi, H.S. Singer
- P29 Neuronal death induced by proteasomal inhibition involves cytochrome-c and caspase-9, but not bcl-2**
I.C. Lang-Rollin, O. Jabado, H.J. Rideout, S. Papantonis, J.M. Angelastro, L. Stefanis
- P30 Neuroplasticity of the MPTP-lesioned non-human primate in behavioral recovery**
G.M. Petzinger, K. Nixon, B. Fisher, T. McNeill, M.W. Jakowec

Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

- P31 Neuroprotection against 6-OHDA toxicity elicited by intranigral infusion of IL-1b in vivo in the rat**
J. Saura, M. Pares, J. Bove, E. Tolosa, M.J. Marti
- P32 Parkin knockdown induces the apoptotic cell death in human neuroblastoma cells**
Y. Machida, Y. Tanaka, T. Chiba, N. Hattori, K. Tanaka, Y. Mizuno
- P33 Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat**
M. Forsberg, M. Lehtonen, M. Heikkinen, J. Savolainen, T. Jarvinen, P.T. Mannisto
- P34 Preserved learning ability of a visuo-motor task in Parkinson's Disease patients**
R. Inzelberg, N. Feirstein, P. Nisipeanu, R.L. Carasso, S. Hoeherman
- P35 Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide**
W. Le, S.Z. Imam, W. Xie, S. Ali, J. Jankovic
- P36 Role of Heat Shock Proteins in proteasomal inhibition-induced inclusion formation and death of cultured cortical neurons**
H.J. Rideout, A. Perger, O. Jabado, S. Papantonis, L. Stefanis
- P37 Subthalamic neuronal resting activities in humans with and without Parkinson's Disease**
E.B. Montgomery, Jr., K.B. Baker, A. Rezai, H.O. Luders, W. Bingaman, G. Barnett
- P38 Subthalamic nucleus (STN) neuronal activity in meaningful and non-meaningful speech**
P. Watson, E.B. Montgomery, Jr., K.B. Baker, A. Rezai, N. Boulis, J. Henderson
- P39 The Antiparkinsonian agent, piribedil, possesses a distinctive profile of dopamine D₂/D₃ agonist and α₂-adrenoceptor antagonist properties: a multivariate comparison to other Antiparkinsonian agents at recombinant, human monoaminergic receptors**
M.J. Millan, D. Cussac, L. Maiofiss, V. Audinot, N. Bodjarian, A. Newman-Tancredi
- P40 The developmental time course of glial cell line-derived neurotrophic factor (GDNF) and GDNF receptor α-1 mRNA (GFR α-1) expression in the striatum and substantia nigra**
J. Cho, N.G. Kholdilov, R.E. Burke
- P41 The effect of chronic lisuride treatment on behavioral sensitization and gene expression in dopamine denervated striatum**
G. Sahin, E.S. Topcuoglu, T. Dalkara, B. Elibol
- P42 The novel AMPA receptor potentiator, LY40187, is neuroprotective in experimental models of Parkinson's Disease**
M.J. O'Neill, K. Whalley, M.A. Ward, P. Skolnick, S. Woodhouse, T.K. Murray
- P43 The novel AMPA receptor potentiator, LY404187, is neurotrophic in a nigral 6-hydroxydopamine model of Parkinson's Disease**
T.K. Murray, K. Whalley, M.A. Ward, C.A. Hicks, M.J. O'Neill
- P44 TorsinA immunoreactivity in inclusion bodies in neurodegenerative disorders**
R.H. Walker, P. Good, P. Shashidharan
- P45 Tracing the neuronal progenitor cells (NPCs) derived from the subventricular zone (SVZ) in the adult mice: migration, differentiation and apoptosis**
M. Yamada, M. Onodera, H. Mochizuki, Y. Mizuno
- P46 A family with E3D40 mutations in the Parkin gene: evidence for autosomal recessive inheritance of young onset benign Parkinsonism rather than autosomal dominant inheritance**
D.S. Sa, R.P. Munhoz, E. Rogaeva, P.S. Hyslop, M.J. Farrer, A.E. Lang
- P47 A screen of GTP cyclohydrolase I in Parkinson's Disease patients**
A. Singleton, C. Evey, K. Gwinn-Hardy, A. Singleton
- P48 A Yorkshire kindred with young onset atypical PSP and central hypoventilation due to a novel homozygous S352L tau mutation**
D.J. Nicholl, M.A. Greenstone, P. Rizzu, C.E. Clarke, D. Crooks, P. Heutink
- P49 Apolipoprotein e4 and e2 alleles associated with higher risk and earlier onset of psychosis in patients with Parkinson's Disease**
N. Giladi, B. Feldman, J. Chapman, A.D. Korczyn
- P50 Association between genetic polymorphism of angiotensin converting enzyme gene and Parkinson's Disease**
J.J. Lin, K.Y. Yueh, D.C. Chang
- P51 Association of the C677T and A1298C polymorphisms in the MTHFR gene with Essential Tremor risk in Turkey**
A. Sazci, E. Ergul, K. Bayulkem
- P52 Autosomal recessive juvenile Parkinsonism: heterozygosity and disease**
O. Tunkel, S. Hassin-Baer, Y. Shinnar, H. Matsumine, N. Hattori, Y. Mizuno
- P53 Case-control study of the synuclein, alpha interacting protein gene (SNCAIP) and Parkinson's Disease**
D.M. Maraganore, M.J. Farrer, T.G. Lesnick, M. de Andrade, J.A. Hardy, W.A. Rocca
- P54 CASPR2 is interrupted in a family with Gilles de la Tourette Syndrome**
A.J. Verkerk, C.A. Mathews, M. Joosse, B. Eussen, P. Heutink, B.A. Oostra
- P55 Characterization of the molecular defect and genotype-phenotype analysis in Wilson Disease patients from Yugoslavia**
G. Loudianos, P. Solinas, M. Lovicu, M. Svetel, A. Cao, V.S. Kostic
- P56 Clinical and genetic evaluation of two large kindreds with Restless Legs Syndrome from South Tyrol (Northern Italy)**
S. Maniak, C. Klein, B. Culjkovic, N. Kock, P.L. Kramer, P.P. Pramstaller
- P57 Clinical and genetic heterogeneity of 11 Italian families with autosomal recessive spastic paraplegia**
G. De Michele, C. Criscuolo, M. Orio, M. Carella, P. d'Adamo, A. Perretti, L. Santoro, A. De Rosa, V. Scarano, A. Filla
- P58 Complex segregation analysis of Restless Legs Syndrome provides evidence for an autosomal dominant mode of inheritance in early age-at-onset families**
J. Winkelmann, B. Muller-Myhsok, H.-U. Wittchen, B. Hock, T. Gasser, C. Trenkwalder
- P59 Early onset Parkinson Disease and the Parkin gene**
I.F. Matas, V.M. Alvarez, E. Coto, R. Ribacoba, L. Guisasola, C. Salvador
- P60 Ethnic differences of clinical and genetic characteristics of inherited forms of Parkinson's Disease in Russia, Uzbekistan and Zambia**
M. Atadzhanov, P. Mwaba
- P61 Exon 1 nurr1 gene mutations are rare in familial PD**
D.G. Healy, P. Sleiman, M.G. Sweeney, L.H. Eunson, N.W. Wood

Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

- P62 Gene sequencing in Brazilian patients with neurological form of Wilson's Disease**
E.R. Barbosa, J. Genshel, M.M. Deguti, A. Machado, E.L. Cançado, B. Bochow
- P63 Genetic analysis of the Parkinsonism dementia complex of Guam**
H.R. Morris, R. Crook, N. Wood, J. Hardy, J. Steele, J. Perez-Tur
- P64 Genetic structure of autosomal dominant ataxias in different Slavonic populations**
S.N. Illarioshkin, S.A. Klyushnikov, N. Dragasevic, I.A. Ivanova-Smolenskaya, V. Kostic, E.D. Markova
- P65 HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease**
M. Onofrij, A. Thomas, G. D'Andreamatteo, D. Iacono, A.L. Luciano
- P66 Monoamine Oxidase B polymorphism, cigarette smoking and risk of Parkinsons Disease**
E.K. Tan, A. Chai, Y. Zhao, M.C. Wong
- P67 Mutation analysis of the epsilon-sarcoglycan gene in families with myoclonus-dystonia suggests genomic imprinting**
P.M. de Carvalho Aguiar, V. Borges, H.B. Ferraz, K. Sethi, D. Raymond, S.B. Bressman
- P68 Mutational screening of epsilon-sarcoglycan in European patients with Myoclonus-Dystonia Syndrome**
F. Asmus, A. Zimprich, S. Tezenas du Montcel, N. Wood, A. Brice, T. Gasser
- P69 PACP, a novel gene for Parkin function**
A. West, P.J. Lockhart, S. Lincoln, K. Wilkes, M. Farrer
- P70 Parkin gene mutations in young onset Parkinsons Disease**
E.K. Tan, H. Shen, Y. Zhao, W.P. Hu, R. Pavanni, M.C. Wong
- P71 Parkin mutations in young-onset or recessive form of Parkinson's Disease**
N.N. Hattori, H.H. Yoshino, Y.Y. Imamichi, Y.Y. Mizuno
- P72 Phenotypes of juvenile Parkinsonism in Russian patients with mutations in the Parkin gene**
E.D. Markova, T.B. Zagorovskaya, S.N. Illarioshkin, I.A. Ivanova-Smolenskaya, P.A. Slominsky, A. Brice
- P73 Refinement of PARK7 critical region on chromosome 1p36**
V. Bonifati, P. Rizzu, N. Vanacore, F. Squitieri, G. Meco, P. Heutink
- P74 Screening of the epsilon-sarcoglycan gene in ten families with myoclonus-dystonia**
N. Kock, B. Mueller, K. Kabakci, L.J. Ozelius, V. Kostic, C. Klein
- P75 Suggestive linkage to Chromosome 19p in a family with autosomal dominant Parkinson's Disease**
A.M. Bertoli Avella, J.L. Giroud Benitez, V. Bonifati, C.M. van Duijn, L. Heredero Baute, P. Heutink
- P76 Survival duration of Parkinson's Disease patients carrying the G209A alpha-synuclein mutation living in Greece**
S. Papapetropoulos, J. Ellul, A. Athanassiadou, C. Paschalis
- P77 Tau gene linkage disequilibrium analysis implicates region for risk variants in PD and PSP**
L. Skipper, K. Wilkes, M. Baker, M. Hutton, J. Aasly, M. Farrer
- P78 The Nurr1 7048 G 7049 intronic insertion is not associated with Parkinson's Disease**
D.G. Healy, P. Sleiman, M.G. Sweeney, N. Khan, L.H. Eunson, N.W. Wood
- P79 Two different phenotypes of the same Parkin mutation in a large pedigree**
N. Hattori, R. Inzelberg, P. Nisipeanu, S. Blumen, R.L. Carasso, Y. Mizuno
- P80 A 2-year multicenter, placebo-controlled, double-blind parallel-group study of the effect of riluzole on Parkinson Disease progression**
O. Rascol, W. Olanow, D. Brooks, G. Koch, P. Truffinet, R. Bejuit
- P81 A double-blind placebo-controlled crossover trial of riluzole in Multiple System Atrophy**
G. Wenning, K. Seppi, A. Diem, Z. Puschban, J. Mueller, W. Poewe
- P82 A model of experimental Parkinsonism induced by free-radical oxidation of dopamine**
G. Shilau, S. Belugin, O. Shadyro, E. Titovetz
- P83 A multi-center, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's Disease experiencing end-of-dose deterioration**
J.H. Im, B.S. Jeon, M.S. Lee, W.Y. Lee, J.W. Kim, M.C. Lee
- P84 A role for opioid receptor antagonism in the treatment of levodopa-induced motor complications in Parkinson's Disease?**
S. Fox, M. Silverdale, M. Kellett, M. Steiger, N. Fletcher, M. Hill
- P85 A systematic analysis of dose related local anhydrotic effects of botulinum toxin B injections as measured by sudometry**
M. Winterholler, F.J. Erbguth, F. Birklein
- P86 Age-related tolerability of tetrabenazine**
C.B. Hunter, A. Wang, K.D. Vuong, J. Jankovic
- P87 Anti-dyskinetic actions of AMPA receptor antagonists in the MPTP-lesioned marmoset model of Parkinsons Disease**
M.A. Silverdale, S.L. Nicholson, A.R. Crossman, J.M. Brotchie
- P88 Behavior and the basal ganglia: gambling and compulsive shopping in Parkinson's Disease**
H. Shabtai, N. Giladi, A.D. Korczyn
- P89 Clozapine treatment for Parkinson's psychosis. Five years follow-up**
C. Klein, Y. Gordon, T. Prohorov, L. Pollak, J.M. Rabey
- P90 Comparison of the pharmacokinetics of Sinemet \dot{O} and Grifoparkin \dot{O} (generic carbidopa/levodopa 25/250): a single-dose, randomized study**
P. Chana, P. Saez, M. Reyes, N. Barrientos
- P91 Comparison of the UPDRS and the Short Parkinson's Evaluation Scale (SPES) in Parkinsonian patients after levodopa loading**
J.M. Rabey, C. Klein, A. Molochnikov, U. Bonuccelli, P. Krauss, B. Van Hilten
- P92 Continuous transdermal iontophoretic delivery of apomorphine can be optimised by pretreatment with a surfactant in patients with Parkinson's Disease (PD)**
T. Van Laar, J.J. De Vries, G. Li, M. Danhof, J.A. Bouwstra
- P93 Cost-effectiveness analysis (CEA) of Pramipexole (P) in patients with Parkinson's Disease (PD) treated and non-treated with levodopa**
A.B. Guekht, E.I. Gusev, E.S. Chickina, G.V. Serkin, Y.B. Belousov
- P94 Differences in toxicity of two different Catechol-O-Methyltransferase inhibitors to human neuroblastoma cells**
L.V.P. Korlipara, J.M. Cooper, A.H.V. Schapira
- P95 Dopamine D3 receptor acting compounds dramatically improved l-dopa-induced dyskinesia in the MPTP-treated monkey**
E. Bezard, T. Boraud, S. Ferry, P. Sokoloff, C.E. Gross

Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

- P96 Dopamine receptor binding profiles of clinically used dopamine agonists**
M. Gerlach, K.L. Double, P. Riederer
- P97 Double-blind, randomised, parallel comparative Dysport vs Botox study in primary palmar hyperhidrosis**
M. Simonetta-Moreau, J.-M. Senard
- P98 Drug monitoring in the blood and the brain on the treatment of Parkinsonism -levodopa-**
T. Nomura, J. Zhang, A. Nakatsuka, M. Nomoto
- P99 Effects of MDMA administration in the MPTP-lesioned non-human primate model of Parkinson Disease**
P. Ravenscroft, C. Imbert, C.E. Gross, E. Bezard
- P100 Entacapone improves the bioavailability of levodopa and smoothens the plasma fluctuations of levodopa as an adjunct to CR levodopa (Sinemet CR 25-100) after repeat dosing**
O. Ahokoski, R. Huupponen, K. Laine, M. Leinonen, E.-R. Kultalahti, K. Reinikainen
- P101 Entacapone increases the bioavailability of controlled-release L-DOPA and prolongs ON time in patients with Parkinson's Disease (PD)**
L. Barbato, G. Nordera, A. Bolner, T. Caraceni, F. Stocchi
- P102 Gabapentin versus ropinirole in the treatment of Restless Legs Syndrome**
S. Happe, C. Sauter, G. Kloesch, B. Saletu, J. Zeitlhofer
- P103 Levodopa effect on experimental pain in Parkinson's Disease: a clinical and neuroimaging pilot study**
C. Brefel-Courbon, P. Payoux, I. Quelven, T. Claire, M. Galitzky, J.L. Montastruc
- P104 Long-term safety and efficacy of cabergoline in the treatment of Restless Legs Syndrome: first results from a 6 months clinical trial**
H. Benes, C.R. Heinrich, M. Ueberall, the German Cabergoline Safety Study Group
- P105 Madopar HBS in treatment of Parkinson's Disease in patients with cardiovascular disorders**
M.I. Vendrova, V.L. Golubev, R.A. Sadekov, A.M. Vein
- P106 New onset diabetes among Parkinsonian patients on long-term clozapine use**
H.H. Fernandez, J.H. Friedman, S.A. Factor, E.S. Molho, J.D. Coskun, M.C. Lansang
- P107 Pergolide pharmacokinetics in patients with Parkinson Disease**
C. Thalamas, O. Rascol, O. Blin, J. Kulisevsky, I. Rajman, C. Brefel-Courbon
- P108 Piribedil in adjuction to l-dopa in Parkinson Disease patients. A nine months follow up**
G. Salazar, C. Cardiel, P. Rheder, J.C. Jimenez
- P109 Piribedil is able to reverse stress-induced anhedonia in the chronic mild stress model**
M. Papp, P. Gruca, C. Bonhomme, N. Bodjarian
- P110 Pleuropulmonary fibrosis after 11 years of pergolide treatment**
R. Tintner, P. Manian, P. Gauthier, J. Jankovic
- P111 Predicting the need for levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off (EODWO)**
K. Reinikainen, M. Leinonen, J. Isojarvi, S. Kaakkola
- P112 Rapid intravenous loading of levodopa for human research**
K.J. Black, T. Hershey, J.L. Carl, J.M. Hartlein, J.M. Koller, J.S. Perlmutter
- P113 Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis**
T.E. Probst, H. Heise, P. Heise, R. Benecke, D. Dressler
- P114 Ropinirole vs pramipexole as adjunctive therapy to levodopa in Parkinson's Disease**
L. Barbato, C. Cattaneo, A. Monge, G. Nordera
- P115 Safety of Antiparkinsonian drugs: a meta-analysis of adverse drug reactions presented in published randomised controlled trials**
J.J. Ferreira, J. Costa, I. Meneses, M. Batista, M. Coelho, M.M. Rosa
- P116 Sumanrole is neuroprotective in an animal model of neurotoxicity**
R.B. McCall, V.H. Sethy, H. Wu, J. Oostveen, E.H. Hall
- P117 Sumanrole: The first highly A D2 selective dopamine receptor agonist intended for the treatment of Parkinson's Disease**
R.B. McCall, N.F. Nichols, K.A. Svensson, M.D. Meglasson, R.M. Huff
- P118 The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration**
K.L. Double, G. Halliday, D. Rowe, J. Henderson, P. Riederer, M. Gerlach
- P119 The effect of catechol-O-methyltransferase polymorphism on the levodopa pharmacokinetics after co-administration of single dose of levodopa and entacapone in Parkinsonian patients**
R.-M. Wu, I.-W. Yu, Y.-F. Ho, J.-W. Kuo, H. Chern
- P120 The use of TASMAR in treatment of Parkinson's Disease**
R.A. Sadekov, M.I. Vendrova, V.L. Golubev
- P121 Treatment of Parkinson's Disease: experience in Estonia**
P. Taba, T. Asser, U. Krikmann
- P122 Changes affecting both D1 and D2 dopamine receptors in monkeys ranging from normal to dyskinetic MPTP-treated**
I. Aubert, C.E. Gross, L. Cardoit, B. Bioulac, B. Bloch, E. Bezard
- P123 Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro**
M. Gerlach, W. Ukai, H. Ozawa, P. Riederer
- P124 Intracortical excitability in early Parkinson Disease- a one year follow-up paired TMS study**
M. Bares, P. Kanovsky, I. Rektor
- P125 The amygdala in Parkinson's Disease**
A.J. Harding, E. Stimson, J.M. Henderson, G.M. Halliday
- P126 Influence of Parkin gene deletion to subclinical dopaminergic dysfunction: IPT SPECT study in a patient with preclinical Parkinson's Disease**
J.-S. Kim, K.-S. Lee, K.-H. Lee, H.-T. Kim
- P127 Non-dopaminergic brain lesions induced by chronic systemic rotenone infusion in rats**
G.U. Höglinger, J. Féger, P. Champy, M. Ruberg, W.H. Oertel, E.C. Hirsch
- P128 Comparison of Cysteine dioxygenase expression in normal and Parkinsonian human brain tissue**
S.W. Smith, R.B. Parsons, A.C. Williams, D.B. Ramsden
- P129 Pathoarchitectonic staging of brain destruction related to sporadic Parkinson's Disease**
H. Braak, K. Del Tredici, U. Rueb, D. Sandmann-Keil, E. Braak

Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

- P130** The PPAR γ agonist pioglitazone inhibits neuronal cell loss and glial activation in the substantia nigra of MPTP treated mice
T. Breidert, J. Callebert, M.T. Heneka, G. Landreth, J.-M. Launay, E.C. Hirsch
- P131** The decline of dopaminergic neurons in Parkinson's Disease is non-linear: a serial positron emission tomography study with 18-Fluorodopa
R. Hilker, K. Schweitzer, M. Ghaemi, S. Weisenbach, K. Herholz, W.-D. Heiss
- P132** Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin
C. Hapdey, K. Parain, E. Rousset, V. Marchand, B. Duméry, E.C. Hirsch
- P133** Behavioral consequences of bicuculline injection in the subthalamic nucleus and the zona incerta in rat
C. Périer, L. Tremblay, J. Féger, E.C. Hirsch
- P134** Do levodopa and/or ropinirole induce an internalization of D1 and/or D2 dopamine receptors?
M.-P. Muriel, G. Orioux, E.C. Hirsch
- P135** Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons or dose of Parkinsonian toxin MPTP in mice
E. Rousset, C. Joubert, J. Callebert, K. Parain, L. Tremblay, E.C. Hirsch
- P136** Role of TNF- α receptors in mice intoxicated with the Parkinsonian toxin MPTP
E. Rousset, J. Callebert, K. Parain, C. Joubert, S. Hunot, E.C. Hirsch
- P137** Caspase-11 plays an important role in the dopaminergic cell death induced by acute MPTP treatment not but chronic treatment
T. Furuya, H. Mochizuki, M. Yamada, M. Miura, J. Yuan, Y. Mizuno
- P138** Inhibition of mitochondrial apoptotic cascade can block MPTP toxicity as anti-apoptotic therapy in Parkinson's Disease
H. Mochizuki, H. Hayakawa, M. Yamada, M. Migita, Y. Mizuno
- P139** Metabolic activity of the cortical neurons projecting to the subthalamic nucleus in a rat model of Parkinson's Disease
G. Orioux, C. François, J. Féger, E.C. Hirsch
- P140** Zonisamide increases dopamine synthesis by inducing TH mRNA
M. Murata, E. Horiuchi, Y. Takahashi, I. Kanazawa
- P141** Lewy bodies and neuronal degeneration in preclinical stage of Parkinson's Disease
A. Krygowska-Wajs, D. Adamek, A. Szczudlik, J. Kaluza
- P142** Measurement of the function and density of dopamine transporter in peripheral lymphocyte of Parkinson's Disease
Z. Weng, J. Zhang, S. Chen, Z. Liu, J. Fei
- P143** Accelerated formation of α -synuclein aggregates in differentiated SH-SY5Y neuroblastoma cells
T. Hasegawa, M. Matsuzaki, A. Kikuchi, K. Furukawa, A. Takeda, Y. Itoyama
- P144** Asymmetrical IBZM binding in patients with Parkinson's Disease is due to a preexisting physiological striatal asymmetry in IBZM binding
C.C. Verstappen, W.W. Oyen, M.M. Horstink
- P145** Transplantation of differentiated murine embryonic stem cells in a 6-OHDA rat model for Parkinson's Disease
P.C. Baier, J. Schindehuetter, K. Thinyane, W. Paulus, P. Gruss, C. Trenkwalder
- P146** Entacapone combined with L-DOPA enhances Antiparkinsonian activity and avoids dyskinesia in the MPTP-treated primate model of Parkinson's Disease (PD)
P. Jenner, G. Al-Barghouthy, L. Smith, M. Kuoppamaki, M. Jackson, S. Rose
- P147** The effects of TNF α on glial cells overexpressing α -synuclein
N. Stefanova, L. Klimaschewski, G.K. Wenning, M. Reindl
- P148** Plastic-adherent cells from human bone marrow differentiate into neural cells: implication for Parkinson's Disease
Y.S. Levy, S. Bulvik, V. Holdengreber, Y. Barhum, E. Melamed, D. Offen
- P149** Viral delivery of GAD antisense genes to basal ganglia output neurons promotes behavioral recovery in a rat Parkinson model
D.W. Anderson, P. Cordelier, D.S. Strayer, J.S. Schneider
- P150** The frontal lobe synaptic pathology in Parkinson's Disease. A Golgi and electron microscope study
M.A. Arnaoutoglou, A.C. Arnaoutoglou, E.N. Arnaoutoglou, V. Kosta, S.J. Baloyannis
- P151** Oxidative stress induced by 6-hydroxydopamine increases ubiquitin-conjugates and protein degradation: Implications for the pathogenesis of Parkinson's Disease
H. Elkon, E. Melamed, D. Offen
- P152** 6-hydroxydopamine affects proteasome activity in the PC12 cell line
H. Elkon, E. Melamed, D. Offen
- P153** Annonacin, the major acetogenin of *Annona muricata* (Annonaceae) induces neurodegeneration and astrogliosis in rats
P. Champy, G. Höglinger, J. Féger, C. Gleye, R. Hocquemiller, E.C. Hirsch
- P154** CD4 memory increase and programmed cell death decrease in peripheral blood of Parkinson's Disease patients
L. Speciale, M. Saresella, E. Calabrese, C. Mariani, N. Canal, P. Ferrante
- P155** A new scoring system for detection of Parkinsonian symptoms in the chronic MPTP intoxication model in the minipig
E. Vaudano, M. Pierri, M. Berendt, T. Sager
- P156** Dopamine D₂, but not D₃, receptor activation is responsible for the Anti-Parkinsonian actions of ropinirole in the MPTP-lesioned marmoset model of Parkinson's Disease
M. Silverdale, H.P. Michael, A.R. Crossman, M.J. Millan, R. Catherine, B.M. Jonathan
- P157** Quantitative gene expression studies in animal models of Parkinson's Disease
A.D. Medhurst, S.L. Colombo, D. Virley, C. Reavill
- P158** Overexpression of wild type and mutant alpha synuclein in a neuroblastoma cell line
L.V.P. Korlipara, K. Messmer, J.M. Cooper, A.H.V. Schapira
- P159** Alpha-synuclein is aggregated by the lipid peroxidation product 4-Hydroxynonenal (HNE)
M. Wang, Y. Chikaoka, K. Shiba, N. Hattori, Y. Mizuno
- P160** Piribedil reverses L-DOPA induced dyskinesia in MPTP treated common marmosets
P. Jenner, L. Smith, M. Jackson, M. Kuoppamaki, G. Al-Barghouthy, C. Bonhomme

Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

- P161 Bilateral subthalotomy and levodopa-induced motor complications in a rodent model of Parkinsonism**
C. Marin, A. Jiménez, M. Bonastre, J. Bové, E. Tolosa
- P162 An infection with filterable forms of *Nocardia Asteroides* in the midbrain nigral lesion in Parkinson's Disease**
S. Kohbata, R. Hayashi, T. Tamura
- P163 Ecstasy (3,4-Methylenedioxymethamphetamine) inhibits dyskinesia expression and normalises locomotor activity in Parkinsonian primates**
M.M. Iravani, M.J. Jackson, G. Al-Barghouthy, M. Kuoppamaki, P. Jenner
- P164 Mitochondrial complex I and complex IV activities in lymphocytes from patients with Parkin gene mutations**
O. Dalmizrak, M. Muftuoglu, F.B. Atac, I.H. Ogun, N. Ozer, B. Elibol
- P165 Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model possibly through inhibition of p38 MAP kinase and its related kinases**
Z. Ma, F. Gao, R.C. Dodel, W.H. Oertel, M.R. Farlow, Y. Du
- P166 In vivo expression and subcellular localization of Parkin in patients with autosomal recessive Parkinson's Disease**
S.-I. Kubo, N. Hattori, Y. Chikaoka, O. Komure, B. Elibol, Y. Mizuno
- P167 Nuclear factor kB and p53 mediate AMPA excitotoxicity to dopaminergic neurons "in vitro"**
G.A. de Erasquin, D. Dorsey, M. Dokucu, D. Mamah, D.H. Masco, M. Soriano
- P168 Identification of up-regulated genes in the MPTP model of Parkinson's Disease**
L. Zhang, J.S. Hong, M. Shimoji, A.S. Mandir, V.L. Dawson, T.M. Dawson

Poster Session 2 - Monday, November 11 12:30 pm - 2:00 pm

Poster numbers 169-338

Parkinson's Disease

- P169 Drug adherence in Parkinson's Disease**
N.A. Leopold, M. Polansky, M. Hurka
- P170 SLV318, a novel agonist for the dopamine D₂ and D₃ receptor: *in vitro* and *in vivo* neurochemical characterization**
M.B. Hesselink, M. van der Neut, T. Adolfs, R. Feenstra, S. Long, G. van Scharrenburg
- P171 A comparative assessment of surgical and conservative treatment of Parkinsonism**
V.M. Tiurnikov, V.V. Peresedov, A.S. Kadykov, L.P. Metyolkina, A.V. Shirshov
- P172 Mutation screening and association analysis of the Parkin gene in Parkinson's Disease patients from South West China**
R. Peng, Y. Gou, Q. Yuan, T. Li, H. Latsoudis, D.A. Collier
- P173 Spectral EMG characteristics correlates with clinical improvement on dopamine agonist treatment in patients with early stage of Parkinson's Disease**
O.Y. Khutorskaya, I.G. Smolentseva, O.S. Levin, N.V. Fedorova
- P174 Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's Disease**
G. Linazasoro
- P175 Synaptic effects of dopamine agonist therapy in fluctuating Parkinsonian patients**
A.A. Monge, F.F. Viselli, F.F. Stocchi, L.L. Barbato, G.G. Nordera
- P176 A biochemical marker for central dopaminergic cell loss**
K.L. Double, D. Rowe, G. Halliday, the DEDCel Research Group, P. Riederer, M. Gerlach
- P177 High pramipexole dosage in the management of fluctuating Parkinsonian patients**
F. Viselli, A. Monge, L. Barbato, F. Stocchi, G. Nordera
- P178 CEP-1347 - a new neuroprotective agent**
J.S. Christophersen, P. Robertson, E.T. Hellriegel, M.I. Watling
- P179 Drug utilization in Parkinson's Disease: a pharmaco-epidemiological study in a cohort of ambulatory patients attending a Parkinson's Disease center**
S. Sacco, S. Cristina, D. Michielotto, C. Pacchetti, E. Martignoni, O. Leoni, R. Zangaglia, M. Cosentino, S. Lecchini, G. Nappi, G. Frigo
- P180 Efficacy and tolerability of pramipexole in routine treatment of advanced Parkinson's Disease (PD) patients in outpatient departments**
J. Benetin, D. Richter
- P181 Changes of reaction and movements times after STN DBS and clinical improvement in IPD**
M.-S. Lee, S.-H. Oh, W.-C. Kim, J.-G. Lee
- P182 Quetiapine: no QTc interval prolongation in psychotic Parkinson patients?**
N. Kuehnl, M.H. Strothjohann, D. Emmans

Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

- P183** Effects of bilateral STN stimulation on grip force control in otherwise untreated Parkinson's disease
F. Baronti, J. Ghika, J.G. Villemure, M. Wiesendanger, J.M. Burgunder, F. Vingerhoets
- P184** Pre and postsurgical polysomnography in Parkinson disease
I. Lambarki, E. Lezcano, J.C. Gomez, G. Bilbao, P. Madoz, J.J. Zarranz
- P185** Severe valvular heart disease associated with the use of an ergot-derivative dopamine agonist in a patient with Parkinson's disease
J. Horvath, P.R. Burkhard, S. Liaudat, R. Lerch, H. Stalder
- P186** Apomorphine: its value in managing Parkinson's Disease
L. Macnamara, J. Sharma
- P187** Establishment of in vivo delivery system of pigment epithelium-derived factor (PEDF) using adeno-associated virus vector
K. Wada, T. Furuya, Y. Sugita, J.P. Schwartz, H. Mochizuki, Y. Mizuno
- P188** Protections of Anti-Parkinson drugs on levodopa and dopamine-induced toxicity in primary rat mesencephalic cells
Q. Xiao, S. Chen, J. Fei, Z. Weng, Z. Liu
- P189** Alternative medicine in Parkinson's Disease: a survey of 75 patients
J. Marjama-Lyons, L. Smith, B. Mylar, J. Urso, L. Carriero, D. Boggs
- P190** Tai Chi and reduced rate of falling in Parkinson's Disease: a single blinded pilot study
J. Marjama-Lyons, L. Smith, B. Mylar, J. Nelson, G. Holliday, D. Seracino
- P191** Does ventrolateral thalamotomy worsen or improve rapid alternating movements?
C. Duval, M. Panisset, E. Duerden, A.F. Sadikot
- P192** Potential applications of the α_2 -adrenergic antagonist, JP-1730, in reducing the problem of L-DOPA-induced motor fluctuations in Parkinson's Disease: studies in the rodent and primate models of Parkinson's Disease
M.P. Hill, J.M. Savola, H. Merivuori, S.G. McGuire, A.R. Crossman, J.M. Brotchie
- P193** Botulinum toxin B reduced sialorrhea in Parkinsonism
B.A. Racette, L.M. Good, S. Sagitto, J.S. Perlmutter
- P194** Excessive daytime sleepiness and unintended sleep episodes in Parkinson's Disease patients taking dopaminergic agonists
T. Roth, L. Borchert, C. Bartlett, D. Blivise, C. Cantor, J. Gorell
- P195** Clozapine in the treatment of levodopa induced dyskinesias in Parkinson's Disease: a double-blind placebo controlled study (Clozapark)
F. Durif, B. Debilly, F. Viallet, O. Rascol, M. Borg, E. Broussolle
- P196** Think big: a new physical therapy intervention for bradykinesia
B.G. Farley, G.F. Koshland
- P197** Cost-effectiveness analysis of spa therapy in Parkinson's Disease
C. Brefel-Courbon, K. Desboeuf, C. Thalamas, M. Galitzky, J.M. Senard, O. Rascol
- P198** Use of dopamine agonists in aged patients with Parkinson's Disease
G. Fabbrini, P. Barbanti, C. Aurilia, C. Pauletti, N. Vanacore, G. Meco
- P199** Subthalamic nucleus stimulation in Parkinsonian patients and laryngeal contributions to voice and speech: an acoustic analysis
L. Jankowski, B. Teston, A. Purson, T. Witjas, J.C. Peragut, F. Viallet
- P200** Improvement in vocal characteristics in a Parkinson's Disease patient with bilateral subthalamic nucleus deep brain stimulation
M. Rezak, S.M. Vergenz, T.W. Eller, L.P. Bernstein, E.K. Nenonene, A.G. Pollack
- P201** Prescribing pattern and factors influencing neurologists choice of anti-Parkinsonian medications
A.P. Yeo, V. Tan, E.K. Tan
- P202** Excessive daytime sleepiness in untreated Parkinson's Disease patients: follow-up after 1 year of dopaminergic drug therapy
G. Fabbrini, P. Barbanti, C. Aurilia, G. Meco, N. Vanacore
- P203** Effectiveness of sertraline in treatment of depression with Parkinson's Disease
K. Bayulkem, F. Torun
- P204** Therapeutic efficiency of Venlafaxin in depressive patients with Parkinson's Disease
K. Bayulkem, F. Torun
- P205** Sleep attacks, daytime sleepiness and dopamine agonist use in Parkinson's Disease
S. Paus, H.M. Brecht, J. Koester, G. Seeger, T. Klockgether, U. Wuellner
- P206** The effect of levodopa on visuospatial analysis in patients with Parkinson's Disease with motor fluctuations
Y. Balash, J. Schaafsma, A. Bartels, N. Giladi
- P207** A 10-year retrospective audit of long-term apomorphine use in Parkinson's Disease
H.L. Tyne, J. Parsons, A. Sinnott, S. Fox, M.J. Steiger, N.A. Fletcher
- P208** Systematic review of antidepressant therapies in Parkinson's Disease
T.H. Chung, C.E. Clarke, K.H.O. Deane, S. Ghazi-Noori, H. Rickards
- P209** Telemedicine for delivery of health care in Parkinson's Disease
A. Samii, P. Ryan-Dykes, B. Mamerto, R.A. Tsukuda, W.P. Nichol
- P210** Patients with Parkinson's Disease get benefit from declarative memory-guided sequences of instructions for sub-components of the movements to improve performance in daily life activities
M.E.P. Piemonte, G.F. Xavier
- P211** Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's Disease
L. Morgante, A. Epifanio, A. Antonini, F. Stocchi, D. De Gaspari, C.M. De Vita
- P212** Cannabis and Parkinson's Disease: subjective improvement of symptoms and drug-induced dyskinesias
K. Venderova, E. Ruzicka, P. Visnovsky
- P213** Entacapone extends the clinical benefits of L-dopa/DDCI and improves the clinical condition of PD in a range of common L-dopa dosage regimens
S.C. Beck
- P214** Cardiovascular effects of methamphetamine in Parkinson's Disease patients
N. Pavese, O. Rimoldi, A. Gerhard, D.J. Brooks, P. Paola

Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

- P215 Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun and increases enzymatic activity in nigral neurons in the rat's 6-OHDA model of Parkinsons Disease**
C. Winter, K. Hosmann, W. Meissner, D. Harnack, R. Morgenstern, A. Kupsch
- P216 The advantage of combining two dopamine agonists in the management of Parkinson's Disease**
L. Vacca, A. Berardelli, M. Onofri, M. Manfredi, S. Ruggieri, F. Stocchi
- P217 A2A receptor antagonist prevents the development of dopamine agonist-induced motor complications in primate and rodent models of Parkinson's Disease**
F. Bibbiani, J.D. Oh, J.P. Petzer, N. Castagnoli, Jr., J.F. Chen, M.A. Schwarzschild
- P218 Intraintestinal infusion of levodopa methyl ester in patients with advanced Parkinson's Disease: A clinical and pharmacokinetic study**
F. Stocchi, L. Vacca, S. Ruggieri, W.C. Olanow
- P219 Practicability of treatment with entacapone (Comtess) in the very elderly**
K. Hahn, D. Bremen, G. Ebersbach
- P220 Entacapone (Comtess) in outpatients with Parkinson's Disease**
A. Kupsch, T. Trottenberg, D. Bremen
- P221 Improvement of sleep and cognitive performance by entacapone in Parkinson's Disease**
B. Holinka, J. Malak, H. Ruff, N. Siepmann, C. Calabrese, W. Gehlen
- P222 The effect of entacapone on motor performance in non-fluctuating patients with Parkinson's Disease analyzed with computerized movement analysis**
M. Mrowka, B. Johnels, D. Bremen, P. Odin
- P223 Symptom duration is a key risk factor for development of L-DOPA-induced dyskinesias in Parkinsonian monkeys**
J.S. Schneider, H. Goncz, E. Decamp
- P224 Exposure to pesticides and Parkinson's Disease: a community-based case-control study among a population characterized by a high prevalence of exposure**
J.S. Vidal, A. Elbaz, J. Clavel, B. Delemotte, A. Alperovitch, C. Tzourio
- P225 Assessing the integrity of the dopamine system in Parkinson's Disease: the inpatient relation between pharmacokinetic-pharmacodynamic modeling and [¹²³I]FP-CIT SPECT**
M. Contin, P. Martinelli, R. Riva, M. Dondi, S. Fanti, A. Baruzzi
- P226 Waiting for 'on' - a major problem in patients with Parkinson's Disease and 'on-off' motor fluctuations**
D. Merims, R. Djaldetti, E. Melamed
- P227 Video registration of freezing and festination in Parkinson's Disease in the home situation**
A.M. Nieuwboer, R. Dom, W. De Weerd, D. Van Gool
- P228 Manual transport in Parkinsons Disease**
B. Hejdukova, N. Hosseini, B. Johnels, G. Steg, T. Olsson
- P229 Speech dysfluency characteristics in patients with Parkinson Disease**
Y. Manor, S. Patel, M. Menachemi, H. Shabtai, R. Ezrati-Vinacour, N. Giladi
- P230 Longterm drug-withdrawal and STN DBS reverse levodopa-induced dyskinesia**
H. Russmann, J. Ghika, P. Combremont, J.G. Villemure, J. Bogousslavsky, F.J. Vingerhoets
- P231 Individualized motor control responses to deep brain stimulation (DBS) in Parkinson's Disease (PD) characterized using neuromotor channel capacity (NMCC)**
R.M. Stewart, G.V. Kondraske, M.K. Sanghera, J.M. Desaloms, J. Vazquez
- P232 A double-blind three-month parallel study of the effects of pramipexole, pergolide and placebo on tremor in Parkinson's Disease**
P. Navan, L.J. Findley, J. Jeffs, R.K. Pearce, P.G. Bain
- P233 How cautious should we be to maximise drug therapy in Parkinson's Disease?**
A.M. Nasar, P. Dyer, A.-M. Hunter, C. Short, G. Greenwood, L. Wright
- P234 Unified Parkinson's Disease Rating Scale (UPDRS) and Webster Rating Scale (WRS) rating by psychiatry and neurology trainees**
E.M. Dunn, N.L. Read, S. Christou, R.H. Mindham, E.G. Spokes
- P235 Improvement in motor performance of patients with Parkinsons Disease by application of a physiotherapeutic scheme, based on a supervised weekly program of home-exercises**
M.E.P. Piemonte, C. Iorio, M.M. Morimoto, C. Rodrigues, V. Yamaschira, E.R. Barbosa
- P236 Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells**
T.H. Pan, P.Y. Xu, W.J. Xie, C. Hunter, J. Jankovic, W.D. Le
- P237 Parkinson's Disease: Why did subthalamic stimulation fail?**
B. Jarraya, A.M. Bonnet, C. Duyckaerts, J.L. Houeto, P. Cornu, Y. Agid
- P238 Excessive daytime sleepiness(EDS) in patients with Parkinson Disease and efficacy of deprenyl on EDS**
N. Sasaki, M. Kawakami, T. Sato, Y. Takahasi, S. Tochigi
- P239 Quetiapine in the treatment of drug-induced psychosis in patients with Parkinson's Disease**
L.J. Lopez Del Val, T. Casadevall, S. Santos
- P240 Analysis of sleep and daytime sleepiness in PD patients with and without sudden onset of sleep under dopaminergic medication**
M. Rethfeldt, J.C. Moller, Y. Korner, K. Stiasny, W. Cassel, W.H. Oertel
- P241 Application of artificial intelligence to Parkinson's Disease (PD) pharmacological therapy**
K. Honczarenko, J. Honczarenko, A. Jardzioch, J. Sierdzinski
- P242 Two trials demonstrating disease-slowing effects of ropinirole, compared with L-dopa, in early Parkinson's Disease**
A.L. Whone, J.S. Rakshi, R.L. Watts, D.J. Brooks
- P243 Low-dose apomorphine test in Parkinson's Disease: correlation of growth hormone response with striatonigral degeneration**
S. Happe, T. Tings, M. Canelo, J. Meller, W. Paulus, C. Trenkwalder
- P244 A pharmacokinetic/pharmacodynamic study on akinesia following a single intravenous infusion of piribedil in Parkinson's Disease patients**
N. Simon, N. Frey, J. Micallief, J.C. Reynier, M. Lesourd, T. Witjas
- P245 Can Fava beans monotherapy delay the use of levodopa in de novo patients with Parkinson Disease?**
M.G. Jabre, R. Rahme, B.P.W. Bejjani
- P246 Pergolide monotherapy titration in Parkinson's disease**
P. Nausieda, M. Stern, J. Hubble, D. Silver, M. Wess, R. Watts

Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

- P247 A comparative analysis of patient care in Parkinson's Disease patients in Europe. European Cooperative Network for research, diagnosis, and the therapy of Parkinson's Disease (EuroPa)**
S. V. Campenhausen, K. Berger, R. Wick, W.H. Oertel, R. Dodel, Members of EuroPa
- P248 Gait improvement after chronic bilateral subthalamic neurostimulation: a quantitative study**
M.G. Ceravolo, M. Capecci, C. Catalano, G. Ghetti, P. Pace, L. Provinciali
- P249 The efficacy and safety of Entacapone in patients with Parkinson's Disease in true practice conditions**
G. Linzasoro, L. Galiano
- P250 The effectiveness of olanzapine for treatment of hallucinations and psychosis in Parkinson's Disease**
M. Kapisyzi, V. Prifti, J. Kruja
- P251 Treatment of drooling in Parkinson's Disease and Motoneuron Disease with Botulinumtoxin-A**
T. Trottenberg, A. Lipp, D. Beyer, G. Arnold, A. Kupsch
- P252 Deep brain stimulation in late stage Parkinson's Disease: a retrospective cost analysis in Germany**
W. Meissner, D. Schreiter, J. Volkmann, G. Deuschl, J. Vesper, F. Klostermann
- P253 The effect of yohimbine on falls in patients with Parkinson's Disease and Parkinsonian syndromes**
N. Lev, E. Melamed, R. Djaldetti
- P254 The impact of levodopa on axial impairments of the patients with Parkinson's Disease: a motion analysis study during gait before and after levodopa therapy**
E. Nikfekar, S. Attfield, K.M. Kerr, C.D. Ward, D.E. Playford
- P255 Improved trunk control during stance and gait tasks with deep brain stimulation for Parkinson's Disease**
J.E. Visser, J.H. Allum, M.C. Carpenter, R.A. Esselink, J.D. Speelman, F. Honegger, B.R. Bloem
- P256 Subjective appraisal of daytime sleepiness in patients with Parkinson's Disease using ergot or nonergot dopamine agonists**
G.A. Dowling, M.J. Aminoff, J. Mastick, J.H. Carter
- P257 Can homocysteine affect superoxide dismutase activity in Parkinson's Disease?**
S. Bostantjopoulou, Z. Katsarou, G. Kyriazis, T. Fragia, G. Kiosseoglou, A. Kazis
- P258 Initial management of Parkinson's Disease**
T.A. Zesiewicz, S.N. Carter, J.F. Staffetti, P.B. Dunne, K. Barber, R.A. Hauser
- P259 CEP-1347 in Parkinson's Disease: a pilot study**
S.R. Schwid, the Parkinson Study Group
- P260 Effect of Rivastigmine on tremor in demented patients with Parkinson's Disease**
T.Y. Gurevich, H. Shabtai, A.D. Korczyn, E.S. Simon, N. Giladi
- P261 Chronic pallidal deep brain stimulation in advanced Parkinson's Disease: effects on off-period dystonia, cramps and sensory symptoms**
T.J. Loher, J.M. Burgunder, S. Weber, R. Sommerhalder, J.K. Krauss
- P262 Increased noradrenergic tone with reboxetine treatment in Parkinson's Disease (PD) and Progressive Spontanuclear Palsy (PSP): effects on motor and depressive symptoms**
A. Antonini, G. Pezzoli
- P263 Rasagiline improves quality of life in patients with early Parkinson's Disease**
S.R. Schwid, the Parkinson Study Group
- P264 A survival study of Parkinson's Disease patients switched to liquid carbidopa/levodopa**
K.A. Janko, C. Goetz, G. Stebbins
- P265 The effect of unilateral pallidotomy on motor disability, and L-DOPA induced dyskinesia in Parkinsonian marmosets**
M.M. Iravani, S. Costa, M.J. Jackson, G. Al-Bargouthy, P. Jenner
- P266 Freezing of gait in Parkinson's Disease: potential benefit from Botox injection**
M. Wieler, A. Jones, W. Martin
- P267 Acute subthalamic administration of LY293558, an AMPA glutamate antagonist, attenuates striatal TH depletion in rats with a partial lesion of the nigrostriatal pathway**
M. Bonastre, C. Marin, A. Jiménez, E. Tolosa
- P268 Long term Antiparkinsonian effects of bilateral deep brain stimulation (DBS) in advanced Parkinson's Disease (PD): a 3 years multicenter study**
M.C. Rodriguez Oroz, on Behalf of the Group of APDPMSS (Advanced Parkinson's Disease Postmarket Surveillance)
- P269 Should we operate Parkinsonian under anesthesia ?**
D. Maltete, S. Navarro, M.L. Welter, S. Roche, Y. Agid, P. Cornu
- P270 Does the dopaminergic status influence the non-motor performances of Parkinsonian patients in pre-surgical evaluation?**
P. Ollivier, T. Witjas, J.P. Azulay
- P271 Controlled trial of speech therapy and intra-parotid botulinum toxin for the treatment of salivary drooling in Parkinson's Disease**
J.D. O'Sullivan, K. Turner, L. Marks, A.J. Lees
- P272 Behavioral disorders, Parkinson's Disease and subthalamic stimulation: a prospective study**
V. Mesnage, L. Mallet, J.L. Houeto, M. Gargiulo, C. Behar, M.L. Welter
- P273 Deep brain stimulation to improve balance in Parkinson's Disease**
J.E. Visser, J.H. Allum, M.C. Carpenter, R.A. Esselink, J.D. Speelman, B.R. Bloem
- P274 Bilateral dorsal subthalamotomy in Parkinson's Disease(PD): initial response and evolution after 2 years**
L. Alvarez, R. Macias, G. Lopez, E. Alvarez, C. Maragoto, J.A. Obeso, N. Pavon, M.C. Rodriguez-Oroz, J. Juncos, J. Guridi, E.S. Tolosa, W. Koller, M.R. DeLong
- P275 Paradoxical response to levodopa and apomorphine in the Parkinson's Disease**
M.A. Garcia-Soldevilla, I. Puertas, B. Barcenilla, Y. Sayed, E. Garcia-Albea, F.J. Jiménez-Jiménez
- P276 The Lee Silverman Method in Parkinson's Disease: groups of phonotherapy**
A.E. Dias, L.L. Mansur, E.R. Barbosa
- P277 Acoustic analysis of prosody in Parkinson's Disease (PD): effect of l-dopa**
L.L. Azevedo, F. Cardoso, C. Reis
- P278 The effects of bilateral subthalamic nucleus stimulation on motor speech function in a patient with severe dysarthria and Parkinson's Disease**
D.G. Theodoros, A.M. Farrell, E.C. Ward, P. Silburn, B. Hall
- P279 Efficacy and tolerability of amantadine: a retrospective review of old and new indications at a tertiary referral center**
C. Singer, G. Uzategui, K. Lyons, A. Facca, W. Koller

Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

- P280 Cardiovascular evaluation in Parkinson Disease patients treated with selegiline**
N.N. Vanacore, A.A. Giovani, S.S. Di Rezze, V.V. Bonifati, C.C. Mastrocola, G.G. Meco
- P281 Bilateral stimulation of the subthalamic nucleus improves the late phase of a grasping to lift task in Parkinsonian patients**
F. Kopper, R. Wenzelburger, J. Herzog, H.M. Mehdorn, G. Deuschl, P. Krack
- P282 The evolution of the acute response to levodopa in Parkinson's Disease**
A.J. Hughes, A.J. Lees
- P283 The electrophysiological consequences of subthalamic nucleus and substantia nigra pars reticulata during high frequency stimulation in normal and unilateral 6-hydroxydopamine-lesioned rats**
C.H.C. Tai, T.T. Bordaoud, C.C. Gross, B.B. Bioulac, A.A. Benazzouz
- P284 Striatal expression of FosB-related transcription factors in human Parkinson's Disease: relation to L-DOPA-induced dyskinesia**
A.M. Cenci, M. Andersson, S.E. Daniel, A.E. Kingsbury, L. Kilford, A.J. Lees
- P285 Effects of pharmacological and electrical manipulation of the subthalamic nucleus on the behavior and the expression of c-fos protein in the rat**
L. Vila, R. Bouali-Benazzouz, A.L. Benabid, C. Gross, A. Benazzouz
- P286 Botulinum toxin type a as a complementary treatment in Parkinson's Disease**
M. Porta, M. Camerlingo, G. Maggioni, A. Perretti, E. Dell'Anna, C. Ferrante
- P287 Motor complications in young-onset Parkinson's Disease are reduced by early therapy with a dopamine (DA) agonist**
I. Zamarbide, F. Alonso-Frech, M. Rodriguez-Oroz, J. Obeso
- P288 Effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on dual task performance in Parkinson's Disease**
T. Schubert, C. Preuschhof, J. Volkmann, M. Mehdorn, G. Deuschl
- P289 Low-dose apomorphine test in Parkinson's Disease: Does growth hormone response depend on previous treatment with levodopa?**
T. Tings, S. Happe, M. Canelo, W. Wuttke, W. Paulus, C. Trenkwalder
- P290 Pharmacokinetic evaluation of Cabergoline treatment in Parkinson's Disease**
T. Hatano, Y.S. Hatano, Y. Okuma, N. Hattori, Y. Mizuno
- P291 Chronic intraputaminial infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's Disease**
N.K. Patel, P. Heywood, G.R. Hotton, D.J. Brooks, C.N. Svendsen, S.S. Gill
- P292 Tolerability and safety of buccal JP-1730: A phase I study in healthy male volunteers**
J.M. Peltonen, R. Huupponen, O. Ahokoski, H. Merivuori, J.M. Savola, P. Juujarvi
- P293 Apomorphine pharmacokinetic-pharmacodynamic correlations following single and repeated subcutaneous injections in patients with Parkinson's Disease**
P.B. Bottini, A. Shaw, M.-Y. Huang, J.H. Sherry
- P294 Population pharmacokinetic (PPK) modeling and evaluation of the relationship between sumanirole exposure and orthostatic hypotension (OH) in Parkinson's Disease (PD) patients**
G.A. DSouza, J.S. Owen, J.A. Passarell, K. Liolios, B.J. Carel, E.C. Wright
- P295 Safety and efficacy of piribedil as adjunctive treatment for Parkinson's Disease: 6 months placebo controlled study**
N. Fedorova, Z. Jamrozik, A. Takacs, E. Ruzicka, S. Del Signore, H. Kwiecinski
- P296 Intraoperative electrophysiological characterization of neurons encountered in electrode trajectories aimed for the subthalamic nucleus (STN) in patients undergoing deep brain stimulation (DBS) for the treatment of Parkinson's Disease (PD)**
M.K. Sanghera, J.M. Desaloms, R.M. Stewart, R.K. Simpson
- P297 The effect of melatonin treatment on sleep and sleepiness in dopamine agonist treated patients with Parkinson's Disease**
G.A. Dowling, M.J. Aminoff, J. Mastick, E. Colling, J.H. Carter, C.M. Singer
- P298 Treatment of dopaminergic psychosis with Quetiapine. Uses and secondary effects**
M. Alvarez, J. Chacon, E. Duran, D. Paramo, R. Vahi
- P299 Fluoxetine in Parkinson's Disease patients**
E. Dzoljic, M. Mijajlovic, I. Kovacevic, A. Andjelkovic, M. Pokrajac, V. Kostic
- P300 Non-compartmental analysis (NCA) and drug interaction analysis using population pharmacokinetics (PPK) of sumanirole in Parkinson's Disease (PD) patients**
G.A. DSouza, J.S. Owen, K. Liolios, E. Didier, B.J. Carel, E.C. Wright
- P301 Reversion of shortening in the duration of levodopa-induced motor response by adenosine A2A antagonists is associated to changes in striatal dynorphin mRNA expression in Hemiparkinsonian rats**
J. Bové, J. Serrats, G. Mengod, R. Cortés, E. Tolosa, C. Marin
- P302 A tolerability study of intranasal apomorphine powder (5mg), in subjects with Parkinson's Disease and motor fluctuations, over a seven day period: a phase two study**
M. Wickremaratchi, S. Hadjikoutis, P. Lambert, S. Freear, K. Wareham, R. Weiser
- P303 Multiple developmental forms of Parkinson's disease**
P. Riederer, P. Foley
- P304 Utility of a guide dog to facilitate gait in Parkinson's Disease**
A.L. Adkin, W.E. McIlroy, J.M. Miyasaki
- P305 Medications reduce errors in antisaccade tasks in Parkinson's Disease patients**
A.E. Cain, S.C. Amador, K.A. Briand, A. Alrefai, M.C. Schiess, A.B. Sereno
- P306 Testosterone replacement for testosterone deficient male Parkinson Disease patients: results of a pilot study**
M.S. Okun, B.L. Walter, W.M. McDonald, J.L. Tenover, J. Green, J.L. Jorge
- P307 Treatment of hypophonia with collagen vocal fold augmentation in patients with Parkinson's Disease**
A.N. Hill, J. Jankovic, D.P. Vuong, D. Donovan
- P308 Domperidone-induced reversible hyperprolactinemia and sexual dysfunctioning in a patient with Parkinson's Disease: A case report**
J. Lutke Farwick, T. van Laar, R. Bruggeman, K. Leenders
- P309 Changes in quality of life resulting from treatment for persons with early Parkinson's Disease: sumanirole versus placebo**
J. DuChane, C. Jenkinson

Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

- P310 Efficacy of Aricept in the treatment of Parkinson's Disease dementia syndrome**
R. Duchidze, E. Devidze
- P311 Nighttime cabergoline substitution for daytime sleepiness induced by dopamine agonists in Parkinson's Disease**
P. Del Dotto, G. Gambaccini, S. Agostini, S. Bernardini, U. Bonuccelli
- P312 Kinematic analysis and segmentation of targeted forearm movements in Parkinson's Disease: quantifying dysfunction and evaluating treatment efficacy**
K.E. Novak, E.K. Nenonene, L.P. Bernstein, T.W. Eller, S.M. Vergenz, M. Rezak
- P313 Home monitoring in patients with advanced Parkinson's Disease: a feasibility study. The CHRONIC Consortium**
A. Antonini, C. Castiglioni, J. Aguilo', R. Farre', A. Falco, G. Pezzoli
- P314 Mirtazapine in levodopa-induced dyskinesias**
E. Fabrizio, N. Vanacore, L. Pratesi, S. Di Rezze, A. Alessandri, G. Mecco
- P315 Stereotaxic intrastriatal implantation of retinal pigment epithelial cells attached to gelatin microcarriers: a 12-month, open-label trial in six advanced Parkinson Disease (PD) patients**
R.L. Watts, N.P. Stover, M.L. Cornfeldt, A.W. Schweikert, R.C. Allen, R.E. Bakay
- P316 Long-term treatment with the dopamine agonist pramipexole without levodopa: determination of predictive factors for response in patients with early Parkinson's Disease**
B. Musch, L.D. Borchert, W. Spalding
- P317 Switching on to switching off: the development of a definition and diary to assist people with Parkinson's Disease to identify and monitor wearing-off complications**
A. Bowron
- P318 [¹⁸F]FDOPA PET and clinical features in a PD patient with manganese exposure**
B.A. Racette, J. Antenor, V. Kotagal, T. Videen, S. Moerlein, J. Goldman
- P319 To evaluate the latency of sublingual atropine and the long-term effect in the management of sialorrhea in Parkinson's Disease**
P. Cotton, B. Hopcutt, M. Flynn
- P320 Improvement of performance in daily life activities in patients with Parkinson's Disease by using declarative memory-guided sequences of instructions. II. A 4-year follow-up study**
M.E.P. Piemonte, E. Okamoto, M. Morimoto, G.F. Xavier
- P321 The role of the Parkinson's Disease nurse specialist in the multidisciplinary management of fluctuating Parkinson's Disease patients**
E. Williams
- P322 Effect of chronic STN deep brain stimulation on the sense of smell in patients with Parkinson's Disease**
S. Joergens, C. Dohle, M. Pichatzek, S. Kelm, N. Allert, J. Volkmann
- P323 Sumanitrole is a promising new agent in the treatment of Parkinson's Disease**
B. Gomez-Mancilla, Sumanitrole Study Group, K.A. Selzer, K. Chapman, M. Wang, S. Simpson
- P324 The Total Functional Capacity Scale: a useful and rapid assessment tool for monitoring Parkinson's Disease disability**
M.A. Stacy, R.A. Hauser, J.E. Samanta, T.A. Zesiewicz, D.L. Sebade, C. Cimino
- P325 Tolerability profile of sumanitrole in advanced Parkinson's Disease**
B. Gomez-Mancilla, K.A. Selzer, K. Chapman, M. Wang, S. Simpson, Sumanitrole Study Group
- P326 Assessment of the rate of progression in Parkinson's Disease by [^{99m}Tc]TRODAT-1 SPECT imaging**
Y.H. Weng, C.S. Lu, T.C. Yen
- P327 An observational survey of the therapeutic value of entacapone in 76 "natural " Parkinson's Disease patients in daily clinical practice in Switzerland**
A.M. Hew-Winzeler, I. Zangger, M. Huebschen
- P328 Treatment strategies in Parkinson's Disease patients in daily clinical practice - correlation with published treatment recommendations in Switzerland**
I. Zangger, A.M. Hew-Winzeler, M. Huebschen
- P329 Comparison of two methods of subthalamic nucleus targeting: direct anatomical vs. AC-PC measurements**
C.T. Pappas, V.L. Wheelock, K.A. Sigvardt
- P330 Application of clinical trial simulation to evaluate the ELLDOPA trial design**
P.L.S. Chan, N.H.G. Holford, J.G. Nutt, Parkinson's Study Group
- P331 Disease progression and increased levodopa efficacy with time in Parkinson's Disease**
N.H.G. Holford, P.L.S. Chan, Y.Y. Lee, J.G. Nutt
- P332 Glutathione does not improve Parkinson's Disease**
D.L. Kreitzman, N.V. Nadel, S.H. Isaacson
- P333 Assessment of long-lasting efficacy of cabergoline (CBG) on Parkinsonian akinesia using actigraphy**
S. Katayama, K. Watanabe
- P334 The Short Parkinson's Evaluation Scale (SPES) in routine use in a Pramipexole study**
P.H. Kraus, P. Martinez Martin, U. Bonicelli, H. Marinus, J.J. van Hilten, M. Rabey
- P335 Motor and non motor off-periods in Parkinson's Disease : various clinical forms and long-term Apomorphine pump treatment**
J.E.G. Vanderheyden
- P336 Postural instability in Parkinson's Disease: immediate and persistent effects of bilateral subthalamic deep brain stimulation (B-STN DBS)**
H. Bronte-Stewart, G. Heit, T. Courtney
- P337 Gait analysis in de novo and advanced Parkinson's Disease: influence of acute L-dopa administration on spatiotemporal, kinematic e kinetic parameters studied by a 3D computerised system**
M. Guidi, C. Catalano, O. Scarpino, P. Pace, G. Ghetti
- P338 An item analysis of the Unified Parkinson Disease rating scale (UPDRS) in individuals with early Parkinson's Disease (PD) treated initially with pramipexole or levodopa: a sub analysis of the 4-year CALM-PD trial**
K.M. Biglan, R.G. Holloway, I. Shoulson, the Parkinson's Study Group

Poster Sessions

Poster Session 3 - Tuesday, November 12

7:00 am - 8:30 pm

Poster numbers 339-520

Parkinson's Disease

- P339** Metronome stimulation in Parkinson's Disease patients with gait freezing
E. Cubo, C.G. Moore, C.G. Goetz
- P340** The impact of L-dopa-induced dyskinesia on direct health care and non-health care costs associated with patients with Parkinson's Disease: a prospective European study
M.R. Pechevis, C.E. Clarke, P. Vieregge, M. Ziegler, C.T. Voinet
- P341** Turning difficulties associated with Parkinson's Disease (PD)
E. Stack, A. Ashburn, H. Rassoulian
- P342** Validity and reliability of the video-based Standing-start 180° Turn Test (SS-180) in adults with and without Parkinson's Disease (PD)
E. Stack, A. Ashburn, H. Rassoulian
- P343** The Parkinson's Early Intervention Program (PEIP): theoretical model and evaluation of a self-management program to facilitate improved quality of life for people with Parkinson's
R.A. Gruber, M.P. Huijbregts
- P344** Motor fluctuations and quality of life in Parkinson's Disease
S. Chapuis, O. Metz, L. Gerbaud, F. Durif
- P345** Activities of daily living score in UPDRS is an appropriate indicator of health-related quality of life in Parkinson's Disease
T. Haapaniemi, K. Sotaniemi, E. Taimela, EcoPD Study Group
- P346** Differential diagnosis of Parkinson Disease via visuo-motor testing is confirmed by Quantitative SPECT (QSPECT) imaging
M. Schwartz, D. Groshar, S. Hoeherman
- P347** Shaking Palsy or Amyotrophic Lateral Sclerosis: the case of the Count of Lordat by James Parkinson
P. Nisipeanu, R. Inzelberg
- P348** Neuropsychiatric symptoms in Parkinsonian patients: clinical and anatomical correlations
F. Viselli, A. Monge, N. Modugno, M. Paradiso, F. Stocchi, S. Ruggieri
- P349** Healthcare utilization and drug therapy in a cohort of Parkinson's Disease ambulatory patients
D. Michielotto, S. Sacco, E. Martignoni, M. Cosentino, D. Calandrella, G. Riboldazzi, O. Leoni, C. Oria, S. Lecchini, G. Nappi, G. Frigo
- P350** Blink rate as a mechanism to monitor motor fluctuations in Parkinson's Disease
E.A. Fazzini, M.R. Wells
- P351** Psychotic symptoms induced by DBS of the STN in a patient with Parkinson Disease: a case report
S.A. Abbasi, B. Cook
- P352** Autonomic dysregulation in conjunction with freezing of Parkinsonian patients: an ambulatory monitoring study
J. Jörg, S. Jock, W. Boucsein, F. Schaefer
- P353** Late-onset autosomal dominant familial Parkinson Disease. Clinico-pathological study of Western Nebraska family (Family D)
Z.K. Wszolek, R.F. Pfeiffer, Y. Tsuboi, R.D. McComb, R.J. Uitti, D.W. Dickson, A. Strongosky, M. Farrer, T. Gasser
- P354** Inter- and intra- rater reliability and discriminative ability of five measures of bradykinesia in subjects with and without Parkinson's Disease
R.A. Gruber, J. Marinus, M. Visser, J.J. van Hilten
- P355** Epidemiology of Parkinson's Disease in Iwamizawa City, Japan
K. Itoh, F. Moriwaka, K. Kuroshima, S. Kikuchi, K. Tashiro
- P356** Repetitive trans-cranial magnetic stimulation in Parkinson's Disease: a prospective study of 33 cases
C.A. Mhiri, I. Feki, F. Belahsen, M. Jabali, F. Choyakh, N. Zouari
- P357** Clinical tests for postural instability in patients with Parkinson's Disease
M. Visser, J. Marinus, B.R. Bloem, H. Kijes, B.M. van den Berg, B.J. van Hilten
- P358** Multiple Developmental Forms of Parkinson's Disease
P. Riederer, P. Foley
- P359** A study on dopamine D₂ receptor occupancy after multiple oral administration of SLV 308 to healthy male volunteers by means of Positron Emission Tomography using ¹¹C-raclopride
M.H. de Vries, B.J. Hedeman Joosten, M.B. Hesselink, A.A. Winsemius, A. Wall, M. Bergström
- P360** Investigation into the significance of ¹⁸F-desmethoxyfallypride-positron emission tomography in the differential diagnosis of Parkinson Syndromes
S. Haegele, F. Roesch, M. Schreckenberger, T. Vogt
- P361** Mental disorders in Parkinson's Disease: treatment with quetiapine
C. Pacchetti, F. Mancini, S. Cristina, R. Zangaglia, E. Martignoni, G. Nappi
- P362** Tonic and phasic REM sleep features in Parkinson's Disease (PD) with and without REM sleep behavior disorder (RBD)
J.-F. Gagnon, M.-A. Bedard, L. Fantini, S. Rompre, M. Panisset, J. Montplaisir
- P363** High resolution MRI measurement of substantia nigra area in Parkinson's Disease: a pilot longitudinal study on the impact of chronic treatment with L-DOPA or pergolide
A. Righini, M. Canesi, F. Valzania, R. Agati, D. Bravi, G. Pezzoli
- P364** Skin biopsy in patients with Parkinson's Disease: a novel diagnostic tool for evaluation of autonomic impairment
R. Djaldetti, R. Dabby, M. Shachamurov, T. Treves, E. Melamed, I. Avinoach
- P365** The Parkinson's Disease Sleep Scale (PDSS): a new instrument for assessment of sleep, nocturnal disability and daytime sleepiness in Parkinson's Disease
S. Pal, K.R. Chaudhuri, C. Trenkwalder, A. Forbes, K. Bridgman, A. DiMarco
- P366** Motor cortical disturbances in Parkinson Disease: an event-related desynchronization study
E. Labyt, F. Cassim, J.-L. Bourriez, D. Devos, J.-D. Guieu, P. Derambure, L. Defebvre, A. Destee
- P367** Cognitive and regional cerebral blood flow predictive factors of evolution in newly diagnosed Parkinson's Disease patients
L. Defebvre, K. Dujardin, A. Duhamel, P. Lecouffe, M. Steinling, A. Destee
- P368** Sleep-wake cycle and visual hallucinations in Parkinson's Disease
R. Manni, C. Pacchetti, M. Terzaghi, I. Sartori, R. Zangaglia, G. Nappi
- P369** Standardized training tools for the UPDRS activities of Daily Living scale: clinimetric study of a teaching program
C.G. Goetz, P.A. LeWitt, M. Weidenman, P. Quarg

Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

- P370 Cognitive decline and Levo-DOPA responsive Parkinsonism in a longitudinal cohort**
S. Gimeno, S. Diez, R. Gantcheva, B. Bonnefoi-Kyriacou, F. Viallet
- P371 Measurement properties of two common health status questionnaires in Parkinson's Disease**
P. Hagell, D. Whalley, S.P. McKenna, O. Lindvall
- P372 Sequence analysis of promoter region of the brain-derived neurotrophic factor gene in Parkinson's Disease**
A. Parsian, R. Sinha, B. Racette, J.S. Perlmutter
- P373 Elevated taste recognition thresholds in patients with Parkinson's Disease**
M. Welker, D. Small, T. Simuni
- P374 The poetical Parkinsonian: professor and patient**
G.D. Hardacre
- P375 Evaluation of timed tests in Parkinson's Disease**
P.J. Garcia Ruiz, E. Meseguer, V. Sanchez
- P376 Cognitive functions in people with Parkinson's Disease [PWPD] and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy**
I. Rektorova, I. Rektor, M. Bares, V. Dostal, E. Ehler, Z. Fanfrdlova
- P377 Body weight gain in patients with Parkinson's Disease and deep brain stimulation**
M. Barichella, A.M. Marczevska, C.B. Mariani, A. Landi, A. Vairo, G. Pezzoli
- P378 The association of Parkinson's Disease and bone fractures: an assessment of risk**
T.W. Downes, R. Genever, P. Medcalf
- P379 Visual Hallucination and thalamic inclusions in Parkinson's Disease**
T. Fukuda, J. Takahashi, J. Tanaka
- P380 Frequency of MTHFR gene polymorphism in Parkinson's Disease**
A. Sazci, I. Kara, E. Ergul, G. Kaya, G. Kilic
- P381 Body weight changes in patients with Parkinson's Disease received Pramipexole**
I.G. Smolentseva, B. Tserensodnom, O.S. Levin, N.V. Fedorova, V.N. Shtok
- P382 A genome wide linkage disequilibrium screen for Parkinson's Disease**
T. Foltynie, S.J. Sawcer, S.J. Lewis, A. Jonasdottir, A. Hicks, R.A. Barker
- P383 Validation of the French version of the PDQ-8, a short quality of life (QOL) questionnaire for Parkinson's Disease (PD), and its sensitivity to change by dopamine agonists**
F. Tison, J.-L. Thibault, O. Blin, P. Pollack, J.-L. Montastruc, P. Cesaro
- P384 Somatosensory and motor evoked potentials in Parkinson's Disease**
S. Choi, Y.K. Minn, S.R. Lim, J.H. Lee
- P385 Cognition and Parkinson Disease**
M.C. Garrett, M.R. Fonseca, M.J. Rosas, F. Simoes, S. Vieira
- P386 Reliability of limits of stability measures in Parkinson's Disease**
E.J. Protas, M. Thomas, I.T. Cunha, K.S. Caroline, S. Wankadia, J. Jankovic
- P387 The influence of depression on executive functions in early Parkinson's Disease**
J. Uekermann, I. Daum, S. Peters, B. Wiebel, H. Przuntek, T. Mueller
- P388 Loss of muscle mass and strength correlates with severity of Parkinson's Disease**
E.Y. Uc, R.L. Rodnitzky, W.J. Evans
- P389 Putaminal volume in Parkinson's Disease**
M. Iijima, Y. Iizuka, T. Maehara, N. Hattori, Y. Mizuno
- P390 How neurologists and caregivers agree about disability of patients with Parkinson's Disease (PD)? The case of the UPDRS-Section II**
P. Martinez-Martin, J. Benito-Leon, F. Alonso, M.J. Catalan, M. Pondal, I. Zamarbide
- P392 Health-related quality of life evaluation by proxy in Parkinson's Disease. An approach through the PDQ-8 and the EuroQol-5D**
P. Martinez-Martin, J. Benito-Leon, F. Alonso, M.J. Catalan, M. Pondal, I. Zamarbide
- P393 Prevalence of *Parkin* gene mutations and deletions in idiopathic Parkinson's Disease**
R. Sinha, B. Racette, J.S. Perlmutter, A. Parsian
- P394 Social costs of Parkinson Disease in Italy**
G. Pezzoli, A. Zecchinelli, F. Caprari, P. Ponzi, A. Bonetti
- P395 Head trauma preceding Parkinson's Disease (PD): a case-control study**
J.H. Bower, D.M. Maraganore, B.J. Peterson, S.K. McDonnell, J.E. Ahlskog, W.A. Rocca
- P396 Gaucher's disease type 1 and Parkinson's Disease**
L.L. Capus, S.S. Zambito Marsala, M.M. Zorzon, M.M. Gioulis, C.C. Martini, B.B. Bembi
- P397 A clinical comparison of Icelandic familial Parkinson's Disease (PD) patients who contribute to a locus on chromosome 1p32 and those who don't**
S. Sveinbjörnsdóttir, A. Hicks, T. Jónsson, H. Pétursson, A. Kong, J.R. Gulcher, K. Stefansson
- P398 Electromyographic profiles of gait at the onset of freezing in Parkinson's Disease**
A.M. Nieuwboer, R. Dom, W. De Weerd, K. Desloovere, S. Vandegheluwe
- P399 Subclinical pulmonary dysfunctions in Parkinson's Disease**
P.K. Pal, T.N. Sathyaprabha, T. Prasad, K. Thennarasu
- P400 Obsessive-compulsive disorder in idiopathic Parkinson's Disease: Frequency and case report**
A.S. Pinto, A.F. Nascimento, A.F. Maia, E.R. Barbosa, P.R. Menezes, E.C. Miguel
- P401 Gait dynamics in subjects with freezing of gait and Parkinson's Disease: Increased variability during usual walking**
J.M. Hausdorff, J.D. Schaafsma, J. Balash, A. Bartels, T. Gurevich, N. Giladi
- P402 Clinical characterization of freezing of gait and its response to levodopa in Parkinson's Disease**
N. Giladi, S.D. Joanna, B. Jacob, G. Tanya, A. Bartels, H.M. Jeffrey
- P403 The relation between paroxysmal gait disturbance type 1 (freezing of gait) and akinesia in Parkinson's Disease**
N. Giladi, A. Bartels, Y. Balash, J. Schaafsma, T. Gurevich, D. Comanester
- P404 Impact of parental illness on adolescent and adult children of patients with Parkinson's Disease**
M. Jahanshahi, D. Morley, N. Quinn, A. Schrag
- P405 Evaluation by SF 36 of cognitive-behavioural therapy on eight Parkinson's Disease patients and their spouses. Preliminary results**
J.P.J. Brandel, A.A. Schneider, M.M. Ziegler, P.P. Mouglin, H.H. Antaki

Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

- P406 Performance memorization for Parkinson's Disease: a simple approach to help patients to perform daily life activities**
M.E.P. Piemonte, E. Okamoto, M. Morimoto, G.F. Xavier
- P407 Lewy body cortical involvement may not always predict dementia in Parkinson's Disease**
C. Colosimo, A.J. Hughes, L. Kilford, A.J. Lees
- P408 Olfactory function in Parkinson's Disease (PD): Long-term follow-up of de-novo PD patients**
A. Muller, H. Reichmann, A. Livermore, T. Hummel
- P409 EuroPa - using the advantages of a multinational network to improve clinical research and treatment of Parkinson's Disease (PD) in Europe**
R.P. Wick, W. Poewe, C. Sampaio, O. Rascol, R. Dodel, W.H. Oertel
- P410 Can cardiac C11-HED-PET help to distinguish between Parkinson's disease and Multiple System Atrophy?**
C. Schrader, T. Peschel, H. Kolbe, R. Dengler, W. Knapp, G. Berding
- P411 Measuring the rate of progression of early Parkinson's Disease over a 5 years period with b-CIT SPECT**
W. Pirker, I. Holler, W. Gerschlager, S. Asenbaum, G. Zettinig, T. Bruecke
- P412 Frontal lobe dysfunction in Parkinson's Disease**
S.S. Ochudlo, G.G. Opala, A.A. Gorzkowska, B.B. Jasinska-Myga, M.M. Arkuszewski, J.J. Siuda
- P413 Lewy bodies and neuronal degeneration in preclinical stage of Parkinson's Disease**
A. Krygowska-Wajs, D. Adamek, A. Szczudlik, J. Kaluza
- P414 Analysis of direct costs in the treatment of Parkinson's Disease**
S. Keller, T. Kessler, D. Bremen, W. Jost
- P416 Working memory functioning in mild and moderate Parkinson's Disease patients**
M.K. York, E.C. Lai, H.S. Levin, R.G. Grossman
- P417 Are there differences in motor and cognitive disturbances in Parkinson's Disease patients with and without psychosis?**
O.S. Levin, T.V. Naimushina, I.G. Smolentseva
- P418 Smell identification ability in twins discordant for Parkinson's Disease (PD)**
C. Marras, S.M. Goldman, P. Barney, D.A. Aston, M. Korell, K. Comyns
- P419 Quality of life in patients with Parkinson's Disease**
J.W. Kim, S.K. Hong
- P420 Using the EuroQoL(EQ-5D) to derive patients preferences from the UPDRS**
U. Siebert, A. Spottke, A. Schrag, N. Quinn, W.H. Oertel, R. Dodel
- P421 Postural adjustment to tilt in patients with Parkinson's Disease in on and off state: preliminary results**
N. Abou Azar, C. Van Nechel, D. Zegers de Beyl
- P422 Dopamine receptor and hypocretin gene polymorphisms in Parkinson's Disease (PD) patients reporting "sleep attacks"**
I. Rissling, J.C. Moller, Y. Korner, O. Bandmann, K. Stiasny, W.H. Oertel
- P423 Late-Onset Movement Disorder caused by filterable forms of *Nocardia asteroides* in the midbrain of mice**
C. Kadoya, S. Kohbata
- P424 An investigation into the behavioral and neurochemical bases of morphosyntactic language impairments in Parkinson's Disease**
W.L. Arnott, P.A. Silburn, H.J. Chenery, B.E. Murdoch
- P425 Performance on a computerized reaction time test predicts incidental Lewy bodies**
G.W. Ross, H. Petrovitch, R.D. Abbott, C.M. Tanner, D.G. Davis, J.S. Nelson
- P426 Associations of fatigue in Parkinson's Disease**
M.J. Steiger, R. Davies, J. Brooks, H. Tyne, G.A. Baker
- P427 Kinematics analysis of the movements of the hand (tapping test) by Hilbert transformed in patient with Parkinson Disease and controls**
P. Chana, H. Gonzalez, A. Gutierrez, N. Barrientos
- P428 Validation of a screening questionnaire for Parkinson's Disease in Singapore**
L.C. Tan, A.K. Tan, S.-M. Saw, C.-Y. Hong, W.-L. Lee, N. Venketasubramanian
- P429 Multivariate analysis of quality of life in Parkinson's Disease**
J. Slawek, M. Derejko
- P430 Quality of life in long-lasting Parkinson's Disease**
A. Friedman, M. Zach
- P431 Tremor at diagnosis is predictive of slower disease progression in Parkinson's Disease: an ¹⁸F dopa PET study**
A.L. Whone, C. Brefel-Courbon, R.Y. Moore, O. Rascol, D.J. Brooks
- P432 Changes in digestive tract function in Parkinson's Disease (PD) patients receiving Anti-Parkinson agents**
M. Hotta, S. Nemoto, Y. Nomura, T. Suzuki, T. Kamo
- P433 The posturography study of Parkinson's Disease patients**
G.-H. Lee, J.-I. Kim
- P434 Validity of family history data on Parkinson's Disease: evidence for a family information bias**
A. Elbaz, S.K. McDonnell, D.M. Maraganore, D.J. Schaid, J.H. Bower, W.A. Rocca
- P435 The Ali Project: a web-based database for Parkinson's Disease**
K. Thomas, DO, J. Samanta, MD, P. Mahant, MD, K. Williamson, MPH, M. Stacy, MD
- P436 Healthcare utilization and economic impact of Parkinson's Disease**
A. Spottke, R. Martin, K. Berger, O. Machat, W.H. Oertel, R. Dodel
- P437 Predictive factors of falls in elderly subjects and patients with Parkinson's Disease**
G. Kemoun, L. Defebvre, E. Watelain, A. Destee, J.-D. Guieu
- P438 Executive functions, verbal and visual memory in patients with early and stable Parkinson's Disease - effect of levodopa**
S. Singh, S. Shesadri, M. Behari
- P439 Modulation of motor performance by mood in Idiopathic Parkinson's Disease (IPD): time to wake up**
E. Pourcher, P. Chabot, A. Beausoleil
- P440 A pilot study of the effects of Parkinson's Disease on golf**
J.G. Carpenter, J.R. Rinker II, K.D. Sethi
- P441 An evaluation of pull test technique in assessing postural instability in Parkinson's Disease**
R.P. Munhoz, J.-Y. Li, P. Piboolnurak, A. Constantino, S. Fahn, A.E. Lang

Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

- P442 Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's Disease**
H. Chen, S.M. Zhang, M.A. Hernan, M.A. Schwarzschild, W.C. Willett, G.A. Colditz
- P443 Case-only analysis of gene-environment interactions in Parkinson's Disease: preliminary results**
G. De Palma, P. Mozzoni, E. Scotti, L. Buzio, S. Pizzarotti, A. Scaglioni
- P444 Early onset of Parkinson's Disease among subjects professionally exposed to either solvents or metals**
L. Buzio, G. De Palma, P. Mozzoni, A. Negrotti, A. Scaglioni, S. Calzetti
- P445 Anatomic-pathologic findings in a case of Parkinsonism associated with n-hexane exposure**
M.G. Canesi, C. Galli, A. Righini, R. Benti, M. Rango, M. Gambacorta
- P446 Risk factors for dementia in Parkinson's Disease**
G. Opala, B. Jasinska-Myga, S. Ochudlo, J. Tustanowski
- P447 Correlation of firing rates and patterns in subthalamic neurons of Parkinsonian patients with disease severity**
F. Carella, W.D. Hutchison, J.O. Dostrovsky, A.E. Lang, A.M. Lozano
- P448 Screening of Social Anxiety in Parkinson's Disease**
D. Uluduz, N. Kocabasoglu, H. Apaydin, S. Ozekmekci, E. Erginoz
- P449 Apolipoprotein E gene polymorphism and dementia in Parkinson's Disease**
G. Opala, B. Jasinska-Myga, S. Ochudlo, J. Tustanowski, M. Arkuszewski
- P450 Motor sequence learning in normal control subjects and subjects with Parkinson's Disease: differing effects of active attentional control**
M.E.P. Piemonte, M. Voos, G.F. Xavier
- P451 Prospective study of anxiety and risk of Parkinson's Disease**
M.G. Weisskopf, H. Chen, I. Kawachi, A. Ascherio
- P452 PARK7 linkage analysis of Autosomal recessive Parkinson's Disease**
K. Sato, H. Yoshino, Y. Sasaki, H. Nobutaka, Y. Mizuno
- P453 Immunohistochemical study for ER stress and accumulation of Pael-r in autosomal recessive juvenile Parkinsonism with *Parkin* gene mutations**
M. Takanashi, N. Hattori, Y. Imai, H. Inoue, R. Takahashi, Y. Mizuno
- P454 Consolidation in human motor memory does not depend on sleep organisation in Parkinson's Disease**
P. Hoffmann, B. Hauptmann, G. Arnold, R. Khatami
- P455 Early diagnosis of Parkinson's Disease at the primary care level by a questionnaire**
I. Rissling, A. Metz, G. Hoeglinger, V. Ries, E. Baum, W.H. Oertel, A. Heinermann, G. Deuschl, S. Spieker
- P456 Clinical-electrophysiological correlations between the UPDRS and the movement-related neural activity of the human subthalamic nucleus in Parkinson's Disease**
G. Foffani, A. Priori, the DBS Milano Group (Policlinico, San Paolo, Politecnico)
- P457 A multicentric observational study on the prevalence of REM sleep behaviour disorder in an Italian population of idiopathic Parkinson's Disease**
C. Scaglione, L. Vignatelli, R. Marchese, A. Negrotti, S. Bernardini, G. Coccagna
- P458 Do Parkinsonian patients walk in falling?**
M.-L. Welter, M.C. Do, U. Rodriguez Ortiz, O. Messouak, A.-M. Bonnet, Y. Agid
- P459 Seborrhea and constipation in early Parkinson's Disease (PD)**
P. Vrentas, G. Tagaris, S. Sameli, V. Panayiotopoulou, A. Antelli, G. Moukas
- P460 Family-based association study of cigarette smoking and Parkinson Disease**
W.K. Scott, R.A. Caltagirone, R.M. Carney, S.K. Dills, J.M. Stajich, J.M. Vance
- P461 Polymorphism of the apolipoprotein E gene and plasma cholesterol concentrations in Parkinson's Disease patients**
G. Opala, B. Jasinska-Myga, S. Ochudlo, J. Tustanowski, M. Arkuszewski
- P462 Acoustic analysis of prosody in Parkinson's Disease (PD): comparison with normal controls**
L.L. Azevedo, F. Cardoso, C. Reis
- P463 Assessment of health-related quality of life in Parkinsonian patients. Can a short questionnaire be useful?**
Z. Katsarou, S. Bostantjopoulou, A. Kafantari, G. Kiosseoglou, E. Peitsidou, G. Mentenopoulos
- P464 The influence of nuclear encoded mitochondrial complex I single nucleotide polymorphisms (SNPs) on the age of onset (AOO) of Parkinson's Disease (PD)**
G.D. Mellick, J.A. Prince, A.J. Brookes, P.A. Silburn
- P465 Mortality in patients with Parkinson's Disease: a Tyrolean cohort study**
A. Diem, K. Seppi, E. Trinkla, W. Oberaigner, G. Wenning, W. Poewe
- P466 Mitochondrial Complex II/III and Complex IV activities in familial and sporadic Parkinson's Disease**
H.A. Hanagasi, D. Ayribas, K. Baysal, M. Emre
- P467 Occurrence of Parkinson's Disease in an admixed population of European and Indian origin**
M. Ragothaman, U.A. Murgod, G. Gururaj, D. Subbukrishna, U.B. Muthane
- P468 b-CIT SPECT and clinical characteristics in two Parkinson's Disease patients associated with camptocormia**
I. Holler, G. Dirnberger, W. Pirker, E. Auff, W. Gerschlager
- P469 Pulmonary function tests in Idiopathic Parkinson's Disease**
S.-B. Koh, B.-J. Kim, M.-K. Park, K.-W. Park, D.-H. Lee
- P470 Important influences of the developing role of the Parkinson's Disease Nurse Specialist (PDNS)**
C. Noble, D. Lewin, L. Osborne
- P471 Development and validation of a screening tool for epidemiological studies in Parkinson's Disease in a multi-linguistic society with varying levels of literacy**
U.B. Muthane, M. Ragothaman, U.A. Murgod, D.K. Subbukrishna, G. Gururaj
- P472 Parkinson's Disease as possible cause of "idiopathic" olfactory dysfunction**
U. Sommer, K. Cormann, A. Mueller, J. Frasnelli, T. Hummel, H. Reichmann
- P473 The Competence Network Parkinson in Germany**
K. Eggert, S. Spieker, P. Odin, G. Deuschl, T. Gasser, W. Oertel
- P474 Clinical predictivity in Parkinson's Disease**
E. Gasparoli, G. Polesello, T. Scaravilli, L. Santelli, F. Bracco
- P475 Clinical phenotypes of two families with *Parkin* gene mutations: comparison of the clinical phenotypes of monozygotic twin and two sibling**
K. Noda, N. Hattori, M. Yokochi, T. Kondoh, Y. Mizuno

Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

- P476 The relation between hypokinesia and bradykinesia studied with continuous ambulatory multi-channel accelerometry**
J.I. Hoff, N.L. Keijsers, S.C. Gielen, B.J. van Hilten
- P477 Paroxysmal exercise-induced dystonia as the initial manifestation of Parkinson's Disease**
M. Bozi, K.P. Bhatia
- P478 Parkin ubiquitination activity *in vitro* - from a study using CDCrel-1**
T. Kitami, K. Sato, T. Suzuki, N. Hattori, K. Tanaka, Y. Mizuno
- P479 Expression level of the Ala30Pro alpha-synuclein mutant allele correlates with the clinical phenotype in familial Parkinson's Disease**
H. Kobayashi, R. Kruger, K. Markopoulou, Z. Wszolek, B. Chase, H. Taka
- P480 Cigarette smoking in Parkinson's Disease. Influence on disease progression**
G. Alves, M. Kurz, D. Aarsland, J.P. Larsen
- P481 A pilot observational study of phenotypic differences between Indian origin Parkinson's Disease patients in London, UK and Calcutta, India**
L.S. Appiah-Kubi, J.M. Nott, S. Sen, S. Das, K.K. Bhattacharya, K.R. Chaudhuri
- P482 Pain and Parkinson's Disease**
L. Vela, A. Facca, K.E. Lyons, A.N. Lieberman
- P483 A survival analysis of the progression of familial and sporadic Parkinson's Disease**
R. Inzelberg, E. Schechtman, L. Sach, R. Bonwitt, P. Nisipeanu
- P484 Association study of glutathione transferase and N-acetyltransferase polymorphisms in early-onset Parkinsonism**
K. Schumacher, P. Vieregge, H. Jacobs, P.P. Pramstaller, P. Kramer, C. Klein
- P485 Neuronal discharge in the basal ganglia is correlated with EEG in normal and Parkinsonian primates**
T. Wichmann, P.G. Gatev, M.A. Kliem
- P486 Prominent neurofibrillary tangle pathology in a Parkin brain**
J.R. Vaughan, T. Revesz, L. Petrucelli, C. Luecking, M. Farrer, A.J. Lees
- P487 Localization of the 20S proteasome in Parkinson's Disease**
A. Iroi, N. Hattori, M. Takanashi, S. Kubo, K. Tanaka, Y. Mizuno
- P488 Degree of dopaminergic cell loss and the development of levodopa-induced dyskinesia in a rat model of Parkinson's Disease**
V. Paille, P. Brachet, P. Damier
- P489 Identification of a novel substrate for Parkin**
K. Shiba, S.-I. Kubo, Y. Chikaoka, K. Sato, N. Hattori, Y. Mizuno
- P490 Increased MYH and OGG1 in substantia nigral neurons in Parkinson's Disease**
J. Fukae, S.-I. Kubo, M. Takanashi, Y. Nakabeppu, N. Hattori, Y. Mizuno
- P491 Increased levels of a pro-apoptotic protein, Bak, in Multiple System Atrophy**
J. Tong, M. Guttman, Y. Furukawa, S.J. Kish
- P492 PARK3 influences age at onset in Parkinson's Disease: a replication study**
A. Zimprich, B. Muller-Myhsok, N. Wood, A. Durr, Z.K. Wszolek, T. Gasser
- P493 Infrared light beam finger and foot tapping in Idiopathic Parkinson's Disease**
M.S. Eisa, P.J. Moberg, J.E. Duda, D. Weintraub, K.M. Robinson, M.B. Stern
- P494 PARK6 linkage analysis of autosomal recessive Parkinson's Disease**
Y.S. Hatano, K. Sato, T. Kobayashi, H. Yoshino, N. Hattori, Y. Mizuno
- P495 Dopamine-stimulated adenylyl cyclase activity in multiple system atrophy, progressive supranuclear palsy, and Parkinson's Disease**
J. Tong, Y. Furukawa, M. Guttman, S.J. Kish
- P496 Mutational analysis of an AR-JP family with an exonic triplcation in Parkin gene**
Y. Imamichi, H. Yoshino, N. Hattori, Y. Mizuno
- P497 Parkin functions as a regulator for exocytosis**
Y. Chikaoka, S.-I. Kubo, N. Hattori, Y. Mizuno
- P498 A case of camptocormia in Parkinson's Disease with MRI and muscular biopsy showing a myositis**
P. Charpentier, T. Stojkovic, A. Dauphin, L. Defebvre, D. Ferriby, A. Destee
- P499 Changes in quality of life resulting from treatment for persons with advanced Parkinson's Disease: Sumanriole versus placebo**
J. DuChane, C. Jenkinson
- P500 Parkinson's Disease and Parkinsonism among Harris County veterans**
E.C. Lai, S. Waring, S. Moore
- P501 Association of Parkin with late-onset Parkinson Disease**
S.A. Oliveira, W.K. Scott, E.R. Martin, M.A. Pericak-Vance, J.M. Vance, GSK Collaborative Parkinson Disease Group. Center for Human Genetics, Duke University Medical Center, Durham, NC
- P502 Metabolic changes during subthalamic nucleus stimulation in advanced Parkinson's Disease**
T. Peschel, P. Odin, H. Kolbe, C. Schrader, R. Dengler, G. Berding
- P503 3T MRI measures of nigral volume and of transverse and longitudinal relaxation rates in Parkinson's Disease**
J.M. Gorell, N. Gelman, E.M. Spickler, H. Soltanian-Zadeh, A. Kapke, E.L. Peterson
- P504 Genetic polymorphisms of the N-acetyltransferase genes (NAT1 and NAT2) and risk to Parkinson's Disease**
J.M. van der Walt, E.R. Martin, W.K. Scott, M.A. Pericak-Vance, J.M. Vance, GlaxoSmithKline Collaborative PD Group
- P505 Lymphocytes as a potential biomarker for Parkinson's Disease**
A.P. Chou, B. Ritz, C. Breton, E. Choi, J.M. Bronstein
- P506 Caspase-mediated Parkin cleavage**
S. Kahns, M. Kalai, L.D. Jakobsen, P. Vandenabeele, P.H. Jensen
- P507 Substantia nigra echogenicity is normal in non-degenerative cerebral disorders but increased in idiopathic Parkinson's Disease**
U. Walter, R. Benecke, D. Dressler
- P508 To evaluate factors which influence the quality of life in Parkinson's Disease patients**
M. Reuther, A. Spottke, R. Köhne-Volland, S. Spieker, R. Dodel, W.H. Oertel
- P509 Discrimination of idiopathic Parkinson's Disease and atypical Parkinsonian syndromes by brain parenchyma sonography**
U. Walter, L. Niehaus, T.E. Probst, R. Benecke, B.U. Meyer, D. Dressler

Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

- P510 Injuries due to falls in Parkinsonian patients**
S.A. Parashos, C.L. Wielinski, C. Erickson-Davis, R. Wichmann, M. Walde-Douglas
- P511 Relation between movement and single cell discharge in the subthalamic nucleus in Parkinson's Disease (PD)**
F. Alonso-Frech, M.C. Rodriguez-Oroz, M. Alegre, J. Guridi, J. Artieda, I. Zamarbide, M. Rodriguez Diaz, J.A. Obeso
- P512 The impact of early Parkinson's Disease on visual search**
T. Simuni, S. Weintraub, I. Janssen, M. Wolff, R. Srinivasan, M.M. Mesulam
- P513 Genetic variability in tau assessed in Parkinson's Disease in Ireland**
J.A. Wiley, T. Lynch, L. Skipper, F. Matthew
- P514 Familial Parkinsonism in an Ohio Amish pedigree**
S.L. Lee, A. Crunk, L. McFarland, Y. Bradford, T.L. Davis, J.L. Haines
- P515 Proprioceptive regulation of postural control in Parkinson's Disease (PD)**
A.E. Thurell, N. Wijnberg, A.M. Bronstein, N.P. Quinn, A.J. Lees, B.R. Bloem
- P516 When researchers in Parkinson's Disease (PD) say quality of life, what do they measure?**
K.F. Cook, N. Nelson, M. Trail, N. Nelson
- P517 Ratio of large to small rapid alternating movement frequencies (L/S) in the human upper limb: a parameter independent of the joint assessed**
J.-M. Gracies, L.J. Guo, D. Crisan, B. Yang, D.J. Weisz, W. Olanow
- P518 Pseudo-autosomal dominant inheritance of PARK2: gene dosage analysis, social-geographical-historical backgrounds in two families**
T. Kobayashi, H. Matsumine, Y. Imamichi, N. Hattori, S. Tanaka, Y. Mizuno
- P519 Activation and apoptosis in lymphocytes of patients with Parkinson's Disease**
A. Callen, M. Mestre, M. Calopa, J. Bas, E. Buendia
- P520 Relationship between Aggresomes and Lewy bodies**
K.S.P. McNaught, D.P. Perl, C.W. Olanow

Poster Session 4 - Tuesday, November 12

Noon - 1:30 pm

Poster numbers 521-694

Neuroimaging, Surgical Therapy, Transplantation

- P521 b-CIT/SPECT vs clinical examination in Parkinsonian Syndrome: unmasking an early diagnosis**
D.L. Jennings, J.P. Seibyl, J. Murphy, K. Marek
- P522 A correlation between REM sleep behavior disorder and striatal monoaminergic innervation in Multiple System Atrophy**
S. Gilman, R.A. Koeppe, R. Chervin, F. Consens, R. Little, H. An
- P523 Activation brain SPECT using the Wisconsin Card Sorting Test in patients with Parkinson's Disease**
B.A. Pickut, F. Jacobs, K.J. Van Laere, J. Vandevivere, R.A. Dierckx, P.P. De Deyn
- P524 Adenosine A₁ receptor PET in movement disorders**
A. Bauer, M.H. Holschbach, D. Woitalla, H.H. Coenen, H. Przuntek, K. Zilles
- P525 Assessment of CEP-1347 interaction with beta-CIT striatal uptake in Parkinson's Disease**
Parkinson Study Group (Kenneth Marek - presenter)
- P526 Basal ganglia hyperintensities on T1-weighted MRI are associated with high blood and cerebrospinal fluid levels of manganese in Chronic Hepatic Encephalopathy**
M. Miranda, P. Venegas, J. Valera, M. Kagi, F. Duran
- P527 Cardiac MIBG scintigraphy is a sensitive tool for detecting silent Autonomic failure in Parkinson's Disease**
F. Courbon, C. Brefel-Courbon, C. Thalamas, M.J. Alibelli, I. Berry, J.M. Senard
- P528 Cardiac uptake of MIBG in patients with essential tremor and tremor dominant-Parkinson's Disease**
M. Yamamoto, T. Tsuji, Y. Kageyama
- P529 Cerebral blood flow changes induced by low and high frequency stimulation of the subthalamic nuclei in Parkinson's Disease: a [15O]-H₂O PET study**
A. Dagher, A.P. Strafella, A.F. Sadikot
- P530 Cerebrovascular disease affects presynaptic dopaminergic imaging: a 123I -FP-CIT SPECT study**
H.T. Benamer, D.G. Grosset, J. Patterson, D.D. Hadley
- P531 Clinical and PET recovery after neuronal graft in Parkinson Disease (PD) depends on the number of fetal donors**
V. Cochen, M.-J. Ribeiro, J.-P. Nguyen, P. Hantraye, P. Cesaro, P. Remy
- P532 Clinical determinants of progressive dopamine transporter loss measured by b-CIT and SPECT**
D.L. Jennings, J.P. Seibyl, D. Oakes, S. Eberly, K. Marek
- P533 Clinical impact of dopamine transporter SPECT imaging using ¹²³I-loflupane (DaTSCAN[®]) in patients with clinically uncertain Parkinsonian syndromes**
E. Tolosa, A.M. Catafau, on behalf of DaTSCAN CUPS Study Group
- P534 Combined magnetisation transfer imaging and proton magnetic resonance spectroscopy of the lentiform nucleus in idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy**
T. Eckert, J. Kaufmann, C. Schrader, T. Peschel, H.-J. Heinze, M. Sailer

Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

- P535 Comparison of a-dihydroergocryptine and levodopa monotherapy in Parkinson's Disease: assessment of disease progression with dopamine transporter SPECT**
K. Tatsch, G. Poepperl, E. Ruzicka, A. Storch, T. Gasser, J. Schwarz
- P536 Corticobasal degeneration and Parkinson's Disease assessed by SPECT and factorial discriminant analysis**
A. Kreisler, L. Defebvre, P. Lecouffe, P. Charpentier, A. Duhamel, M. Steinling, A. Destee
- P537 D2 receptor dysregulation in patients with Parkin gene mutations**
C. Scherfler, N.L. Khan, N. Pavese, N.W. Woods, N. Quinn, D.J. Brooks, P. Piccini
- P538 Deep brain stimulation of the subthalamic nucleus modulates a fronto-temporal network associated with the fluency task**
U. Schroeder, A. Kuehler, B. Haslinger, V.M. Tronnier, H. Boecker, A.O. Ceballos-Baumann
- P539 Differential effects of VIM thalamus deep brain stimulation upon thalamo-cortical circuitry**
B. Haslinger, H. Boecker, C. Buechel, J. Vesper, V.M. Tronnier, A.O. Ceballos-Baumann
- P540 Differential patterns of dopamine transporter loss in the basal ganglia of Progressive Supranuclear Palsy and Parkinson's Disease: analysis with [123I]IPT single photon emission computed tomography**
J.-H. Im, J.S. Kim, M.C. Lee
- P541 Diffusion-weighted MRI discriminates Progressive Supranuclear Palsy from Parkinson's Disease**
K. Seppi, M. Schocke, R. Esterhammer, W. Jaschke, W. Poewe, G. Wenning
- P542 Dissociation of frontal and prefrontal white matter integrity to cognitive and motor behaviors in Parkinson's Disease: a diffusion tensor imaging study**
G.T. Stebbins, M.C. Carrillo, C.G. Goetz, M.E. Moseley, J.D. Gabrieli
- P543 Dopamine transporter imaging and bilateral subthalamic stimulation for Parkinson's Disease: One year follow up**
A. Lokkegaard, L.M. Werdelin, L. Regeur, J. Brennum, F.F. Madsen, L. Friberg
- P544 Dopaminergic degeneration and perfusional impairment in Lewy Body Dementia (LBD): evidence from a double-tracer SPECT study**
R. Ceravolo, D. Volterrani, G. Dell'Agnello, S. Bernardini, G. Manca, C. Berti, G. Mariani, L. Murri, U. Bonuccelli
- P545 Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's Disease**
P. Ruprecht-Döerfler, D. Berg, O. Tucha, P. Benz, K.W. Lange, G. Becker
- P546 Effects of deep brain stimulation of the STN and Vim nuclei under resting state and during simple movement tasks: a functional MRI study at 1.5 Tesla**
R. Jech, D. Urgosik, J. Tintera, T. Sieger, J. Roth, E. Ruzicka
- P547 Effects of sensory stimulation on striatal dopamine release in normal subjects: a PET 18F-Dopa and 11C-Raclopride study**
S.C. Thobois, V. Leviel, L. Garcia-Larrea, N. Costes, D. Le Bars, E. Broussolle
- P548 Effects of subthalamic high-frequency stimulation on dopamine release in Parkinson's Disease: a [11C]raclopride PET study**
A.P. Strafella, A.F. Sadikot, M. Panisset, A. Dagher
- P549 Effects of subthalamic nucleus stimulation on speech production in Parkinson's Disease: a PET study**
S. Pinto, M. Gentil, S. Thobois, A.L. Benabid, P. Pollak, E. Broussolle
- P550 Establishing safe parameters for magnetic resonance imaging in patients with implanted deep brain stimulation systems**
A.D. Sharan, A.R. Rezai, J. Tkach, G. Hrdlicka, J. Nyenhuis, F.G. Shellock
- P551 Florid white matter abnormalities on MRI in Neuroacanthocytosis**
D.J. Nicholl, I. Sutton, M.T. Dotti, S.G. Supple, A. Danek, M. Lawden
- P552 Functional neuro-anatomy of apraxia in corticobasal degeneration**
L. Carlier, A. Blondel, V. De la Sayette, R.M. Marie, J.C. Baron, F. Viader
- P553 Functional neuroimaging in the differentiation of multiple system atrophy from Parkinson's Disease**
M. Ghaemi, R. Hilker, J. Rudolf, J. Sobesky, W.D. Heiss
- P554 In vivo voxel-based morphometry in Multiple System Atrophy (MSA)**
T. Klockgether, M. Minnerop, M. Abele, J. Reul, K. Specht
- P555 In vivo, longitudinal, 1H Magnetic Resonance Spectroscopy in a transgenic mouse model of Huntingtons Disease**
R.A. Page, R.J. Ordidge, E.B. Cady, J.S. Thornton, G.P. Bates, C.A. Davie
- P556 L-Dopa related changes in early Idiopathic Parkinson's Disease: a fMRI study**
T. Eckert, H.J. Heinze, M. Rotte
- P557 Magnetic Resonance Imaging studies in hyperglycemic hemichorea-hemiballism**
Y.R. Wu, J.C. Tsou, C.J. Chen, S.T. Chen
- P558 Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) : standardized Magnetic Resonance Imaging (MRI) analysis in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
Y. Rolland, M. Verin, E. Kraft, J. Jarosz, G. Schultz, the NNIPPS Study Group
- P559 Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS): preliminary results of the Magnetic Resonance Imaging (MRI) study in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
M. Verin, Y. Rolland, L. Defebvre, C. Delmaire, C. Payan, the NNIPPS Study Group
- P560 Nigrostriatal dysfunction in asymptomatic subjects with a single Parkin mutation**
N.L. Khan, C. Scherfler, E.A. Graham, N.W. Wood, D.J. Brooks, P. Piccini
- P561 PET studies on the extent of cholinergic and dopaminergic neuronal loss in Parkinson Disease, Parkinson Disease with Dementia, and Dementia with Lewy bodies**
C.S. Lee, S. Mann, M. Zamburlini, S. Lee, V. Sossi, M. Adam
- P562 Picturing atrophy patterns of Progressive Supranuclear Palsy (PSP) in vivo using fluid registered MRI**
D.C. Paviour, J.M. Schott, N.C. Fox, J.M. Stevens, A.J. Lees, M.N. Rossor
- P563 Positron emission tomography (PET) characteristics of basal ganglia lesions in acute movement disorders in diabetic uremic patients**
H.C. Wang, J.L. Hsu

Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

- P564 Proton MR spectroscopy in untreated and treated Wilson's Disease**
M. Behari, A.K. Sahani, S. Singh, V. Goyal, R. Jayasundar, S. Gaikwad
- P565 Regional cerebral blood flow profile associated with speech production in normal subjects and Parkinsonian patients**
S. Pinto, M. Gentil, N. Costes, A.-L. Benabid, E. Broussolle, P. Pollak
- P566 Safety of Magnetic Resonance Imaging in patients with deep brain stimulation**
V. Fraix, E. Moro, J.-F. LeBas, S. Grand, A.-L. Benabid, P. Pollak
- P567 Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex: a [¹¹C]raclopride PET study**
A.P. Strafella, T. Paus, M. Fraraccio, A. Dagher
- P568 Striatal dopamine transporter function measured by in vivo [¹²³I]b-CIT pinhole SPECT correlates with nigral dopaminergic cell counts in the 6-OHDA rat model of Parkinson's Disease**
C. Scherfler, E. Donnemiller, M.F. Schocke, C. Decristoforo, W. Poewe, G.K. Wenning
- P569 Studies with ^{99m}Tc-TRODAT-SPECT in patients with different Parkinson's Syndrome**
G. Dibo, M. Argyelan, B. Kanyo, F. Fulop, L. Vecsei, L. Pavics
- P570 Target acquisition in motor sequence learning correlates with caudate dopamine transporter density in early Parkinson's Disease**
M. Carbon, F.M. Ghilardi, Y. Ma, A.S. Feigin, T. Chaly, D. Eidelberg
- P571 The in vivo detection of iron and ferritins by Transcranial Sonography; a new approach for early diagnosis of Parkinson's Disease**
L. Zecca, D. Berg, G. Becker, P. Riederer, M. Musicco, M. Gerlach
- P572 White matter microstructural integrity in Parkinsonian hallucinations: a diffusion tensor imaging study**
C.G. Goetz, M.E. Moseley, M.C. Carrillo, J.D. Gabrieli, G.T. Stebbins
- P573 A blinded, randomized comparison of GPi vs. STN stimulation in advanced Parkinson's Disease**
J.P. Hammerstad, V. Anderson, J. Favre, P. Hogarth, K. Burchiel
- P574 A cardiac pacemaker and thalamic deep brain stimulation (DBS) in the same patient: A case report**
J. Lutke Farwick, T. v. Laar, K. Leenders
- P575 A novel quality of life instrument for deep brain stimulation in movement disorders**
A. Kuehler, G. Henrich, U. Schroeder, B. Conrad, P. Herschbach, A.O. Ceballos-Baumann
- P576 A study of HMPAO TC SPECT before and after sub-thalamic stimulation in advanced PD. Relationship with mood and neuropsychological changes**
P. Charpentier, P. Lecouffe, C. Dujardin, M. Steinling, S. Blond, A. Destee
- P577 Acute neuro-psychiatric symptoms following subthalamic electrodes implantation in Parkinson's Disease**
C. Wider, J. Ghika, J.G. Villemure, A. Perrin, J. Bogouslavsky, F. Vingerhoets
- P578 Adductor Laryngeal Breathing Dystonia after sub-thalamic stimulation in a Parkinson's Disease patient**
G. Salazar, P. Salazar, J.A. Finocchio, J.C. Jimenez, E. Tolosa, S. Starosta
- P579 Adverse effects of subthalamic nucleus deep brain stimulation (STN DBS) in multiple system atrophy**
D. Apetauerova, P. Ryan, T. Norregaard, D. Tarsy
- P580 Age depending anatomical variations of the subthalamic nucleus: a postmortem study**
W.F. den Dunnen, M.J. Staal
- P581 Alleviating drug-induced psychosis and mood swings in a Parkinson's Disease(PD) patient by Subthalamic Nucleus (STN) Stimulation: a case report**
C.C. Chen, C.S. Lu, S.T. Lee, C.Y. Liu, T. Wu
- P582 An unusual phenomenon from STN deep brain stimulation: suppression of paresthesia from traumatic cervical subluxation**
V.L. Wheelock, C.T. Pappas, S. Nielsen, C.K. Na-Lee, K.A. Sigvardt
- P583 Anatomic localization of contacts producing hypomanic personality changes with deep brain stimulation of the subthalamic nucleus**
R. Frysinger, J. Bronstein, A. De Salles, Z. Vanek, I. Subramanian, E. Behnke
- P584 Anatomical, electrophysiological and clinical correlations in subthalamic nucleus stimulation**
T. Witjas, J.-P. Azulay, T. Ochiai, J.-C. Peragut, J. Regis
- P585 Behavioural effects of neurosurgery to the substantia nigra pars reticulata in Parkinsonian monkeys**
J.M. Henderson, D.I. Finkelstein, D. Stanic, D. Tomas, J. Patch, D. Bourke
- P586 Bilateral pallidal stimulation in primary generalized dystonia: preliminary results of the SPiDY French Multi-centric Study**
M. Vidailhet, L. Vercueil, J.L. Houeto, P. Krystkowiak, S. Tezenas Du Montcel, A.L. Benabid
- P587 Bilateral pallidotomy for severe dystonia in a child with Glutaric Aciduria: a case report**
G. Rakocevic, K.E. Lyons, S.B. Wilkinson, J. Kiltyka, R. Pahwa
- P588 Bilateral posteroventral pallidotomy in Generalized Dystonia: a preliminary report**
C. Maragoto, G. Lopez, R. Macias, L. Alvarez, J. Tejero, E. Tolosa
- P589 Bilateral stimulation of the subthalamic nucleus disturbs emotional information processing**
K. Dujardin, L. Defebvre, P. Krystkowiak, S. Blairy, S. Blond, A. Destee
- P590 Bilateral subthalamic stimulation in advanced Parkinson's Disease improves OFF duration and disease-severity at three months after surgery**
F. Valzania, C. Sturiale, S.A. Nasseti, A. Tropeani, A. Bisulli, C.A. Tassinari
- P591 Bilateral subthalamic stimulation using anatomic landmarks on MR Imaging for localization-a preliminary result**
S.Y. Chen, S.Z. Lin, C.C. Lee
- P592 Blood pressure and heart rate in patients with Parkinson's Disease following deep brain stimulation of the internal globus pallidus or subthalamic nucleus**
G.R. Sigurdardóttir, S. Rehnrona, M. Grabowski
- P593 Brain perfusion SPET before surgery and during high frequency stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson's Disease**
A. Antonini, R. Benti, C. Mariani, A. Landi, R. DeNotaris, M. Parolin

Poster Sessions

Poster Session 4 - Tuesday, November 12 Noon - 1:30 pm

- P594 Burr hole ring and cap fixation in STN-DBS: Technical note**
J.C. Jimenez, P.M. Salazar, J.A. Finocchio, M.M. Rojas
- P595 Cardiac pacemakers and deep brain stimulation in patients with movement disorders**
H.H. Capelle, R. Simpson, M. Kronenbuerger, V. Tronnier, J. Michaelsen, J.K. Krauss
- P596 Chronic bilateral medial thalamic (MT) stimulation for the treatment of tics in 3 adult patients with Gilles de la Tourette's Syndrome (GTS)**
C. van der Linden, H. Colle, V. Vandewalle, G. Alessi, D. Rijckaert, L. De Waele
- P597 Chronic intraputaminial infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's Disease: an ¹⁸F-dopa PET study**
G.R. Hotton, S.S. Gill, N.K. Patel, P. Heywood, C.N. Svendsen, D.J. Brooks
- P598 Chronic zona incerta stimulation improved Holmes' Tremor: a case report**
C.S. Lu, C.C. Chen, S.T. Lee, T. Wu, T.C. Yen, H.C. Chang
- P599 Clinical and acoustic study of the effect of bilateral subthalamic nucleus stimulation on Parkinsonian dysarthria**
T. Ronziere, P. Auzou, C. Ozsancak, I. Rivier, Y. Lajat, M. Verin
- P600 Clinical outcome of bilateral subthalamic nucleus stimulation in patients with Parkinson's Disease and previous pallidotomy:**
F.J. Revilla, J.W. Mink, K.M. Rich, J.L. Dowling, A. Loepker, J.S. Perlmutter
- P601 Community referral patterns of candidates for surgical treatment of movement disorders: the UCLA experience**
I. Subramanian, A. DeSalles, J. Bronstein
- P602 Comparison of outcomes of unilateral pallidotomy with unilateral subthalamic nucleus deep brain stimulation for Parkinson's Disease**
V.L. Wheelock, C.T. Pappas, C.I. Higginson, C.K. Na-Lee, N. Khamphay, K.A. Sigvardt
- P603 Computerized Posturography balance assessments of patients with bilateral VIM deep brain stimulation**
W.G. Ondo, H. Cohen, J. Jankovic
- P604 Contemporary bilateral targeting of GPi and STN for DBS in Parkinson's Disease**
P. Mazzone, G. Altibrandi, P. Stanzione, A. Insola
- P605 Contribution of non-neurosurgeons in publications on surgery for Parkinson's Disease: a survey of old and modern literature**
M.I. Hariz
- P606 Correlations between peroperative electrophysiology, localization of the electrode and clinical outcome in STN stimulation for PD**
P. Esposito, P. Krack, S. Chabardes, A. Koudsie, P. Pollack, A.L. Benabid
- P607 Deep brain stimulation - stereotactic target localization using Magnetic Resonance Imaging**
D. Urgosik, J. Vymazal, E. Ruzicka, J. Novotny, Jr., R. Jech, R. Liscak
- P608 Deep brain stimulation in subthalamic nucleus in Parkinson's Disease: clinical results of a simplified technique**
A.P. Jeanjean, A. Collard, J.-M. Guerit, C. Raftopoulos
- P609 Deep brain stimulation in the subthalamic area for severe idiopathic Parkinson's Disease: relationships between location of active contacts and improvement of Parkinsonian symptoms**
J.J. Lemaire, J.Y. Boire, B. Debilly, F. Durif
- P610 Deep brain stimulation of the bilateral subthalamic nucleus reduces the cost of Antiparkinsonian medications**
P.D. Charles, P.E. Konrad, E.J. Battle, B.L. Jacobs, J.Y. Fang, T.L. Davis
- P611 Deep brain stimulation of the subthalamic nucleus: increased striatal dopamine release in Parkinsonian humans?**
R. Hilker, J. Voges, M. Ghaemi, K. Wienhard, V. Sturm, W.D. Heiss
- P612 Differential effects of thalamic stimulation parameters on tremor and paraesthesias in Essential Tremor**
S. Cooper, K. Baker, A. Kuncel, J. Henderson, W. Grill, E. Montgomery
- P613 Differential response of PD symptoms to active electrode position in the subthalamic nucleus during deep brain stimulation**
J.L. Shils, M. Tagliati, J. Miravite, B. Sullivan, R.L. Alterman
- P615 Economic impact of the reduction in medication requirements after STN deep brain stimulation in Parkinson's Disease**
J.L. Shils, J. Miravite, M. Tagliati, R.L. Alterman
- P616 Effect of bilateral deep brain stimulation on subthalamic nucleus in Parkinson's Disease on speech**
A. Perrin, A. Carruzzo, J. Ghika, J.G. Villemure, J. Bogousslavsky, F. Vingerhoets
- P617 Effect of bilateral subthalamic nucleus stimulation on tremor in Parkinson's Disease-a computerized quantitative study**
C. Blahak, H. Baezner, E. Grips, J.C. Woehrl, H.H. Capelle, J.K. Krauss
- P618 Effects of deep brain stimulation and levodopa on a variety of postural tasks in Parkinson's patients**
F.B. Horak, P. Carlson-Kuhta, M. Stephens, A. Gross, P. Hogarth, K. Burchell
- P619 Effects of subthalamic nucleus stimulation on corticospinal pathway and motor cortex excitability in Parkinson's Disease**
V. Fraix, L. Vercueil, F. Manguiere, A.-L. Benabid, P. Pollak
- P620 Effects of thalamic deep brain stimulation on the cerebellothalamocortical pathway**
G.F. Molnar, A. Sailer, C.A. Gunraj, A.E. Lang, A.M. Lozano, R.E. Chen
- P621 Efficacy of subthalamic nucleus stimulation in advanced Parkinson's Disease depends of the accuracy of the intraoperative electrophysiological targeting: Study of 24 consecutive patients**
J.P. Nguyen, J.P. Lefaucheur, F. Von Raison, J.M. Gurrunchaga, H. Kishima, S. Oshino
- P622 Electrophysiologic changes in balance and gait control from bilateral STN-DBS in Parkinson's Disease: an in-depth case study**
G.T. Mandybur, T.S. Horn, A. Leis, L. Loret de Mola
- P623 Electrophysiological recordings of subthalamic neurons in Parkinson's Disease**
U.M. Fietzek, D. Weinert, W. Hamel, A. Morsnowski, J. Volkmann, R. Jan
- P624 Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's Disease (PD)**
R. Tintner, M. Almaguer, M. Sanghera, R. Simpson, W.G. Ondo, J. Jankovic

Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

- P625** **Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced PD**
A. Batir, P. Krack, V. Fraix, A. Koudsie, S. Chabardes, A. Funkiewiez
- P626** **Gait analysis in patients with Parkinson's Disease: different or additive effects on gait parameters induced by levodopa and chronic STN stimulation**
S. Lubik, W. Fogel, V. Tronnier, M. Krause, W.H. Jost
- P627** **GPI-DBS further improves a PD patient with STN-DBS and medication**
J. Ghika, J.G. Villemure, P. Burkhard, H. Russmann, J. Bogousslavsky, F. Vingerhoets
- P628** **Hedonistic homeostatic dysregulation in Parkinson's Disease (PD): is sub-thalamic nucleus (STN) deep brain stimulation (DBS) indicated?**
T. Witjas, J.P. Azulay, J. Régis, A. Ali Chérif, J.C. Péraugot
- P629** **Hemiballism secondary to subthalamotomy for advanced Parkinson's Disease: studies of three cases**
P.C. Su, H.M. Tseng, H.-M. Liu
- P630** **Hemiballismus as a delayed complication following subthalamic nucleus deep brain stimulation surgery for Parkinson's Disease**
S.C. Bose, S.J. Sherman
- P631** **High frequency stimulation of the subthalamic nucleus interferes with glutamate, GABA and dopamine transmission in the substantia nigra: a microdialysis study in freely moving rats**
N. Bruet, A. Poupard, A. Bertrand, E. Lacombe, C. Carcenac, M. Savasta
- P632** **Identification of DBS targets based on criteria of somatosensory evoked potentials**
F. Klostermann, J. Vesper, G. Curio
- P633** **Immediate relief of levodopa-induced dyskinesias after deep brain stimulation of the subthalamic nucleus in Parkinson's Disease**
M. Tagliati, N. Huang, J.L. Shils, J. Miravite, B. Sullivan, R.L. Alterman
- P634** **Implantable guide tubes allow functional neurosurgery to be performed under general anesthesia**
N.K. Patel, S.S. Gill
- P635** **Increases of striatal glutamate and GABA in normal and Hemiparkinsonian rats during high frequency stimulation of the subthalamic nucleus**
N. Bruet, F. Windels, A. Poupard, A. Bertrand, M. Savasta
- P636** **Influence of bilateral subthalamic nucleus stimulation on blood pressure regulation in movement disorder patients**
A. Lipp, J. Jordan, T. Trottenberg, C. Winter, A. Kupsch, G. Arnold
- P637** **Influence of frequency on extracellular glutamate and GABA in substantia nigra and Globus Pallidus during electrical stimulation of subthalamic nucleus in rats**
F. Windels, N. Bruet, A. Poupard, C. Feuerstein, A. Bertrand, M. Savasta
- P638** **Influence of internal globus pallidus and subthalamic nucleus stimulation on the initiation of gait in Parkinson's Disease**
L. Defebvre, P. Krystkowiak, J.L. Blatt, B. Mainguet, S. Blond, A. Destee, J.D. Guieu
- P639** **Influence of subthalamic nucleus and internal globus pallidus stimulation on gait in Parkinson's Disease**
L. Defebvre, P. Krystkowiak, J.L. Blatt, J.L. Bourriez, A. Destee, S. Blond, J.D. Guieu
- P640** **Influence of subthalamic nucleus stimulation on the anticipatory postural adjustments during shoulder flexion in Parkinson's Disease**
S. Bleuse, F. Cassim, L. Defebvre, J.L. Blatt, S. Blond, A. Destee
- P641** **Jaw movements have differing sensitivity to deep brain stimulation, stimulation site, and levodopa in Parkinsonian patients**
L.T. Robertson, P. Hogarth, K. Burchiel
- P642** **Klüver-Bucy like symptoms induced by sub-thalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's Disease (PD)**
T. Witjas, J.P. Azulay, J. Régis, T. Oshiae, A. Ali Chérif, J.C. Péraugot
- P643** **Lateralized effects of STN stimulation in Parkinson's Disease on different characteristics of speech**
P. Santens, M. De Letter, J. Van Borsel, J. De Reuck, J. Caemaert
- P644** **Leksell vs. Talairach system target localization for posteroventral pallidotomy**
A. Cammarota, M. Merello, R. Leiguarda, E. Tenca, C. Artes, J. Antico
- P645** **Long-term effect of subthalamic nucleus stimulation on Parkinsonian voice quality**
M. Gentil, S. Pinto, P. Krack, P. Pollak, A.L. Benabid
- P646** **Long-term follow-up of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with advanced Parkinson's Disease: the Toronto Western Hospital experience**
G. Kleiner-Fisman, D.N. Fisman, E. Sime, A.M. Lozano, A.E. Lang
- P647** **Long-term results of bilateral pallidal DBS in advanced Parkinson Disease (PD)**
J. Volkmann, N. Allert, J. Voges, A. Koulousakis, V. Sturm, H.J. Freund
- P648** **Mechanical failure of the electrode wire in deep brain stimulation**
A.A. Mohit, A. Samii, J.C. Slimp, R. Goodkin
- P649** **Modification of neural networks by bilateral deep brain stimulation of the subthalamic nucleus in advanced Parkinson's Disease**
R. Hilker, S. Weisenbach, J. Voges, M. Ghaemi, V. Sturm, W.D. Heiss
- P650** **Mood changes with STN and GPI DBS for Parkinson's Disease: results of a pilot study**
M.S. Okun, J. Green, R. Saben, R. Gross, K.D. Foote, J.L. Vitek
- P651** **Morbus Parkinson: psychological aspects and high frequency stimulation**
M.H. Strothjohann, M. Krause, D. Emmans, G. Fuchs
- P652** **Motor cortex oscillatory activity improvement under subthalamic nucleus stimulation in Parkinson's Disease**
D. Devos, E. Labyt, P. Derambure, J.L. Bourriez, A. Destée, L. Defebvre
- P653** **Motor cortex stimulation in patients with multiple system atrophy**
G. Kleiner-Fisman, A.M. Lozano, F. Khan, E. Sime, A.E. Lang
- P654** **MRI is safe in patients with deep brain stimulation therapy**
R.J. Uitti, R. Poole, J.D. Putzke, Z. Wszolek, J. Felmlee, R.E. Wharen
- P655** **Neuropsychological changes and bilateral subthalamic deep brain stimulation (DBS-STN) in Parkinson Disease (PD)**
E. Lezcano, J.C. Gomez, A. Molano, I. Lambarri, G. Bilbao, J.J. Zarranz
- P656** **Ninety-nine percent confidence volume and area for optimal DBS location in the Subthalamic nucleus (STN)**
E.B. Montgomery, Jr., K.B. Baker, A. Rezai, N. Boulis, J. Henderson

Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

- P657 Outcome of the STN-DBS in patients that are not ideal candidates**
G.A. Tagaris, A. Koulousakis, P. Zikos, C.E. Karageorgiou
- P658 Pallidal deep brain stimulation for medically refractory dystonias**
W.J. Marks, Jr., H.D. Clay, S.L. Heath, M.C. Mori, P.A. Starr
- P659 Pallidal deep brain stimulation for PD: correlation of long term clinical outcome and active lead location**
B.A. Wallace, K.D. Foote, P. Krack, A. Koudsie, A.L. Benabid, P. Pollak
- P660 Parkinson's Disease (PD) patients with bilateral subthalamic deep brain stimulation (STN-DBS) weight gain**
F. Macia, F. Tison, I. Coman, C. Perlemoine, H. Gin, V. Rigalleau
- P661 Pitfalls in microelectrode-guided stereotactic surgery for movement disorders: problems encountered and how to avoid them**
L.P. Bernstein, E.K. Nenonene, T.W. Eller, K.E. Novak, M. Rezak, S.M. Vergenz
- P662 Possible role of GABA in the therapeutical efficacy of high frequency stimulation of the subthalamic nucleus in Parkinson's Disease: a microdialysis study in rats**
F. Windels, N. Bruet, A. Poupard, C. Feuerstein, A. Bertrand, M. Savasta
- P663 Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's Disease**
R. Tintner, M. Almaguer, K.D. Vuong, W.G. Ondo, J. Jankovic, M. Sanghera
- P664 Pre-operative assessment for DBS: are multiple core evaluations necessary?**
L. Verhagen Metman, S. Hassin, M. Morrissey, J. Arzbaecher, D. Sierens, R. Bakay
- P665 Relationship between vegetative and motor response in subthalamic nucleus during clinical intraoperative stimulation for Parkinson's Disease**
P. Sauleau, M. Verin, I. Rivier, F. Lallement, Y. Lajat, S. Raoul
- P666 Results and adverse events in 50 consecutive PD patients treated by STN-DBS**
F.J. Vingerhoets, H. Russmann, C. Pollo, J.G. Villemure, P.R. Burkhard, J. Ghika
- P667 Safety and efficacy of microelectrode-guided thalamotomy for tremor**
V.L. Wheelock, C.I. Higgison, C.T. Pappas, C.K. Na-Lee, N. Khamphay, K.A. Sigvardt
- P668 Severe dystonic-dysarthria after electrical stimulation of the subthalamic area in a Parkinsonian patient with a previous contralateral pallidotomy**
M. Mata, J.J. Lopez-Lozano, R. Martinez, J. Burzaco
- P669 Sleep effects of bilateral subthalamic stimulation in Parkinson's Disease**
C. Monaca, C. Ozsancak, J.M. Jacquesson, J.L. Bourriez, L. Defebvre, P. Derambure, A. Destee, J.D. Guieu
- P670 Staged lesions through implanted deep brain stimulating electrodes: a new surgical procedure for treating tremor or dyskinesia**
S. Raoul, M. Verin, M. Faighel, I. Rivier, Y. Lajat, P. Damier
- P671 StarFix[®]: a novel approach to frameless stereotactic neurosurgery utilizing a miniaturized customized pretargeted cranial platform fixture-technical description, unique features, and case reports**
J.I. Franck, P.E. Konrad, R. Franklin, F. Haer
- P672 STN DBS in Parkinson's Disease patients above 70 years old**
H. Russmann, J. Ghika, J.G. Villemure, P.R. Burkhard, J. Bogouslavsky, F.J. Vingerhoets
- P673 STN-DBS complicated with cyanoacrylate granulomas and secondary staphylococcal infection**
J.C. Jimenez, P.M. Salazar, J.A. Finocchio, G. Salazar, S. Starosta, R. Weiser
- P674 Subthalamic Nucleus Deep Brain Stimulation (STN DBS)-induced dystonia and management with botulinum toxin (Botox) injections**
R. Kumar
- P675 Subthalamic stimulation does not improve autonomic dysfunction in Parkinson's Disease**
B. Holmberg, B. Johnels, M. Elam, Y. Jansson, O. Corneliusson, J. Ahlberg
- P676 Subthalamic stimulation in Parkinson's Disease. The Gothenburg experience 1993-2000**
B. Johnels, L.E. Augustinsson, O. Corneliusson, B. Holmberg, J. Ahlberg, J.E. Starmark
- P677 Surgical treatment of essential tremor**
I. Valálik, J. Julow
- P678 Surgical treatment of patients with movement disorders at The Johns Hopkins Hospital: a 12-year experience**
I.M. Garonzik, M. Barnes, L.H. Rowland, S.E. Hua, F.A. Lenz, S. Ohara
- P679 The accuracy of pretargeting the subthalamic nucleus**
S. Breit, J.F. LeBas, A. Koudsie, A. Benazzouz, J.B. Schulz, P. Pollak, A.L. Benabid
- P680 The CM-Pf complex- a target for the treatment of movement disorders? Review of previous experience and current pathophysiological concepts**
R. Weigel, J.K. Krauss
- P681 The effects of pallidotomy on articulatory function and perceptual measures of speech function in Parkinson Disease (PD)**
A.M. Farrell, D.G. Theodoros, E.C. Ward, P. Silburn, B. Hall
- P682 The kinetic of the effects of high frequency subthalamic stimulation on Parkinsonian rigidity and akinesia**
M. Faighel, S. Raoul, Y. Lajat, P. Damier
- P683 The timing of Antiparkinsonian treatment reduction after subthalamic nucleus stimulation**
S. Thobois, S. Corvaisier, P. Mertens, G. Chazot, M. Sindou, E. Broussolle
- P684 The use of bilateral deep brain stimulation of the subthalamic nucleus in advanced Parkinsons Disease patients previously reliant on apomorphine**
T.R.K. Varma, S. Fox, P. Eldridge, P. Littlechild, P. Byrne, A. Forster
- P685 Time requirements for assessment and programming of patients undergoing insertion of deep brain stimulators for movement disorders**
K. Hunka, S. Wood, L. Derwent, Z. Kiss, O. Suchowersky
- P686 Unilateral deep-brain stimulation (DBS) of the subthalamic nucleus (STN) in the treatment of advanced Parkinson's Disease (PD)**
N. Van Blercom, A. Lasa, E. Ramos, C. Magarinos, G. Linzasoro

Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

- P687 Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson's Disease: a randomized, observer-blind, multi-center trial**
R.A. Esselink, R.M. Bie de, M.W. Lenders, P.C. Nijssen, M.J. Staal, J.D. Speelman
- P688 Use of unconscious sedation with propofol during implantation of deep brain stimulator (DBS) electrodes**
B.N. Maddux, R.J. Maciunas, B. Dabb, D.E. Riley, C.M. Whitney
- P689 Behavioral correction of Parkinsonian rats by transplantation of immortalized fibroblasts genetically modified by TH gene and GCH gene**
S. Chen, X. Chen, Z. Liu, D. Xu, L. Xu, Z. Zheng
- P690 Human neural stem cell transplantation in the MPTP-lesioned mouse**
M.A. Liker, K. Nixon, G. Petzinger, T. McNeill, M. Jakowec
- P691 In vivo neuronal differentiation of primate parthenogenetic ES cells (Cyno-1) after transplantation into the rat striatum**
R. Sanchez-Pernaute, L. Studer, L. Bjorklund, O. Cooper, O. Isacson
- P692 Stable outcome five years after embryonic dopamine cell transplantation for Parkinson's Disease is compatible with on-going transplant development or lack of disease progression**
C.R. Freed, K.B. Bjugstad, R.E. Breeze, P. Green, D. Eidelberg, S. Fahn
- P693 Survival and migration of transplanted neural stem cell-derived dopamine cells in the brain of Parkinsonian rat**
B.S. Jeon, T.B. Ahn, J.M. Kim, S.H. Lee, K.M. Kwon
- P694 Transplantation of differentiated human embryonic germ cells rescues apomorphine-induced rotation in a mouse model of Parkinson's Disease**
J.M. Savitt, J.W.M. Bulte, V.L. Dawson, J.D. Gearhart, M.J. Shablott, J.M. Hakumaki, J. Axelman, T.M. Dawson

Poster Session 5 - Wednesday, November 13 7:00 am - 8:30 am

Poster numbers 695-850

Non-motor aspects of movement disorders, clinical, parkinsonism

- P695 An abnormal sleep pattern and excessive movements can characterize patients with Huntington's Disease**
M.H. Anca, N. Weizmann, A. Blonder, E. Davidov, N. Giladi, A.D. Korczyn
- P696 Anxietas tibiaram. Depression and anxiety disorders in patients with Restless Legs Syndrome**
J. Winkelmann, R. Lieb, H.U. Wittchen, M. Prager, C. Trenkwalder, A. Strohle
- P697 Arginine-stimulated growth hormone (GH) secretion in patients with idiopathic Parkinson's Disease under chronic dopaminergic therapy**
T. Vogt, S. Schäfer, P. Kann
- P698 Bladder dysfunction in young patients with Parkinson's Disease**
K. Winge, L.M. Werdelin, K. Krøyer, H. Stimpel
- P699 Botulinum toxin type B (Myobloc) for drooling**
J.Y. Fang, T.L. Davis
- P700 Burden and distress in the caregivers of patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
R.G. Brown, J. Hodges, B. Dubois, I. Uttner, L. Lacomblez, Neuropsychology Working Group and NNIPPS Consortium
- P701 Caregiver burden in corticobasal degeneration**
S.L. Lewis, I. Litvan, A.E. Lang, M. Phipps
- P702 Chronic unilateral thalamic stimulation for tremor: the effect of stimulation per se on neurobehavioral functioning**
T.J. Loher, K. Gutbrod, N.L. Fravi, T. Pohle, J.-M. Burgunder, J.K. Krauss
- P703 Cognitive and motor deficits in patients with cerebellar degeneration**
E. Stefanova, I. Ribaric, N. Dragasevic, M. Mijajlovic, M. Svetel, V. Kostic
- P704 Cognitive challenge increases gait variability in patients with Parkinson's Disease**
J.M. Hausdorff, J. Balash, N. Giladi
- P705 Cognitive function in Essential Tremor: a comparison to Parkinson's Disease**
C.I. Higginson, D.S. King, D. Levine, V.W. Wheelock, N.O. Khamphay, K.A. Sigvardt
- P706 Cognitive function in patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
R.G. Brown, B. Pillon, I. Uttner, C. Payan, L. Lacomblez, Members of the Neuropsychology Working Group and NNIPPS Consortium
- P707 Cognitive Linguistic Quick Test (CLQT) and MMSE in Parkinson's Disease**
M.L. Johnson, C.L. Wielinski, S.A. Parashos, M.J. Fuhrman
- P708 Cognitive, psychiatric and MRI findings in Wilson's Disease**
E. Stefanova, S. Pejovic, I. Ribaric, M. Mijajlovic, M. Svetel, V. Kostic
- P709 Correlates of generalized anxiety and panic attacks in dystonia and Parkinson's Disease**
E.C. Lauterbach, K.D. Sethi

Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

- P710 Deep brain stimulation of the subthalamic nucleus versus dopaminergic agents and decision making in Parkinson's Disease**
T.D. Halbig, D. Gruber, U.A. Kopp, A. Kupsch
- P711 Depression in Parkinson's Disease (PD): study of 60 cases**
R.C.P. Prado, E.R. Barbosa
- P712 Differential correlates of mood and cognition in dystonia and Parkinson's Disease**
E.C. Lauterbach, K.D. Sethi
- P713 Differential DIS-ascertained DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson Disease**
E.C. Lauterbach, K.D. Sethi
- P714 Effect of NT-3 on bowel function in Parkinson's Disease**
R.F. Pfeiffer, K. Markopoulou, E.M. Quigley, N. Stambler, J.M. Cedarbaum
- P715 Effect of pramipexole on depression and anhedonia in Parkinson's Disease patients**
M.R. Lemke, M. Brecht, J. Koester, P.H. Kraus, H. Reichmann
- P716 Evaluation of nocturnal pain symptoms in Parkinson's Disease using the Parkinson's Disease Sleep Scale. A case control study**
A.N. Di Marco, S. Pal, C. Whately-Smith, K. Bridgman, C. Brefel-Courbon, K.R. Chaudhuri
- P717 Health related quality of life and sleep disorders in Parkinson's Disease**
T. Scaravilli, E. Gasparoli, G. Polesello, F. Rinaldi, F. Bracco
- P718 Is Parkinsonian phenotype predictive of dementia? A cross-sectional study**
D.J. Burn, E.N. Rowan, I.G. McKeith, J.T. O'Brien, T. Minett, P. Myint
- P719 Long-term outcome of clozapine use for psychosis among Parkinsonian patients**
H.H. Fernandez, E.M. Donnelly, J.H. Friedman
- P720 Neurodegenerative illness and the evolution of art: the effects of corticobasal degeneration in a professional artist**
G. Kleiner-Fisman, S.E. Black, A.E. Lang
- P721 Neuropsychiatric and neurobehavioural symptoms in patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
R.G. Brown, J. Noth, B. Dubois, G. Bensimon, Members of the Neuropsychology Working Group and NNIPPS Consortium
- P722 Orofacial praxis assessment in Parkinsonism**
C. Ozsancak, P. Auzou, K. Dujardin, A. Destee
- P723 Platelets serotonin vesicular membrane transporter (VMAT2) in Parkinsonians with/without depression and controls**
J.M. Rabey, M. Zucher, C. Klein, Y. Gordon, M. Rehavi
- P724 Predictors of cognitive impairment in patients with advanced Parkinson's Disease**
G. Vingerhoets, S. Verleden, P. Santens, M. Miatton, J. De Reuck
- P725 Predictors of time-use in patients with Parkinson's Disease**
R.G. Brown, E. Worthington
- P726 Psychiatric co-morbidities associated with psychosis in patients with Parkinson's Disease**
L. Marsh, M.M. Rocco, J.R. Williams, C. Munro, S. Grill, T.M. Dawson
- P727 Psychometric characteristics of the Hospital Anxiety and Depression Scale in patients with Parkinson's Disease**
J. Marinus, A.F. Leentjens, M. Visser, A.M. Stiggelbout, B. Van Hilten
- P728 Radiotherapy as treatment of hypersalivation in Parkinson's Disease is effective and safe**
T. Van Laar, M.A. Heesters
- P729 Sensory symptoms and radiculopathies in Parkinson's Disease**
D.H. Lee, W. Seo, S.B. Koh, B.J. Kim, M.K. Park, K.W. Park
- P730 A case of post-stroke rhythmic akathisia**
M.W. Seo, K.M. Sung, S.Y. Oh, B.S. Shin, Y.H. Kim
- P731 A case with Episodic Ataxia and Multiple Paroxysmal Dyskinesias**
M. Demirkiran, D. Yerdelen, H. Uysal, Y. Sarica
- P732 A clinical observational study of Restless Legs Syndrome in Parkinson's Disease**
S. Mandal, L.S. Appiah-Kubi, M.-C. Porter, K.R. Chaudhuri
- P733 Alcohol induced movement disorders**
S.A. Groppa, M.T. Ganea, L.E. Zaporozhan, L.D. Luhtimovschi, E.E. Zota
- P734 Assessing characteristics of patients diagnosed with Restless Legs Syndrome using a primary care database**
H. Petri, D. van de Vijver, T. Sampson
- P735 Botulinum toxin treatment for drooling in children with neurological disorders**
S. Hassin-Baer, E. Scheuer, A.S. Buchman, I. Jacobson, B. Ben-Zeev
- P736 Brain MR imaging in patients with Wilson's Disease**
D. Kozic, M. Svetel, R. Semnic, I. Petrovic, N. Dragasevic, V.S. Kostic
- P737 Brainstem interneuronitis causing hyperekplexia, gaze palsies and rigidity**
S. O'Riordan, C. McGuigan, A. Vincent, S. Connolly, M. Hutchinson
- P738 Brainstem involvement as onset of Stiff Limb Syndrome: a case report**
F. Ceriani, N. Massetto, C. Rosci, M. Pietrogrande
- P739 Cabergoline in advanced RLS - a double-blind placebo-controlled multicenter trial**
K. Stiasny-Kolster, M. Ueberall, W. Oertel, German Cabergoline-RLS-Study-Group
- P740 Centrally acting cholinesterase inhibitors in hyperkinetic movement disorders**
K.A. Chung, J.G. Nutt, S.W. Johnson
- P741 Chronic neurological problems in patients with Wilson's Disease**
M. Velickovic, M.L. Schilsky
- P742 Complete remission of severe Restless Legs Syndrome after relief of iron deficiency: a case report**
B. Frauscher, B. Hoegl, E. Brandauer, M. Saletu, A. Muigg, W. Poewe
- P743 Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire**
R. Kohnen, H. Benes, C.R. Heinrich, B. Kurella
- P744 Diagnostic large volume CSF removal in patients with suspected NPH: evaluation of hearing**
O. Leheta, S. Sander, M. Huelse, K. Hoermann, J.K. Krauss
- P745 Ear dyskinesias**
L. Carluer, C. Schupp, G.-L. Defer

Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

- P746 Early onset dystonia/choreoathetosis/ataxia secondary to GLUT-1 deficiency, responsive to ketogenic diet**
J.R. Friedman, E.A. Thiele, D. Wang, D.C. DeVivo, P. Penny, P. Heidi
- P747 Effect of selegiline on autonomic functions in Parkinson's Disease**
M. Behari, R. Thomas, S. Singh, V. Goyal, T. Srivastava, K.K. Deepak
- P748 Effects of Gabapentin on Restless Legs Syndrome. Results of a double-blind, crossover study with polysomnographic control on 24 patients**
D. Garcia-Borreguero, O. Larrosa, K. Verger, X. Masramon, G. Hernandez
- P749 Effects of motor, psychiatric and cognitive impairment on physical disability in Parkinson's Disease**
S.S. Bassett, L. Marsh, T.M. Dawson
- P750 Facial myokymia and chin tremor in Celiac Disease**
P. Vrentas, V. Panayiotopoulou, G. Tagaris, S. Sameli, V. Kiriakakis, C. Clarke
- P751 Familial dementia masquerading as Huntington's Disease**
C.S. Ivan, M. Saint-Hilaire, J.M. Milunsky
- P752 Festination as a symptom of aqueductal stenosis and its treatment by CSF diversion**
O. Leheta, J. Boschert, I. Whittle, J.K. Krauss
- P753 Gait and Balance Scale (GABS): validation and utilization**
M. Thomas, J. Jankovic, M. Suteerawattanon, S. Wankadia, K. Caroline, E. Protas
- P754 Gait variability & fractal dynamics of older adults with high level gait disturbances**
T. Herman, T. Gurevich, R. Baltadjieva, N. Giladi, J.M. Hausdorff
- P755 Hemifacial spasm: a clinical and epidemiological study in 52 patients**
C. Colosimo, M. Chianese, S. Romano, V. Della Chiara, N. Vanacore
- P756 High frequency of affected first and second degree relatives of restless legs probands**
W.A. Hening, T. Washburn, R.P. Allen, C.J. Earley
- P757 Iron-chelating therapy in a case of hereditary ceruloplasmin deficiency with motor disturbances**
U. Bonuccelli, C. Lucetti, L. Petrozzi, S. Bosio, M.C. Bianchi, C. Camaschella
- P758 Long-term kinetics of anti-GAD65 antibody suppression by intravenous gamma globulin in Stiff Person Syndrome**
E.B. George, M.S. Mohamed
- P759 Manifestation of movement disorders after intervertebral disc surgery: causal relationship or coincidence?**
H.H. Capelle, J. Woehrle, R. Weigel, H.J. Baezner, E. Grips, J.K. Krauss
- P760 Minocycline in Huntington's Disease: a pilot study**
M. Thomas, MD, T. Ashizawa, MD, J. Jankovic, MD
- P761 Mirtazapine induces confusion with hallucinations and REM sleep behaviour disorder in Parkinsonism**
M. Onofrij, A.L. Luciano, D. Iacono, G. D'Andreamatteo, A. Thomas
- P762 Movement disorders in Multiple Sclerosis**
A.V. Srinivasan, R.R. Lakshmi Narasimhan, C.U. Velmurugendran
- P763 Neuroacantocytosis: clinico-pathological study of a family with different phenotypes**
G.J. Arango, M. Tenorio, E. Marulanda, G. Toro, P. Lorenzana, W. Fernandez
- P764 Neuropsychological deficits in patients with treated Wilson Disease**
K. Portala, S. Levander, K. Westermark, L. Ekselius, L. von Knorring
- P765 Normal pressure hydrocephalus presenting as chorea**
Z. Unal, E. Gozke, E. Deniz, O. Us
- P766 Painful legs and moving toes : evidence for a central origin**
A. Coeytaux, Y. Blanc, H. Groetzsch, M. Chofflon, T. Landis, P.R. Burkhard
- P767 Paroxysmal dyskinesias and ataxias in the South of Brazil**
H.G. Teive, N. Becker, M.H.B. Herdoiza, L.C. Werneck
- P768 Periodic Limb Movement Disorder after stroke in three patients with supratentorial lesion**
H.I. Ma, S.C. Jeong, K.H. Yu, B.C. Lee
- P769 Plasmapheresis in treatment of Stiff-Man Syndrome with a negative anti GAD antibody**
J. Svatova, H. Machova, J. Pitha
- P770 Platysmal myoclonus in a patient with non-autoimmune thyrotoxicosis**
H.-L. Teoh, E.C. Lim
- P771 Primary Restless Leg Syndrome: absence of specific tau- and alpha-synuclein pathology**
S.J. Pittock, T.J. Parrett, C.H. Adler, J.E. Parisi, D.W. Dickson, E.J. Ahlskog
- P772 Quality of life in Parkinson's Disease: what do we measure and how does it affect our results?**
P. Hagell
- P773 Randomised, open label, crossover, comparator trial of doctor and nurse-given botulinum toxin injections**
P. Moore, D.J. Rog, R. Bulloch, D. Collins
- P774 Restless Legs Syndrome (RLS) is a common disorder rarely diagnosed in Europe or USA: the REST (RLS Epidemiology, Symptoms and Treatment) study in primary care**
R.P. Allen, W.A. Hening, J. Montplaisir, A.S. Walters, T. Brown, A. Myers
- P775 Restless Legs Syndrome in Parkinson's Disease: a case - controlled study**
M. Behari, P.R. Krishnan, M. Bhatia
- P776 Rotigotine CDS (Constant Delivery System) in the treatment of moderate to advanced stages of Restless Legs Syndrome - a double-blind, placebo-controlled pilot study**
K. Stiasny, H. Benes, R. Bodenschatz, J.C. Moller, E. Schollmayer, W.H. Oertel, RTG Study Group
- P777 Stiff-person syndrome associated with anti-amphiphysin antibodies: neuropathology and antibody-binding studies**
M. Naumann, C. Sommer, C. Wessig, K. Toyka
- P778 Stiff-Person's Syndrome presenting with asymmetric axial muscle spasms and hypertrophy**
C. Chuang
- P779 Successful treatment of recalcitrant Restless Legs Syndrome with botulinum toxin A**
K.M. Kudelko, J.S. Rotenberg, M.P. DiFazio, B. Jabbari
- P780 Suppression of syncope after botulinum toxin treatment**
E. Moro, P. Cortelli

Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

- P781 Task force on childhood motor disorders consensus report: classification and definition of hypertonic disorders in childhood**
T.D. Sanger, M.R. Delgado, L. Dure, D. Gaebler-Spira, M. Hallett, J.W. Mink
- P782 The effect of cerebral lesions on gait**
H. Stolze, S. Peters, S. Klebe, G. Deuschl
- P783 The epidemiology of diagnosed Restless Legs Syndrome in primary care in the UK**
D. van de Vijver, H. Petri, T. Sampson
- P784 The Non-Specific Gait Disorder of the elderly. Is it a disorder or a syndrome?**
N. Giladi, T. Herman, T. Gurevich, I. Rieder-Grossover, Y. Assaf, J.M. Hausdorff
- P785 The prevalence of gait disorders and falls in neurology**
H. Stolze, C. Zechlin, C. Baecker, S. Klebe, L. Friege, G. Deuschl
- P786 Transient Restless Legs Syndrome can be induced by spinal anesthesia-a prospective study**
B. Hoegl, B. Frauscher, K. Seppi, H. Ulmer, W. Poewe
- P787 Unusual neurological presentations of Vitamin B 12 deficiency**
T.B. Ahn, J.W. Cho, B.S. Jeon
- P788 Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation**
M.J. Atkinson, R.P. Allen, J. DuChane, C. Murray, Members of the RLS Consortium
- P789 A comparative phenotypic study of Parkinson's Disease in non-white (Indian origin and African-Caribbean) immigrants to the UK and white Caucasian subjects in the UK**
J.E. Nott, C.S. Rao, L.S. Appiah-Kubi, D.v. Brooks, K. Ray Chaudhuri
- P790 A French family with a novel movement disorder and intranuclear inclusions containing ferritin**
O. Rascol, M.-B. Delisle, R. Vidal, C. Goizet, P. Labauge, C. Brefel-Courbon
- P791 A morphologic and morphometric study of the neurons of the substantia nigra in Alzheimer's Disease**
M.A. Arnaoutoglou, I.S. Baloyannis, A.C. Arnaoutoglou, V. Kosta, E.N. Arnaoutoglou, S.J. Baloyannis
- P792 Abnormal involuntary movements after L-Dopa treatment in a rat model of Striatonigral Degeneration (Multiple System Atrophy)**
N. Stefanova, M. Lundblad, M.A. Cenci, W. Poewe, G.K. Wenning
- P793 Abnormal plasticity in the human motor cortex of writer cramp patients after paired associative stimulation**
A. Quartarone, S. Bagnato, V. Dattola, A. Scalfari, F. Morgante, F. Battaglia, P. Girlanda
- P794 An unusual case combining the pathology of adult polyglucosan body disease (APGBD) and Multiple System Atrophy (MSA)**
E. Krim, A. Vital, F. Macia, F. Yekhlief, F. Tison
- P795 Anxiety and depression in PSP: common, but unrelated to disease severity**
A.J. Zernansky, Y. Ben-Shlomo, R. Thomson, A.J. Lees, D.J. Burn
- P796 Assessing urinary symptom severity in Multiple System Atrophy (MSA) compared to Parkinson's Disease (PD) and controls**
F. Tison, F. Yekhlief, E. Balestre, G. Amarengo
- P797 Atrophy of superior cerebellar peduncles in Progressive Supranuclear Palsy. Autopsy morphometric study of 48 cases**
J. Slowinski, Y. Tsuboi, Z.K. Wszolek, R.J. Uitti, D.W. Dickson
- P798 Atypical PD in a movement disorders practice : clinical characteristics**
E.C. Lim, C.W. Olanow
- P799 Atypical phenotype of corticobasal degeneration (CBD): based on the pathologically proved cases**
H. Mori, M. Takanashi, F. Yokochi, Y. Motoi, T. Kobayashi, Y. Mizuno
- P800 Cancer incidence and causes of death in patients with Parkinson's Disease among autopsy cases in Japan**
H. Oizumi, H. Mochizuki, T. Arai, H. Mori, Y. Mizuno
- P801 Clinical features of patients with pathology confirmed vascular Parkinsonism**
J. Zijlmans, S. Daniel, A. Lees
- P802 Comparison of the neuropathology of two unrelated individuals with the N279K mutation in the Tau gene**
B. Ghetti, Y. Tsuboi, Z.K. Wszolek, M.-B. Delisle, D.W. Dickson
- P803 Comparison of time tests in a cohort of patients with subthalamic deep brain stimulation and contralateral subthalamic lesioning**
P.C. Su, H.M. Tseng, H.M. Liu, R.-F. Yen, H.H. Liou
- P804 Depression and severity of depressive symptoms in Multiple System Atrophy (MSA) compared to Parkinson's Disease (PD) and controls**
F. Yekhlief, E. Balestre, F. Tison
- P805 Difference of intracortical inhibitory mechanism in Parkinsonian Syndromes**
T. Kawakami, K. Fujimoto
- P806 Differentially expressed genes in Multiple System Atrophy**
I.R. Vogt, B.O. Evert, L. Planko, S.E. Daniel, T. Klockgether, U. Wuellner
- P807 Differentiation of atypical Parkinsonism syndromes with MRI**
O.G.P. Barsottini, H.B. Ferraz, C.J. Silva, A.C.M. Maia Junior, A.J. Rocha
- P808 Divalproex-induced Parkinsonism: a retrospective review of cases**
C.D. Foley, J.T. Slevin, E.J. Kasarskis
- P809 Do published criteria improve diagnostic accuracy in Multiple System Atrophy?**
Y. Osaki, Y. Ben-Shlomo, G. Wenning, S. Daniel, A. Lees, N. Quinn
- P810 Dysphagia, a major cause of death, is predictable in Multiple System Atrophy, not in Progressive Supranuclear Palsy**
F. Bloch, M.L. Welter, S. Tezenas du Montcel, A.M. Bonnet, G. Bensimon, the NNIPPS Study Group
- P812 Epigallocatechin-3-gallate, a green tea polyphenol, reduces MPTP-induced neurotoxicity by down-regulation of inducible nitric oxide synthase**
J.M. Kim, J.J. O, S.K. Suh, C.W. Park, S.H. Lee, B.S. Jeon
- P813 European Multiple System Atrophy Study Group (EMSA-SG): validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)**
G.K. Wenning, K. Seppi, C. Sampaio, N.P. Quinn, W.H. Poewe, F. Tison
- P814 Falls and injuries in Progressive Supranuclear Palsy (PSP)**
B.R. Bloem, G. Mazibrada, A. Schrag, R. Viswanathan, A.J. Lees, N.P. Quinn
- P815 Freezing and hemifreezing gait without Parkinsonism due to dominant hemisphere frontal lobe lesion**
A. Sesar, M. Arias, I. Requena
- P816 Gliomatosis Cerebri may mimic the clinical features of Multiple System Atrophy (MSA)**
M. Ijaz, E.S. Molho

Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

- P817 Gluten sensitivity in Multiple System Atrophy**
M.T. Pellecchia, G. Ambrosio, K. Longo, C. Vitale, G. De Michele, P. Barone
- P818 Guam retinal pigment epitheliopathy (GRPE) and the amyotrophic lateral Sclerosis/Parkinsonism-Dementia Complex (ALS/PDC): the association of two unusual diseases of Guam and a possible clue to the etiology of tauopathy**
J.P. Jano-Edward, J.C. Steele, R. Wresch, Y. Ben-Schlomo, J. Keystone, T. Cox
- P819 Health-related quality of life in patients with Progressive Supranuclear Palsy (PSP)**
A. Schrag, C. Selai, J. Davis, A. Lees, N. Quinn
- P820 Instrumental kinematic approach for assessing upper limb motor control in Parkinson's Disease (PD): case report**
F. Molteni, M. Caimmi, E.S. Maini, A.M. Sabatini, M. Rossini, A. Franzini
- P821 Juvenile onset Parkinsonism in a patient with Chediak-Higashi Syndrome: a case report**
L.V.P. Korlipara, D.J. Burn, A.H.V. Schapira
- P822 Lack of association between Progressive Supranuclear Palsy and arterial hypertension: a clinico-pathological study**
C. Colosimo, Y. Osaki, N. Vanacore, A.J. Lees
- P823 Locomotor and cognitive evaluation in patients with normal pressure hydrocephalus before and after shunting. Comparison to locomotor pattern in Parkinson's Disease**
J.P. Azulay, S. Mesure, A. Donnet, F. Grisoli, J. Pouget
- P824 Maurice Ravel and tau**
F. Cardoso
- P825 MRI abnormalities in substantia nigra in post encephalitic Parkinsonism**
C.S. Savant, B.S. Singhal, A.M. Khan
- P826 MSA patients in the Neurological Department of Semmelweis University**
K. Fornadi, M. Farsang, A. Takats, I. Szirmai
- P827 Neuroprotection & Natural History in Parkinson Plus Syndromes (NNIPPS): design and progress report of a clinical trial of the efficacy and safety of riluzole in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
G. Bensimon, P.N. Leigh, A. Ludolph, L. Lacomblez, M. Vidailhet, B. Landwehrmeyer, D. Burn, M. Dib, S. Zierz, V. Meininger, A. Lees, Y. Agid, the NNIPPS Study Group
- P828 Neuroprotection and natural history in Parkinson Plus Syndromes (NNIPPS): construction and validation of a functional scale for disease progression assessment in Parkinson Plus Syndromes, Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)**
C.A.M. Payan, M. Vidailhet, L. Lacomblez, F. Viallet, M. Borg, F. Durif, B. Landwehrmeyer, J. Fermandjian, A. Ludolph, P.N. Leigh, G. Bensimon, the NNIPPS Study Group
- P829 Nicotine prevents MPTP-induced dopaminergic neurodegeneration**
J.M. Kim, J.J. O, K.W. Seo, Y.O. Kim, K.B. Kim, B.S. Jeon
- P830 Parkinsonian phenotype is associated with late onset and low abnormal range of CAG repeat in Formosa SCA2 families**
C.S. Lu, Y.H. Wu Chou, P.C. Kuo, H.C. Chang, T.C. Yen, Y.H. Weng
- P831 Parkinsonism and dropped head (PADRHE): a coincidental finding or a new presentation of mitochondrial disorders?**
M. Merello, J.C. Legarre, A. Javelier, G. Piran Arce, M. Garcia Alvarez, A. Cammarota
- P832 Parkinsonism and the response to treatment in Dementia with Lewy Bodies (DLB)**
A.A. Rojo, M.M. Aguilar, I.I. Navas, S.S. Quintana
- P833 Parkinsonism responsive to plasmapheresis treatment in a case of Multiple Sclerosis**
S.U. Schuele, J. Tavee, M.R. Rensel, P.J. Sweeney
- P834 Parkinsonism, manganese and brain imaging in liver failure**
M.A. Brodsky, M.L. Schilsky, D.J. Bronster, G. Fatterpekar, T.P. Naidich, W. Olanow
- P835 Pathology of primary progressive freezing gait: a case report**
S.A. Factor, J. Qian, A.J. Santiago
- P836 Progressive Supranuclear Palsy and Multiple System Atrophy: difficulties of diagnostic**
F. Bloch, M.L. Welter, O. Messouak, A.M. Bonnet, M. Vidailhet, the NNIPPS Study Group
- P837 Protective effect of riluzole in a double lesion rat model of Multiple System Atrophy (Striatonigral Degeneration)**
N. Stefanova, T. Sather, W. Poewe, G.K. Wenning
- P838 PSP: MRI and clinical correlates**
H.M. Ross, I.I. Reider-Groswasser, Y. Segev, N.J. Patronas, M. Hallett, I. Litvan
- P839 Quality of death certification in Progressive Supranuclear Palsy (Steele-Richardson-Olszewski Syndrome)**
U. Nath, Y. Ben-Shlomo, R. Thomson, A. Lees, D. Burn
- P840 Re-emergence of Encephalitis lethargica-like syndrome: evidence of CNS autoimmunity**
R.C. Dale, A.J. Church, R.A. Surtees, A.J. Lees, B.G. Neville, G. Giovannoni
- P841 Service use and costs of Parkinson's Plus Syndromes**
P. McCrone, Y. Agid, G. Bensimon, N. Leigh, A. Ludolph
- P842 SLV318: novel antiparkinsonian agent with antidepressant and anxiolytic-like actions**
L.C. Johnston, A.C. McCreary, M.B. Hesselink, A. Herremans, T. Tuinstra, J. van der Heyden, J. Glennon, L. Smith, P. Jenner, G. van Scharrenburg
- P843 Sputum and serum substance P in Parkinson's Disease**
T. Arai, K. Yamashiro, H. Mochizuki, Y. Mizuno
- P844 Subtle mirror movements in Hemiparkinsonism: a useful clinical sign (preliminary observations)**
A.J. Espay, J. Li, R. Chen, A.E. Lang
- P845 The accuracy of clinical diagnosis of Progressive Supranuclear Palsy**
Y. Osaki, C. Colosimo, Y. Ben-Shlomo, G. Wenning, N. Quinn, A. Lees
- P846 The sensitivity and specificity of weight-loaded, computer-assisted polymyography in the differential diagnosis of tremor**
P. Kanovsky, M. Bares, J. Dufek, M. Varga, I. Rektor
- P847 Three dimensional magnetic resonance based volumetry in Multiple System Atrophy**
M. Schocke, K. Seppi, C. Kremser, W. Jaschke, W. Poewe, G. Wenning
- P848 Transcranial magnetic stimulation in corticobasal degeneration: a report of two cases**
S. Thonke, H. Baas
- P849 Upper body involvement in lower body Parkinsonism - a study based on three-dimensional computerized movement analysis**
H. Baezner, J. Schanz, E. Grips, J.C. Woehrle, M.G. Hennerici
- P850 Use of the Thermoregulatory Sweat Test to discriminate Multiple System Atrophy from Parkinson Disease with autonomic failure and from Progressive Supranuclear Palsy**
R.M. Hutchman, J.E. Ahlskog, R.D. Fealey

Poster Sessions

Poster Session 6 - Wednesday, November 13

Noon - 1:30 pm

Poster numbers 851-1020

Clinical Electrophysiology, Dystonia

Poster numbers 851-1020

- P851 A case of "painful shoulder, undulating deltoid" syndrome**
Z. Mari, M. Hallett
- P852 A study of abnormal head retraction reflex elicited by facial sensory stimulation**
A. Hayashi, Y. Kohno
- P853 Acoustic startle reflex, acoustic blink reflex and eletro-oculography in atypical Parkinsonian Syndromes: a prospective study**
A. Gironell, J. Kulisevsky, C. Roig, B. Pascual-Sedano, A. Rodriguez-Fornells, P. Otermin
- P854 An EMG-analysis of Parkinsonian gait**
G.G. Fuss, J.J. Spiegel, C.C. Krick, J.R.J. Moringlane, G.G. Becker, U.U. Dillmann
- P855 Applications of transcranial magnetic stimulation in movement disorders**
R. Tarletti, R. Cantello
- P856 Assessment of impairment of cortical inhibitory mechanisms in blepharospasm and cervical dystonia: a study of silent period evoked by transcranial magnetic stimulation**
R. Cakmur, B. Donmez, F. Uzunel, H. Aydin, S. Kesken
- P857 Automatic EMG in assessment of cervical dystonia treated with botulinum toxin**
S.W. Cichy, C.W. Glazowski, M. Wieclawska
- P858 Bilateral pallidal deep brain stimulation and somatosensory processing in dystonia** S.R. Filipovic, S. Gill, P. Heywood
- P859 Cortical activation related to voluntary muscular relaxation**
F. Cassim, E. Labyt, J.L. Bourriez, P. Derambure, A. Destee, J.D. Guieu
- P860 Cortical silent period in Essential Tremor**
M. Behari, G. Shukla, M. Bhatia, R.M. Pandey
- P861 Deficient sensorimotor integration in Parkinson's Disease**
A. Sailer, G.F. Molnar, G. Paradiso, A.E. Lang, R. Chen
- P862 Effect of aging on anticipatory postural adjustments: interest of vertical torque**
S. Bleuse, F. Cassim, J.L. Blatt, L. Defebvre, A. Destee, J.D. Guieu
- P863 Effect of high-frequency stimulation on the cellular activity of subthalamic nucleus in Parkinson's Disease**
A.F. Sadikot, A.P. Strafella
- P864 Effects of subthalamic nucleus deep brain stimulation and muscle vibration on motor cortex excitability in advanced Parkinson's Disease**
T. Peschel, J. Daeuper, C. Schrader, R. Dengler, J.D. Rollnik
- P865 Excitability changes of group II afferents interneuronal transmission in rigid lower limb of de novo patients with Parkinson's Disease**
M. Simonetta-Moreau, S. Meunier, M. Vidailhet
- P866 Gait disturbances induced by bilateral pallidal lesions**
P. Krystkowiak, L. Defebvre, J.L. Blatt, J.D. Guieu, A. Destee
- P867 High frequency repetitive TMS can cause lasting effects on cortico-cortical coupling of motor areas with behavioural consequences**
A. Oliviero, L.H. Strens, V. Di Lazzaro, P.A. Tonali, P. Brown
- P868 Illustration of a micro lesion effect by semi microrecording of the STN**
H.L. Journée, L. Lamers, A.A. Postma, M.J. Staal, T. vanLaar, on Behalf of the Groningen Functional Stereotaxy Study Group
- P869 Intracortical modulation of transcallosal inhibition**
P.A. Shanahan, G. Mazibrada, J.C. Rothwell
- P870 Intraoperative recording of local field potentials for assisting localisation of the targets for deep brain stimulation**
X. Liu, D. Nandi, J.F. Stein, T.Z. Aziz
- P871 Neurophysiological explanation of possible role of Peripheral Facial Palsy in development of cranial dystonia** T.A. Filippova, O.R. Orlova, A.M. Vein
- P872 Peripheral silent periods in Essential Tremor**
M.M. Behari, G.G. Shukla, M.M. Bhatia, R.M.R. Pandey
- P873 Premovement potentials from the subthalamic nucleus and ventrointermedius nucleus of the thalamus in humans with self-paced and externally triggered movements**
G. Paradiso, D. Cunic, G.F. Molnar, A.E. Lang, A.M. Lozano, R. Chen
- P874 Quantitative measurement for Parkinson's Disease: DatacqO gloves**
Y. Su, U. Brechany, D.J. Burn, D. Geng, D. Bell, C.R. Allen
- P876 Relevance of multi channel microelectrode recording in deep brain stimulation of the subthalamic nucleus in Parkinson's Disease**
D. Servello, L. Geremia, V. De Simone, C. Pacchetti, S. Radice, M. Fornari
- P877 Results of neurophysiological investigation in Parkinson's Disease patients**
E.I. Gusev, A.B. Guekht, G.V. Serkin, E.S. Chikina, Y.A. Merkulov
- P878 Short-term effects of pallidal stimulation on motor cortex output in patients with dystonia: a TMS-study**
A.A. Kuehn, A. Kupsch, T. Trottenberg, G.H. Schneider, S.A. Brandt, B.U. Meyer
- P879 Single tract semi-micro electrode recording to identify the subthalamic nucleus in Parkinson's Disease**
E.C. Lamers, H.L. Journee, A.A. Postma, T. Laar van, M.J. Staal
- P880 Spectral differences in local field potentials recorded from globus pallidus in treated and untreated Parkinsons Disease (PD) and dystonia**
P. Silberstein, P. Brown, A. Kuhn, A. Kupsch, V. Di Lazzaro, T. Azziz
- P881 Tapping and peg insertion after apomorphine injection in Parkinsonian patients**
T. Muller, S. Benz, C. Bornke, H. Przuntek
- P882 Transcallosal inhibition in patients with corticobasal degeneration**
C. Trompetto, A. Buccolieri, R. Marchese, L. Avanzino, G. Abbruzzese
- P883 Trigemincervical reflexes: normative data and application to cervical dystonia patients**
A.B. Danilov, T.A. Filippova, L.A. Petrova, O.R. Orlova, A.M. Vein
- P884 Visual evoked potentials in Lewy body dementia and Alzheimer's Disease**
Z. Pirtosek
- P885 12 Years follow-up and natural history of Blepharospasm and Meige-Syndrome treated with Botulinum toxin A**
P. Haussermann, S. Marczocho, C. Klingler, M. Landgrebe, B. Conrad, A. Ceballos-Baumann

Poster Sessions

Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

- P886 12 years follow-up and natural history of Cervical Dystonia treated with Botulinum toxin A**
P. Haussermann, C. Klingler, S. Marczych, M. Landgrebe, B. Conrad, A. Ceballos-Baumann
- P887 A Clinical trial with Cabergoline in patients with advanced Parkinson Disease: one or several doses. A clinical preview**
M.E. Esteguy, J.F. Fusillo
- P888 A novel mutation in the epsilon-sarcoglycan gene causing atypical Myoclonus-Dystonia Syndrome in a large Danish family**
L.E. Hjermland, L.M. Werdelin, H. Eiberg, B. Krag-Olsen, E. Dupont, S.A. Soerensen
- P889 A phenotypic study of Irish families with adult-onset focal craniocervical dystonia**
S. O'Riordan, T. Lynch, S. Bressman, M. Hutchinson
- P890 A remarkable association of generalized dystonia, Huntingtons Disease, Progressive Supranuclear Palsy and Secondary Paroxysmal Dyskinesia in one family**
N.M. Russo, M.J. Edwards, B.A. Summers, J.E. Morton, D. Peake, K.P. Bhatia
- P891 Abnormalities of somatotopy of sensorimotor interactions in patients with focal dystonia**
S. Tamburin, P. Manganotti, A. Andreoli, A. Fiaschi, G. Zanette
- P892 Aids-related symptomatic dystonia improvement after botulinum toxin type a treatment: a case report**
G. Lagalla, M. Millevolte, C. Gioia, M. Danni, L. Provinciali, M. Ceravolo
- P893 An ¹¹C-diprenorphine PET study investigating opioid binding in DYT1 dystonia**
A.L. Whone, S. von Spiczak, M.J. Edwards, A. Hammers, K. Bhatia, D.J. Brooks
- P894 Anti-occupational dystonia**
D. Paramo, J. Chacon, E. Duran, R. Vahi, M. Alvarez
- P895 Ataxia with vitamin E deficiency and severe dystonia: report of a case**
A. Roubertie, B. Biolsi, F. Rivier, V. Humbertclaude, R. Cheminal, B. Echenne
- P896 Autosomal Recessive, DYT-2-like Primary Torsion Dystonia: a new family**
N.L. Khan, N.W. Wood, K.P. Bhatia
- P897 Autosomal-dominant segmental Dystonia-Plus Syndrome associated with Cerebral Calcinosi. Study in progress**
Z.K. Wszolek, Y. Tsuboi, D.F. Broderick, J. Allanson, J. Carr, R.J. Uitti, A. Strongosky, M. Baker, M. Hutton, D.B. Calne
- P898 Beneficial effect of cigarette smoking on generalized dystonia with tremor**
I. Schlesinger, P. Ravin
- P899 Bilateral deep brain stimulation for idiopathic cervical dystonia : results in four patients after one year**
S. Raoul, J. Saint-Cyr, T. Hoque, A.E. Lang, A.M. Lozano
- P900 Bilateral pallidal stimulation for treatment of Meige Syndrome**
H.H. Capelle, R. Weigel, J.K. Krauss
- P901 Blinded evaluation for the frequency of chorea in dystonia patients both on and off anticholinergic medication**
S. Horn, V.K. Hinson, M. Morrissey, C.G. Goetz
- P902 Botulinum neurotoxin B in blepharospasm and hemifacial spasm: a pilot study**
M. Chianese, M. Giovannelli, F. Contarino, A.R. Bentivoglio, C. Colosimo
- P903 Botulinum toxin in writer's cramp - experience with 155 patients**
R. Borgohain, M.A. Kanikannan, S. Sattaluri, J. Mani, M. Surath
- P904 Botulinum toxin type B (Myobloc) is safe and effective for treating adductor spasmodic dysphonia**
C.H. Adler, S.F. Bansberg, K. Krein-Jones, M. Lind, J.G. Hentz
- P905 Botulinum toxin type B (Myobloc[®]) at doses > 10,000 units for the treatment of cervical dystonia: two case studies**
L.K. Struck
- P906 Botulinum toxin type B (Myobloc[®]) for the treatment of hemifacial spasm and blepharospasm**
L.K. Struck
- P907 Brain activation during complex finger tapping in patients with writer's cramp: a functional MRI study**
G. Iannetti, A. Curra, P. Pantano, A. Suppa, L. Bozzao, A. Berardelli
- P908 Camptocormia secondary to adult-onset dopa-responsive dystonia**
J.A. Van Gerpen, D.M. Maraganore
- P909 Candidate gene research in focal dystonia excludes involvement of ATP7A, ATP7B, ATOX, HLA-DR and MTHFR**
O. Bandmann, D. Sibbing, F. Asmus, I. Koenig, M. Grundmann, A. Ziegler
- P910 Central effects of botulinum toxin in patients with writers cramp**
B. Boroojerdi, I.G. Meister, H. Foltys, R. Topper, L.G. Cohen, M. Hallett
- P911 Cervical dystonia as first manifestation of Multiple Sclerosis: a case report**
M. Bühlmann, S. Rüegg, S. Renaud, A. Steck, L. Kappos, P. Fuhr
- P912 Characterization of dystonic movements by means of accelerometry**
N. Diakonova, L. Cif, M. Azais, S. Hemm, N. Vayssiere, P. Coubes
- P913 Characterization of DYT1 transgenic mice**
N. Sharma, J. Petravic, S.J. Augood, L.J. Ozellus, D.G. Standaert, X.O. Breakefield
- P914 Clinical and genetic evaluation in a french population presenting with primary focal dystonia**
X. Douay, C.M. Dhaenens, P. Krystkowiak, B. Sablonniere, A. Destee
- P915 Clinical applications of botulinum toxin type B (Bot B) in movement disorders**
E.S. Molho, S.A. Factor
- P916 Clinical characterization of cranio-cervial dystonia treated with botulinum toxin type a**
C. Maragoto, F. Mendoza, L. Alvarez, J.M. Morales, G. Rodriguez, E. Alvarez
- P917 Clinical study of different writer's cramp forms: spasmodic and tremulous**
O.A. Shavlovskaya, O.R. Orlova, V.L. Golubev, A.M. Vein
- P918 Cognition and affect in patients with cervical dystonia without tremor**
K. Vermilion, J. Peterson, D. Duane
- P919 Comparison of efficacy and immunogenicity of original versus current BOTOX in cervical dystonia**
J. Jankovic, K.D. Vuong, J. Ahsan
- P920 DBS for treatment of residual symptoms after stroke**
D. Lenartz, A. Koulousakis, J. Volkmann, J. Voges, V. Sturm
- P921 Deep brain stimulation for dystonia: does clinical experience confirm a somatotopic organization in the GPI?**
N. Vayssiere, N. Van Der Gaag, L. Cif, S. Hemm, P. Frerebeau, P. Coubes

Poster Sessions

Poster Session 6 Wednesday, November 13, Noon - 8:30 pm

- P922 Deep brain stimulation in dystonia**
G. Broggi, A. Franzini, N. Nardocci, G. Zorzi, C. Marras, M. Marchetti
- P923 Development of Parkinson's Disease in patients with blepharospasm**
F.E. Micheli, M.C. Scorticati, S. Folgar, E.M. Gatto
- P924 Developmental expression of rat TorsinA mRNA**
J. Xiao, M.S. LeDoux
- P925 Diurnal post-traumatic Bruxism: a case report**
M.E. Esteguy, C.A. Gomez Roca, A. Amengual, P. Rodriguez
- P926 Dopa-responsive dystonia in monozygotic twins**
H. Groetzsch, M. Morris, H. Schnorf, J. Horvath, P.R. Burkhard
- P927 Dystonia and electrical stimulation of the internus globus pallidus : criteria for the patient's selection**
L. Cif, M. Azais, N. Vayssiere, S. Hemm, N. Diakonova, P. Coubes
- P928 Dystonia and neuromyotonic activity secondary to electrical injury**
K.G. Yiannopoulou, T.G. Avramidis, R.S. Divari, A.L. Papadimitriou
- P929 Dystonia in *encephalitis lethargica***
D.E. Riley
- P930 Dystonia in adolescents and adults associated with anti-basal ganglia antibodies**
M.J. Edwards, R.C. Dale, A.J. Church, G. Giovannoni, K.P. Bhatia
- P931 Dystonia of the scalp secondary to cysticercosis**
K.P. Frei, D.D. Truong
- P932 Dystonia secondary to hypoxic-ischemic encephalopathy response to trihexyphenidyl**
C. Maragoto, G. Rodriguez, M.A. Ortega, I. Sarduy, T. Gonzalez, A. Garcia
- P933 DYT1 mutation in Korean dystonia patients**
T.B. Ahn, J.H. Im, K.B. Kim, S.B. Ko, B.S. Jeon
- P934 DYT1 mutation in primary torsion dystonia in Serbian population**
V.S. Kostic, T. Major, M. Svetel, K. Kabaksi, C. Klein, S. Romac
- P935 Early, limb-onset dystonia with late generalisation in an Irish family in which the TOR1A GAG deletion has been excluded**
S. O'Riordan, T. Lynch, S. Bressman, M. Hutchinson
- P936 Effect of chronic GPi deep brain stimulation in patients with intractable generalized and segmental dystonia**
S. Kelm, N. Allert, C. Dohle, J. Volkmann, J. Voges, R. Lehrke
- P937 Efficacy of botulinum toxin type B (Myobloc[®]) for treatment of blepharospasm: report of two cases**
J.E. Samanta, M.A. Stacy
- P938 Efficacy of botulinum toxin type B (Myobloc[®]) in a case of hemifacial spasm**
J.E. Samanta, M.A. Stacy
- P940 Enhanced metabolic suppression of frontal motor areas after inhibitory repetitive TMS of the lateral premotor cortex in primary dystonia**
H.R. Siebner, J.B. Rowe, S. Filipovic, C. Cordivari, J.C. Rothwell, K. Bhatia
- P941 Epidemiological and clinical differences between adductor and abductor laryngeal dystonia**
P.J. Garcia Ruiz, C. Gomez Escalonilla, A. Echeverria, C. Cenjor
- P942 Epileptic dystonia. An intracranial video-EEG study**
R. Ivan, K. Robert, B. Milan
- P943 Evaluation of childhood hypertonia using the Prochazka rigidity analyzer**
T.D. Sanger
- P944 Factors modulating symptoms in Spasmodic Torticollis**
D.E. Riley, G.W. Paulson
- P945 Fluctuations in self-assessed benefit following botulinum toxin type A treatment in cervical dystonia**
J.A. Jaglin, C.L. Comella, M. Morrissey
- P946 Fracture of the axial dens - a serious complication of cervical dystonia**
C. Konrad, S. Knecht, J. Vollmer-Haase
- P947 Functional assessment of cervical dystonia using a motion analysis system: preliminary results**
M. Gambini, J. Carpaneto, M.C. Carboncini, G. Galardi, S. Micera, M. Borghesi
- P948 Genetic heterogeneity in Myoclonus Dystonia Syndrome (MDS)**
A. Misbahuddin, M.R. Placzek, A. Nemeth, C. Shaw-Smith, T.T. Warner
- P949 Genetic susceptibility in cervical dystonia: confirmation of a role for the dopamine D5 receptor gene**
E.M. Valente, F. Brancati, N. Vanacore, G. Galardi, A. Berardelli, B. Dallapiccola
- P950 Growth and puberty in children with generalized dystonia treated by electrical stimulation of the internal globus pallidus**
C. Monnier, F. Paris, L. Cif, S. Hemm, P. Coubes, C. Sultan
- P951 Hand dystonia after subcortical fronto-parietal infarct**
J. Shi, S.M. Kuniyoshi, T.C. Chelimsky, B.N. Maddux
- P952 Impaired muscle spindle function following botulinum toxin-A injection in man**
P.P. Urban
- P953 Impaired surround inhibition in focal hand dystonia during voluntary movement**
Y.H. Sohn, M. Hallett
- P954 Impairment of repetitive finger oppositions in dystonia**
R. Agostino, A. Curra, L. Dinapoli, M. Manfredi, A. Berardelli
- P955 Improvement of dystonia with topiramate**
R.S. Isaacson, N.V. Nadel, S.H. Isaacson
- P956 Influence of bilateral deep brain stimulation of the entopeduncular nucleus on the severity of dystonic attacks in the dt(sz) hamster model of dystonia**
D. Harnack, M. Hamann, W. Meissner, R. Morgenstern, A. Kupsch, A. Richter
- P957 Intratecal Baclofen and DBS of Gpi for generalized dystonia: our experience**
A. Lavano, G. Volpentesta, G. Ferraro, C. Veltri, M. Aloisi, C. Signorelli
- P958 Investigations into the normal function of the DYT1 protein TorsinA**
R.E. Goodchild, B. Luring, R. Hen, Y. Schmitz, W. Dauer
- P959 Is botulinum toxin Dysport effective in Botox-resistant patients with blepharospasm or hemifacial spasm?**
S. Badarny, Z. Susel, S. Zivziner, S. Honigman
- P960 Long-term follow-up of pallidal deep brain stimulation in non DYT-1 generalized dystonia and choreoathetosis**
J.K. Krauss, T.J. Loher, R. Weigel, S. Weber, H.H. Capelle, J.M. Burgunder

Poster Sessions

Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

- P961 Long-term safety, efficacy, and dosing of botulinum toxin type B (Myobloc) in cervical dystonia (CD) and other movement disorders**
R. Kumar, L.C. Seeberger
- P962 Mirror dystonia (mirror movements) in writer's cramps and therapeutic outcome with botulinum toxin - a prospective study**
R. Borgohain, M.A. Kanikannan, S. Sattaluri, J. Mani, M. Surath
- P963 Motor planning and interhemispheric relationship in dystonia and Parkinson's Disease**
M.I. Vendrova, O.R. Orlova, R.A. Sadekov, V.L. Golubev, A.E. Morenkova, A.M. Vein
- P964 Movement disorders, cervical spondylosis and myelopathy**
T.J. Loher, C.B. Barlocher, J.K. Krauss
- P965 Muscle relaxation is impaired in dystonia: a reaction time study**
G. Abbruzzese, A. Buccolieri, R. Marchese, C. Trompetto, L. Marinelli
- P966 Neuronal GP activity in patients with generalized dystonia**
M. Merello, F. Micheli, D. Cerquetti, J. Antico, A. Cammarota, E. Tenca
- P967 Novel neuropathological findings in 'Lubag' or x-linked Dystonia-Parkinsonism**
V.G.H. Evidente, D. Dickson, A. Singleton, F. Natividad, J. Hardy, D. Hernandez
- P968 Ontogenetic increases of striatal GABAergic interneuron density in a genetic animal model of primary paroxysmal dystonia**
A. Richter, M. Hamann
- P969 Pallidal DBS in seven patients with primary and secondary generalized dystonia**
M. Tagliati, J.L. Shils, S. Bressman, R.L. Alterman
- P970 Paroxysmal dystonia in a MS patient with cervical spinal cord lesion**
L. Carluer, I. Leber, G.-L. Defer
- P971 Patients with cervical dystonia thought to be secondary non responders to botulinum toxin treatment should be given a trial of EMG guided injections**
C. Cordivari, A. Vincent, V.P. Misra, S. Catania, K.P. Bhatia, A.J. Lees
- P972 Postsynaptic dopaminergic function in idiopathic cervical dystonia: a PET study**
H.M. Ruottinen, H. Erjanti, K. Nagren, V. Oikonen, R. Marttila
- P973 Prevalence of primary dystonia in the Belgrade population. Preliminary report**
T. Pekmezovic, N. Ivanovic, M. Svetel, V.S. Kostic
- P974 Pseudoathetosis or sensory dystonia**
N.M. Biary, B.A. Yaqub, S.M. Al Deeb
- P975 Quantitative EMG and MRI-volumetry of cervical muscles in Torticollis spasmodicus**
P. Haussermann, C. Bischoff, N. Draheim, H. von Einsiedel, B. Conrad, A. Ceballos-Baumann
- P976 Reliability and validity of the PTWIST: cervical dystonia patient self-assessment scale**
M. Welsh, C. Kawai, G. Broutman, B. Lopez, M. Lew
- P977 Retrospective evaluation of Dysport® and BOTOX® drug utilization in the management of patients with cervical dystonia or blepharospasm**
R. Magar, A. Marchetti, F. Ahmed, I. Ferguson
- P978 Role of the platysma muscle in Cervical Dystonia and experience with surgical denervation/resection of this muscle**
C.A. Arce
- P979 Safety and efficacy of Botulinum Toxin "BT" in facial hemispasm**
G. Ianieri, A. Santamato, F. Saponieri, P. Dicillo, G. Megna
- P980 Safety and efficacy of injection of psoas major muscle with botulinum toxin type A in early adulthood-onset idiopathic torsion dystonia**
S.S. Ochudlo, G.G. Opala, J.J. Baron
- P981 Screening methods for Dystonia: Beth Israel Medical Center Dystonia Telephone Screen**
J. Shriberg, J. Soto, K. Habermann, D. Raymond, S. Bressman, R. Saunders-Pullman
- P982 Screening of a large cohort of movement disorder patients and controls for the GAG deletion in the DYT1 gene and detection of a novel mutation**
K. Kabakci, P.P. Pramstaller, K. Hedrich, L.J. Ozelius, V. Kostic, C. Klein
- P983 Selective peripheral denervation for the treatment of Spasmodic Torticollis: technique and results**
A.A. Cohen-Gadol, E.J. Ahlskog, J.Y. Matsumoto, M.A. Swenson, D.H. Davis
- P984 Sensitivity and specificity of a screening method for dystonia**
R.J. Saunders-Pullman, J. Shriberg, D. Raymond, D. deLeon, L. Bershiski, S. Bressman
- P985 Sensori-motor coupling is deficient in focal task dystonia M.**
Simonetta-Moreau, M. Vidailhet, J. Lourenço, S. Meunier
- P986 Sequence learning is impaired in clinically unaffected carriers of the DYT1 mutation**
M.F. Ghilardi, M. Carbon, G. Silvestri, V. Dhawan, M. Tagliati, S. Bressman
- P987 Seven-year experience of craniocervical spasm disorders treatment with Botulinum-A toxin: short- and long-term effects**
S.L. Timerbaeva, E.D. Markova, I.A. Ivanova-Smolenskaya, N.G. Savitskaya, O.Y. Rebrova
- P988 Signs for shoulder girdle dystonia in selected patients with cervical disc prolapse**
G. Becker, D. Berg, N. Kruse, U. Schröder, M. Warmuth-Metz, P. Rieckmann, M. Naumann, K. Reiners
- P989 Similarities and dissimilarities between patients with cervical dystonia with and without tremor and essential tremor: family history, cognition and affective state**
J.D. Peterson, K.J. Vermillion, D.D. Duane
- P990 Somatosensory processing in cranial dystonia: neurophysiological observations and effect of botulinum toxin treatment**
O.R. Orlova, T.A. Filippova, A.E. Morenkova, A.B. Danilov, N.N. Yakhno, A.M. Vein
- P991 Spasmodic torticollis and hemifacial spasm after electrically induced injury**
S.M. Kuniyoshi, D.E. Riley
- P992 Spinocerebellar ataxia 3 (SCA3) cousins presenting as dopa-responsive dystonia**
J.H. Tan, E. Wilder-Smith
- P993 Stimulated volume and energy consumption in improved dystonic patients treated by high frequency GPi stimulation**
S. Hemm, N. Diakonova, G. Mennessier, N. Vayssiere, L. Cif, P. Coubes
- P994 Stimulation - drug interactions in chronic deep brain stimulation of the internal globus pallidus for risperidone-responsive segmental dystonia**
J.C. Wohrle, R. Weigel, E. Grips, C. Blahak, H.H. Capelle, J.K. Krauss

Poster Sessions

Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

- P995** **Striatal extracellular monoamine levels in a genetic animal model of primary paroxysmal dystonia**
M. Hamann, A. Richter
- P996** **Study of mutant and wild type torsinA in human SH-SY5Y cell lines**
M.R. Placzek, A. Misbahuddin, J.W. Taanman, J.M. Cooper, T.T. Warner
- P997** **Study of the electrical stimulation of the internal globus pallidus by functional Magnetic Resonance Imaging**
M. Zanca, B. Bataille, G. Morrot, N. Vayssiere, S. Hemm, P. Coubes
- P998** **Subthalamic nucleus deep brain stimulation (STN-DBS) in a patient with X-linked Dystonia-Parkinsonism (XPD): a case report**
O.V. Kopyov, R.F. Young, K. Sipes, B. Copcutt, J.P. Sutton
- P999** **Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex in writer's cramp**
N. Murase, R. Kaji, N. Murayama, T. Igasaki, J.C. Rothwell, H. Shibasaki
- P1000** **Sudden loss of benefit from botulinum toxin for Spasmodic Torticollis**
D.E. Riley
- P1001** **Surround inhibition is impaired in patients with focal hand dystonia during movement preparation**
F.M. Molloy, Y.H. Sohn, M. Hallett
- P1002** **Temporal discrimination of unimodal and cross-modal tactile and visual stimuli in primary dystonia**
M. Tinazzi, M. Fiorio, N. Smania, S. Tamburin, A. Fiaschi, S.M. Aglioti
- P1003** **The auditory startle response in cervical dystonia**
J. Mueller, M. Kofler, W. Poewe
- P1004** **The differences between dystonical movement in primary and secondary dystonia**
J.S. Dedic, N.S. Ivanovic, M.V. Svetel, S.N. Dedic, V.S. Kostic
- P1005** **The disorder of cortical excitability and cortical inhibition in focal dystonia is lateralized: an evidence from somatosensory evoked potentials and transcranial magnetic stimulation recordings**
P. Kanovsky, M. Bares, H. Streitova, H. Klajblova, P. Daniel, I. Rektor
- P1006** **The effects of clozapine on treatment of generalized and focal dystonia**
M. Kapisyzi, J. Kruja
- P1007** **The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia; results of the first US study**
D.D. Truong, D.D. Duane, J. Jankovic, C. Singer, C.L. Comella, the US Dysport Dystonia Study Group
- P1008** **The efficiency of continuous intrathecal baclofen for the treatment of generalized dystonia. Our experience in four cases**
J. Chacon, R. Vahi, M.A. Grande, E. Duran, M.D. Paramo, M. Alvarez
- P1009** **The MIND Patient Registry: capturing the clinical uses of Myobloc**
M. Royal, C. Towey, D. Bevers, C. O'Brien
- P1010** **The natural history of posttraumatic torticollis**
K.P. Frei, M. Pathak, S.W. Jenkins, D.D. Truong
- P1011** **The yips: an electrophysiologic evaluation**
C.H. Adler, J.N. Caviness, D. Crews
- P1012** **Transient blepharospasm secondary to striatal infarction**
L. Lopez, S. Garcia, F. Diaz, A. Gil, A. Traba, F. Grandas
- P1013** **Treatment of adductor laryngeal breathing dystonia with tetrabenazine**
M.G. Jabre, W.W. Bejjani, B.-P.W. Bejjani
- P1014** **Treatment of dystonia due to Pantothenate Kinase Associated Neurodegeneration (PKAN) by GPI stimulation (DBS)**
A. Gannau, P.A. Castelnau, L. Cif, S. Hemm, P. Evrard, P. Coubes
- P1015** **Treatment of hemi facial spasm with Botulinum toxin-B (Myobloc)**
A. Ahmed, A. Kanwaljit, T. Subramanian, J.S. Perumal
- P1016** **Treatment of limb dystonia with botulinum toxin - type B**
M.A. Stacy
- P1017** **Two cases of task-specific movement disorders**
J.S. Baik, J.H. Park, J.Y. Kim, Y.K. Minn
- P1018** **Unusual phenotypes in DYT1 dystonia - a report of 5 cases and a review of the literature**
M.J. Edwards, N.W. Wood, K.P. Bhatia
- P1019** **What are the predictive factors of good outcome in writer's cramps treated with Botulinum toxin injections?**
R. Djebbari, S. Tezenas du Montcel, S. Sangla, J.-S. Vidal, M. Vidailhet
- P1020** **Writer's cramp treated with hand immobilization**
S. Badarny, J. Meer, T. Drori, S. Zivziner, S. Honigman

Poster Sessions

Poster Session 7 - Thursday, November 14

7:00 am - 8:30 am

Poster numbers 1021-1182

Ataxia, Chorea, Drug-induced Movement Disorders, Myoclonus, Spasticity, Stereotypies, Tics, Tremor

- P1021 Abnormal striatal dopaminergic function in SCA2 revealed by beta-CIT and IBZM SPECT**
S.M. Boesch, M. Schocke, K. Seppi, P. Hollosi, W. Poewe, G.K. Wenning
- P1022 Antioxidant treatment of patients with Friedreich's Ataxia: 3 year follow up**
P.E. Hart, R. Lodi, B. Rajagopalan, J.L. Bradley, D.J. Taylor, J.M. Cooper
- P1023 Ataxia: a common movement disorder in central nervous system Whipple's disease**
L.K. Jones, K. Josephs, D.A. Saad, A. Aksamit, J.E. Ahlskog
- P1024 Cerebellar degenerative ataxias - terminology, classification and diagnostic criteria**
N.P. Nikojevski
- P1025 Clinical and electrophysiological peculiarities of ataxia of different origin**
M. Ganea, S. Groppa, E. Zota, L. Luhtimovschi
- P1026 Concordance between two methods for measurement of dysmetria**
O. Carvajal M., D. Carvajal M., G. Garcia C., C. Amador O., P. Lorenzana P., W. Fernandez E.
- P1028 Early-onset ataxia associated with ocular motor apraxia and hypoalbuminemia (EAOH), a variant form of Friedreich's Ataxia. -Clinical and genetic analyses-**
O. Onodera, H. Date, A. Yokoseki, S. Igarashi, H. Tanaka, S. Tsuji
- P1029 Gluten sensitivity In Huntington's Disease**
K.O. Bushara, C.M. Gomez, M. Nance
- P1030 High-dose Piracetam is effective on cerebellar ataxia in a patient with cerebellar cortical atrophy**
M. Vural, S. Ozekmekci, H. Apaydin, A. Altinel
- P1031 Idiopathic late onset cerebellar ataxia: a follow-up study of 12 years**
H.G. Teive, W.O. Arruda, L.C. Werneck
- P1032 Movement disorders in a series of 83 spinocerebellar ataxia families**
H.G. Teive, W.O. Arruda, L.C. Werneck
- P1033 Open-label trial of gluten-free diet in sporadic and hereditary cerebellar ataxia with gluten sensitivity**
K.O. Bushara, H.S. Shill, M. Hallett
- P1034 Progressive cerebellar syndrome as the first manifestation of HIV infection**
I. Puertas, F.J. Jiménez-Jiménez, C. Gómez-Escalonilla, Y. Sayed, F. Cabrera-Valdivia, R. Rojas
- P1035 Relentlessly progressive myoclonic ataxia in gluten sensitivity: a case presentation**
M. Eccher, M.A. Werz, D.E. Riley
- P1036 SCA 10: description of 2 families with different phenotype**
H.G. Teive, T. Ashizawa, S. Raskin, W.O. Arruda, B. Roa, L.C. Werneck
- P1037 SCA2 and Multiple Sclerosis: a case report**
P. Hollosi, M. Schocke, S.M. Boesch
- P1038 Validation and use of assessment protocols to determine clinical progression in Friedreich's Ataxia**
J.L. Bradley, P.E. Hart, M. Al Khayatt, A.H. Schapira, J. Cooper
- P1039 A case of abetalipoproteinemia with a choreic-ataxic syndrome and none of the known mutations**
S. Konitsiotis, C. Mokou, S. Kalantaridou, M. Syrrou, M. Kravariti, A. Tsatoulis
- P1040 A case of hemichorea with an ipsilateral thalamic infarction**
J.S. Baik, J.H. Park, J.Y. Kim, Y.K. Minn
- P1041 Assessment of Huntington's Disease - correlation between motor and cognitive deficits**
R. Reilmann, F. Kirsten, L. Quinn, H. Henningsen, K. Marder, A.M. Gordon
- P1042 Benign Hereditary Chorea: neuropathological findings**
G. Kleiner-Fisman, W. Halliday, A.E. Lang
- P1043 Chorea and contraceptives. A case report with PET study**
L. Vela, C. Singer, G.N. Sfakianakis, D. Heros, W.C. Koller
- P1044 Chorea and orobuccal dyskinesia due to Hansen's Disease**
L.S. Boylan
- P1045 Chorea in a 21-year-old female associated with multiple risk factors**
M. Rezak, S.M. Vergenz
- P1046 Clinical and genetic heterogeneity in Benign Hereditary Chorea**
G.J. Breedveld, C. Yapijakis, A.K. Percy, E. Ippel, P. Heutink, W.F. Arts
- P1047 Clinical care for HD-patients: five years of experience in Germany**
J. Andrich, C. Saft, I. Wilhelms, P.H. Kraus, H. Przuntek
- P1048 Clinical characteristics of Huntington's Disease in Albania**
M. Kapisyzi, A. Kuqo, G. Nurja, G. Vreto, J. Kruja
- P1049 Clinical improvement after neuronal graft in Huntington Disease (HD) is related to striatal and cortical metabolic changes**
V. Gaura, A.C. Bachoud-Lévi, J.P. Nguyen, P. Hantraye, M. Peschanski, P. Remy
- P1050 Cortical dopamine D2 receptor dysfunction in Huntington's Disease**
N. Pavese, A.E. Rosser, D.J. Brooks, R.A. Barker, S.B. Dunnett, P. Piccini
- P1051 Creatine therapy for Huntington's Disease (HD): clinical and ³¹P MRS findings in a one year pilot study**
S.J. Tabrizi, B. Rajagopalan, P. Styles, D. Manners, A.H. Schapira, T.T. Warner
- P1052 Disease modifying therapy with metabotropic Glutamate receptor (mGluR) specific drugs in a mouse model for Huntington's Disease**
J. Schiefer, C. Puls, A. Spruenken, E. Milkereit, A. Milkereit, C.M. Kosinski
- P1053 European-Huntington's-Disease-Initiative (EHDI)-Trial: objectives, design and description of the study population at the end of inclusion**
B. Dubois, M. Brand, M. Dib, J. Garcia de Yabenes, W. Gaus, R. Genthon, I. Kermadi, H.P.H. Kremer, A.C. Ludolph, I. Margalet, the EHDI-Trial Study Group
- P1054 Hemiballism (HB) triggered by hyperglycemia: report of two cases**
R.J. Giannaula, A.M. Malmierca, O. Stella, M.F. Huerta, J.C. Maiques, M.G. Closter

Poster Sessions

Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

- P1055 Highly disabling, cerebellar, juvenile-onset Huntington Disease**
F. Squitieri, G. Pustorino, M. Cannella, A. Toscano, L. Morgante, G. Tortorella
- P1056 Identification of spermine in spectroscopic profiles of the putamen in presymptomatic Huntington's Disease with Magnetic Resonance Scanning at 0.5 Tesla**
N.C. Reynolds, R.W. Probst, L.P. Mark
- P1057 In vitro cell models of Huntington's Disease using N-terminal and full length Huntingtin: the relationship between excitotoxicity, mitochondrial dysfunction, and free radicals**
C. Turner, L. Jones, L. Elliston, J.M. Cooper, A.H.V. Schapira
- P1058 Long term prognosis of vascular hemiballism**
A.J. Ristic, J. Marinkovic, N. Dragasevic, D. Stanisavljevic, I.N. Petrovic, V.S. Kostic
- P1059 Mitochondrial impairment in Huntington's Disease: a magnetic resonance spectroscopy study**
C. Saft, J. Zange, J. Andrich, K. Mueller, P.H. Kraus, L. Schoels
- P1060 Mutations in TITF-1 are associated with Benign Hereditary Chorea**
G.J. Breedveld, J. van Dongen, H. van der Linde, M. Joosse, B.A. Oostra, P. Heutink
- P1061 Novel features in a patient with hyperglycaemic hemichorea**
J.H. Tan, B.P.L. Chan, E. Wilder-Smith, E. Lim
- P1062 Objective assessment of motor slowness in Huntington's Disease: two years follow-up**
J.P.P. van Vugt, K.K.E. Piet, S. Siesling, A.H. Zwinderman, H.A.M. Middelkoop, R.A.C. Roos
- P1063 Oral-buccal-lingual dyskinesia caused by nonketotic hyperglycemia: a case report**
S.H. Park, Y.H. Hong, J.M. Kim, J.Y. Kim
- P1064 Paraneoplastic choreo-dystonia in a patient with non-Hodgkin Lymphoma and CRMP-5 autoantibody**
A. Samii, D.D. Dahlen, A.M. Spence, N.C. Maronian, E.E. Kraus, V.A. Lennon
- P1065 Quantitative kinematic analysis of chorea**
J.W. Mink
- P1066 Reversal of synaptic plasticity impairment in motor cortex in a conditional model of Huntington's Disease**
F. Battaglia, F. Trinchese, A. Yamamoto, A. Quartarone, R. Hen, O. Arancio
- P1067 Reversible chorea associated with novel antidepressants**
S. Pappa, C. Mantas, V. Mavreas, S. Konitsiotis
- P1068 Safety and tolerability of lamotrigine in Huntington Disease**
D.S. Higgins, K. Illouz, P. Subramanian
- P1069 Short-term motor effects of riluzole in Huntington's Disease: an open label study**
R. Granata, K. Seppi, J. Mueller, W. Poewe, G. Wenning
- P1070 Tetrabenazine in the treatment of symptomatic pediatric chorea**
A. Chatterjee, S.J. Frucht
- P1071 The caudate nucleus atrophy in Huntington Disease and its relation to clinical and genetic parameters**
J. Roth, J. Klempir, R. Jech, J. Zidovska, T. Uhrova, P. Dousek
- P1072 The characterisation of Huntington's Disease(HD) skeletal muscle: mitochondrial respiratory chain, ultrastructural and light microscopic study**
C. Turner, L. Jones, J.M. Cooper, A.H.V. Schapira
- P1073 Topiramate in vascular hemichorea**
F.E. Micheli, E.M. Gatto, M.F. Gorga, M.C. Uribe Roca, S. Folgar
- P1074 Treatment of Sydenham Chorea (SC) with corticosteroids**
F. Cardoso, D.P. Maia, M.C.Q. Cunningham, M.E. Silva, G. Valença
- P1075 A comparison of olanzapine to typical neuroleptics for the treatment of stereotyped movement disorder: acute and long-term effects**
K.M. Newell, J.W. Bodfish, S.L. Mahorney, G.R. Breese
- P1076 A novel case of bupropion induced palatal and limb myoclonus: hypothesis on the mechanism of action**
A.D. Hohler, J.E. Hartmann
- P1077 A prospective, 6-month multicenter, open label dose-rising study of the effect of Sarizotan on dyskinesia in Parkinson's Disease**
C.W. Olanow, C. Goetz, T. Mueller, J. Nutt, O. Rascol, H. Russ
- P1078 Attenuation of haloperidol-induced orofacial dyskinesia by cyclooxygenase inhibitors**
S.K. Kulkarni, P.S. Naidu
- P1079 Automatic assessment of dyskinesia in daily life**
N. Keijsers, M. Horstink, S. Gielen
- P1080 Complete cessation of orofacial dyskinesias with bilateral internal pallidum stimulation in a 39 year old woman with tardive dyskinesia**
C. van der Linden, H. Colle, E. Foncke, G. Alessi, D. Rijckaert, L. De Waele
- P1081 Do Serotonin Reuptake Inhibitors aggravate extrapyramidal symptoms in Parkinson's Disease? A pharmacoepidemiological study in the French Pharmacovigilance Database**
J.L. Montastruc, M. Gony, M. Lapeyre-Mestre, O. Rascol, and the French Network of Pharmacovigilance Centres
- P1082 Dopamine agonist induced punting**
A.H. Evans, R. Katzenschlager, J. O'Sullivan, P.R. Vaughan, L.J. Andrew
- P1083 Drug-induced orthostatic tremor**
F.J. Jiménez-Jiménez, M. Orti-Pareja, J.M. Zurdo, A. Tallón-Barranco, I. Puertas, M. de Toledo-Heras
- P1084 Increased rates of antipsychotic-induced EPS in mood disorders: myth or reality?**
R.W. Baker, P.A. Cavazzoni, P.H. Berg, M. Millikan, M. Tohen, H. Wei
- P1085 Movement disorders induced by cinnarizine and flunarizine**
V. Kiriakakis, P. Vrentas, N. Tsiftis
- P1086 Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study**
B.J. Kinon, V.L. Stauffer, K.T. Thi, S. Kollack-Walker
- P1087 Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine - a cross-sectional study**
G. Fabiani, P.C. Pastro, C. Chouza
- P1088 Quercetin reversal of haloperidol-induced orofacial dyskinesia: possible antioxidant mechanism**
P.S. Naidu, S.K. Kulkarni
- P1089 Remote methamphetamine abuse as a potential cause of tardive dyskinesia: a report of five cases**
P. Hogarth
- P1090 Reversible Extrapontine Myelinolysis with Parkinsonism in a 25-year-old female**
V. Ries, K. Shiratori, S. Bien, W.H. Oertel
- P1091 'Familial Cortical Tremor with Epilepsy' in a Dutch pedigree**
F. van Rootselaar, P.M. Callenbach, H.H. Koelman, R.R. Frants, O.F. Brouwer, M.A. Tijssen

Poster Sessions

Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

- P1092 A unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin**
A.J. Espay, P. Ashby, H. Ritsuko, M.S. Jog, A.E. Lang
- P1093 Alterations in opioid binding in Restless Legs Syndrome (RLS) patients: an ¹¹C-diprenorphine PET study**
S. von Spiczak, A.L. Whone, A. Hammers, W. Paulus, C. Trenkwalder, D.J. Brooks
- P1094 Analysis of the e-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity**
E.M. Valente, A. Misbahuddin, F. Brancati, M.R. Placzek, B. Dallapiccola, T.T. Warner
- P1095 Long-term efficacy of levetiracetam in cortical myoclonus**
M. Kofler, R. Schauer, L. Saltuari
- P1096 Multifocal myoclonus caused by hepatic encephalopathy**
C. Saft, J. Andrich, I. Wilhelms, P.H. Kraus, H. Przuntek
- P1097 Myoclonus in Dementia with Lewy bodies**
J.N. Caviness, C.H. Adler, C.J. Richard, H.L. Jose
- P1098 Myoclonus in epilepsy partialis continua : successful treatment with botulinum toxin**
D. Ranoux, C. Soufflet, B. Gueguen, J.-L. Mas
- P1099 Myoclonus of peripheral origin**
F. Cassim, P. Krystkowiak, J.-F. Hurtevent, P. Derambure, A. Destee
- P1100 Neurostimulation as a treatment for Myoclonic Dystonia; a case report**
H.L. Tyne, H. Cameron, P. Littlechild, T.R. Varma, M.J. Steiger
- P1101 Open label comparative study on the efficacy of Pramipexole (PMX) vs. Ropinirole (RPN) for the treatment of Restless Legs Syndrome (RLS)**
N. Galvez-Jimenez, C. Lampuri, G.A. Locker, M.R. Hanson, L. Smolley, M.J. Hargreave
- P1102 Patient's perspective of hemifacial spasm - the Singapore experience**
W.L. Au, L.C. Tan, A.K. Tan
- P1103 Propriospinal myoclonus after electrical injury**
F. Cassim, C. Boisselier, C. Monaca, O. Dereeper, J.-D. Guieu
- P1104 Pseudo-sporadic myoclonus-dystonia due to a mutation in the epsilon-sarcoglycan gene**
S. Hauenschild, B. Mueller, N. Kock, J. Sperner, P.P. Pramstaller, C. Klein
- P1105 Restless Legs Syndrome in patients treated with low-density lipoprotein apheresis**
T. Tings, V. Schettler, M. Canelo, W. Paulus, C. Trenkwalder
- P1106 The treatment of Unverricht-Lundborg Disease with N-Acetylcysteine**
M.J. Edwards, I.P. Hargreaves, S.J. Heales, S.J. Jones, V. Ramachandran, K.P. Bhatia
- P1107 Unconstant reduction of myoclonus with levetiracetam**
F. Bourdain, J.-S. Vidal, E. Apartis, M. Vidailhet
- P1108 Botulinum toxin A in a treatment of spasticity caused by infantile Cerebral Palsy**
R. Mego, M. Brozmanová
- P1109 Different types of increased resistance of a knee joint in CP children**
M.K. Lebledowska, J.R. Fisk
- P1110 Flexor reflex recording: comparison between spastic patients before and after intrathecal baclofen therapy**
S. Romito, V. Rigo, E. Costantini, N. Rizzuto, L. Bertolasi
- P1111 Management of tolerance with intrathecal Baclofen therapy**
A. Koulousakis, D. Lenartz, M. Weber, G. Koutosumbelis
- P1112 Methylphenidate does not improve spasticity in patients with hereditary spastic paraplegia (HSP). Results of an open controlled trial**
S. Klebe, H. Stolze, J. Volkmann, F. Kopper, R. Wenzelburger, G. Deuschl
- P1113 Modulation of the transmission in group II heteronymous pathways by Tizanidine in spastic hemiplegic patients**
M. Simonetta-Moreau, E. Maupas, P. Marque
- P1114 Reciprocal Ia inhibition in patients with asymmetric spinal spasticity**
Y. Okuma, Y. Mizuno, R.G. Lee
- P1115 Role of gait analysis in decision making in long-term spasticity treatment by Baclofen Pump in deambulatory patients**
U. Dimanico, M. Coletti Moja, M. Knafitz, V. Cavaciocchi, L. Tallone, E. Grasso
- P1116 Safety and efficacy of botulinum toxin "BT" in Cerebral Palsy: four-year study**
G. Ianieri, A. Santamato, F. Saponieri, P. Di Cillo, G. Megna
- P1117 Cautious use of intrathecal baclofen in severely spastic walking patients**
I. Dones, M. Marchetti, M. Sinisi, G. Broggi
- P1118 Stereotypic gait as the presenting feature of normal pressure hydrocephalus**
K.A. Kujawa, D.M. Dijk
- P1119 A case of adult onset tic disorder following carbon monoxide intoxication**
S.B. Ko, T.B. Ahn, B.S. Jeon
- P1120 A voxel-based morphometry study of tic disorders**
A.M. Goldfine, T. Hanakawa, G. Garraux, A. Mason, M. Hallett
- P1121 Cognitive deficits in patients with Tourette's Syndrome of different ages**
G.M. Moscovtseva, O.S. Levin, G.M. Glozman
- P1122 Explosive outbursts in children with Tourette Syndrome: relationship to comorbid symptoms in parents**
N. Djerroud, P. Lesperance, S. Chouinard, G. Rouleau, F. Richer
- P1123 Gilles de la Tourette Syndrome: a refractory case treated with bilateral cingulotomy, capsulotomy, and clozapine**
H.F. Chien, E.R. Barbosa, D.P. Bassit
- P1124 Metabolic brain networks in Tourette Syndrome**
A. Feigin, C. Budman, D. Zgaljardic, V. Dhawan, D. Eidelberg
- P1125 Olanzapine treatment in Tourette Syndrome: an open label trial**
J.-J. Lin, D.-C. Chang
- P1126 Premonitory sensations in tics**
C.H. Kwak, J. Jankovic
- P1127 Safety and efficacy of ziprasidone in Tourette Syndrome**
J.L. Juncos, S.A. Shea, N. Stover, M.S. Okun
- P1128 Sleep structure in Tourette Syndrome: polysomnographic data from a pediatric sample**
M. Desjardins, P. Lesperance, S. Chouinard, M. Robert
- P1129 Status ticcus in Gilles de la Tourette Syndrome: identification of clinical condition and therapeutical approach**
E. Dell'Anna, M. Porta, M. Camerlingo, A. Perretti, G. Maggioni
- P1130 Successful treatment of tics with bilateral internal pallidum (GPI) stimulation in a 27 year old male patient with Gilles de la Tourette's Syndrome (GTS)**
C. van der Linden, H. Colle, V. Vandewalle, G. Alessi, D. Rijckaert, L. De Waele

Poster Sessions

Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

- P1131 Tetrabenazine in the treatment of Tourette Syndrome**
C.B. Hunter, A. Wang, K.D. Vuong, J. Jankovic
- P1132 The treatment of vocal tics in Tourette patients using botulinum toxin type A**
M. Porta, M. Camerlingo, G. Maggioni, A. Perretti, E. Dell'Anna
- P1133 Tics following peripheral trauma**
M.H. Anca, A.D. Korczyn
- P1134 Topiramate in children and adolescents with Tourette Syndrome (TS)**
T.Y. Nelson, M.T. Bost, P.S. Lesser, J.F. Hulihan
- P1135 Tourette Syndrome and attention deficit hyperactivity disorder - are there shared genetic susceptibility factors?**
O. Bandmann, S. Schoenian, I. Koenig, H. Remschmidt, A. Ziegler, W. Oertel
- P1136 Tourette Syndrome in African-Americans. Prevalence and clinical features**
N. Galvez-Jimenez, G. Erenberg, G. Locker
- P1137 A double-blind placebo-controlled trial of Topiramate for Essential Tremor**
D. Tarsy, D. Apetauerova, A.F. Griffith, D.Z. Press, P. Ryan, C.S. Wu
- P1138 A multicenter randomized double-blind crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor**
K.S. Lee, J.S. Kim, J.W. Kim, W.Y. Lee, B.S. Jeon
- P1139 A wider clinical spectrum of essential palatal tremor**
M. Samuel, G. Kleiner-Fisman, A.E. Lang
- P1140 Accelerometric identification of freezing-of-gait in Parkinson's Syndrome**
J.W. Tetrud, E.E. Sabelman, R. Yap
- P1141 Almost absolute concordance for essential tremor in monozygotic twins of old age**
D. Lorenz, H. Frederiksen, H.W. Moises, K. Christensen, G. Deuschl
- P1142 Assessing factors which can influence spirometry performance in patients with essential tremor**
W.G. Ondo, A. Wang, M. Thomas, K.D. Vuong
- P1143 Clinical and electrophysiological characteristics of post-stroke tremor**
M.W. Seo, Y.H. Kim
- P1144 Clinical and electrophysiological study of Cortical Tremor**
A. Delval, P. Krystkowiak, F. Cassim, P. Charpentier, A. Destee, L. Defebvre
- P1145 Clinical efficacy of Mirtazapine in patients with Essential Tremor**
K. Bayulkem, H. Efendi, G. Karabas
- P1146 Clozapine in the treatment of drug-resistant tremor in Parkinson's Disease: double-blind study**
M.A. Relja, S. Telarovic
- P1148 Demographic and clinical characteristics of Essential Tremor in Kocaeli City**
K. Bayulkem, H. Efendi, G. Karabas
- P1149 Diagnostic accuracy of a computerized upper limb performance test for tremor**
E. Schechtman, R. Inzelberg, P. Nisipeanu, E. Sagi-Ophir, T. Barlev-Zion, S. Hocherman
- P1150 Dopamine transporter imaging with ¹²³I-FP-CIT SPECT demonstrates marked presynaptic nigrostriatal dopaminergic deficit in orthostatic tremor**
R. Katzenschlager, D. Costa, W. Gerschlagler, J.D. O'Sullivan, A.J. Lees, P. Brown
- P1151 Dose-escalation study of oral 1-octanol in patients with essential tremor**
H.A. Shill, M. Reich, K.O. Bushara, G. Grimes, M. Hallett
- P1152 Drinking tremor: a new situational tremor with participation of buccal (type 1) or cervical (type 2) muscles**
D. Gayraud, B. Bonnefoi-Kyriacou, F. Viallet
- P1153 EEG-EMG coherence in Essential and Parkinson Tremor**
T. Mima, K. Toma, T. Oga, H. Shibasaki, M. Hallett
- P1154 Efficacy and safety of levetiracetam for Essential Tremor (ET)**
A. Handforth, D.M. Wilson, F.C. Martin
- P1155 Efficacy of thalamic stimulation in Multiple Sclerosis action tremor**
H. Hosseini, E. Waubant, P. Jedynek, B. Stankoff, Y. Agid, J.P. Nguyen
- P1156 Efficacy of Topiramate on cervical tremor with mild dystonic features**
E. Pourcher, P. Chabot, A. Beausoleil
- P1157 Electrophysiological differentiation of dystonic and psychogenic tremor**
J.H. McAuley, N.P. Quinn, J.C. Rothwell
- P1158 Elevated blood b-carboline alkaloid concentration in Essential Tremor: a clue about etiopathogenesis?**
E.D. Louis, W. Zheng, J. Chen, P. Factor-Litvak, M. Parides
- P1159 Gait analysis in essential tremor**
S. Levy, I. Friedman, I. Dobrov, R. Levy, S. Hassin-Baer
- P1160 Harmonic and noise analyses of tremor accelerometry in differentiating Parkinsonian and Essential Tremor**
M. Demirci, G. Sahin, B. Elilbol
- P1161 Holmes Tremor. Description of 18 patients**
F. Cardoso, A.C.S. Esmeraldo
- P1162 Is the rhythm of physiologic tremor involved in cortical motor planning?**
J. Raethjen, A. Morsnowski, M. Lindemann, U. Fietzek, C.E. Elger, G. Deuschl
- P1163 Limitations of accelerometry in motion analysis**
R.J. Elble
- P1164 Octanol for Essential Tremor. A double-blind, placebo-controlled trial**
K.O. Bushara, H.S. Shill, M. Hallett
- P1165 Ocular flutter associated with thalamic lesion**
M.W. Seo
- P1166 Olanzapine in essential tremor: a double-blind, crossover, placebo controlled trial**
T. Entner, J. Wissel, J. Mueller, K. Seppi, G.K. Wenning, W. Poewe
- P1167 Parkinsonism, tremor and ataxia in a female fragile X carrier**
M.A. Leehey, J. Grigsby, D. Rubinstein, S. Jacquemont, C. Greco, L. Zhang
- P1168 Pathophysiology of Orthostatic Tremor: a multiple case study**
M.W. Seo, K.W. Lee
- P1169 Prevalence and clinical characteristics of Essential Tremor in the community: results from a study based on computerized tremor analysis**
J. Mueller, K. Seppi, G.K. Wenning, S. Kiechl, J. Willeit, W. Poewe


Poster Sessions

Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

- P1170 Prevalence of self-reported physician-diagnosed Essential Tremor in the elderly: the Cardiovascular Health Study**
E.D. Louis, L.P. Fried, A.L. Fitzpatrick, W.T. Longstreth, A.B. Newman
- P1171 Primary orthostatic tremor is an exaggeration of a physiological response to instability**
A.D. Sharott, J.F. Marsden, P. Brown
- P1172 Resetting of Orthostatic Tremor by transcranial magnetic stimulation**
J.J. Spiegel, G.G. Fuss, C.C. Krick, U.U. Dillmann
- P1173 Routine tremor analysis as a diagnostic tool. Application of a standardized tremor analysis procedure in two different specialty centers for movement disorders**
J. Raethjen, F. Pawlas, M. Lauk, B. Koester, J. Timmer, G. Deuschl
- P1174 Surgical alleviation of Complex Action Tremor - role of zona incerta and field potentials**
D. Nandi, P.G. Bain, X. Liu, J. Yianni, J.F. Stein, T.Z. Aziz
- P1175 The quality of life in patients with Essential Tremor**
P.V. Makedonsky, O.S. Levin, T.V. Naimushina
- P1176 The syndrome of progressive ataxia and palatal tremor (PAPT)**
M. Samuel, T.J. Paul, N. Turon, A.E. Lang
- P1177 The syndromic associations of Orthostatic Tremor: a review of 41 patients**
W. Gerschlager, A. Munchau, R. Katzenschlager, P. Brown, J.C. Rothwell, N. Quinn
- P1178 Tremor and deep white matter changes in a-methylacyl-CoA racemase deficiency: extending the clinical phenotype**
C.E. Clarke, S. Alger, M.A. Preece, S. Dennis, S. Ferdinandusse, R.J. Wanders
- P1179 Tremor Disability Scale (TREDS): reliability and relationship to bedside clinical ratings of tremor severity**
D.A. Lundervold, R. Pahwa, P.A. Ament, D.E. Corbin
- P1180 Tremor in Multiple Sclerosis: a population based study in Olmsted County, Minnesota**
S.J. Pittock, W.T. Mayr, M. Rodriguez, J.Y. Matsumoto
- P1181 VIM thalamic DBS suppressed action tremor associated with IgM monoclonal gammopathy**
E. Ruzicka, D. Urgosik, K. Zarubova, R. Jech, J. Roth, O. Vesela
- P1182 Zonisamide (ZNS) for Essential Tremor (ET) and Cerebellar Outflow Tremor (COT)**
N. Galvez-Jimenez, M. Hargreave
- P1183 New recessive ataxias**
M. Koenig, M.C. Moreira, P. Bomont, S. Klur, M. Gribaa, C. Lagier - Tourenne, M. Schmitt, and numerous collaborators

COMTAN Significantly Improves

Mean percentage improvements from baseline in UPDRS scores at 24 weeks^{1,7}




- ◆ Significant increases in "on" time, the primary study end point, were evident within 2 weeks and persisted through 24 weeks in patients treated with COMTAN ($P < 0.008$ vs placebo)¹
- ◆ Significant improvements in ADLs, a secondary study end point, were observed in patients who had COMTAN added to their levodopa treatment regimen¹

Used only in conjunction with carbidopa/levodopa, COMTAN 200 mg tablets are indicated for patients with idiopathic Parkinson's disease experiencing the signs and symptoms of end-of-dose "wearing off." The most commonly reported COMTAN side effects were dopaminergic in nature, such as dyskinesias, and were generally managed by lowering the carbidopa/levodopa dose. In rare cases, COMTAN may be associated with orthostatic hypotension and severe diarrhea. COMTAN should not be taken with nonselective monoamine oxidase (MAO) inhibitors. COMTAN should be used with caution in patients with liver problems.

Patients' Patient Performance

More than 90% of patients maintained or improved daily "off" time after 3 years vs baseline⁶



9 out of 10 patients treated with COMTAN demonstrated continued benefits in daily "off" time as measured by the UPDRS vs baseline in a 3-year, open-label extension trial (N=132)⁶

Reduced mean daily levodopa dose after 3 years^{*6}



*Levodopa dose reductions are typically required to alleviate dopaminergic side effects when COMTAN is added.

Patients were maintained on lower mean daily levodopa intake vs baseline⁶

COMTan[®]
(entacapone) tablets



Helps patients stay active...longer

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

ORION
Under license from
Orion Corporation

Comtan® (entacapone)

Tablets

Rx only

BRIEF SUMMARY: Please see package insert for full prescribing information.

INDICATIONS: Comtan (entacapone) is indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off" (see **CLINICAL PHARMACOLOGY, Clinical Studies in the full prescribing information**). Comtan's effectiveness has not been systematically evaluated in patients with idiopathic Parkinson's Disease who do not experience end-of-dose "wearing-off". **CONTRAINDICATIONS:** Comtan (entacapone) tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. **WARNINGS:** Monoamine oxidase (MAO) and COMT are the two major enzyme systems involved in the metabolism of catecholamines. It is theoretically possible, therefore, that the combination of Comtan (entacapone) and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. For this reason, patients should ordinarily not be treated concomitantly with Comtan and a non-selective MAO inhibitor. Entacapone can be taken concomitantly with a selective MAO-B inhibitor (e.g., selegiline). **Drugs Metabolized by Catechol-O-methyltransferase (COMT):** When a single 400-mg dose of entacapone was given together with intravenous isoproterenol (isoproterenol) and epinephrine without coadministered levodopa/dopa decarboxylase inhibitor, the overall mean maximal changes in heart rate during infusion were about 50% and 80% higher than with placebo, for isoproterenol and epinephrine, respectively. Therefore, drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyl-dopa, apomorphine, isotherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction may result in increased heart rates, possibly arrhythmias, and excessive changes in blood pressure. Ventricular tachycardia was noted in one 32-year-old healthy male volunteer in an interaction study after epinephrine infusion and oral entacapone administration. Treatment with propranolol was required. A causal relationship to entacapone administration appears probable but cannot be attributed with certainty. **PRECAUTIONS: Hypotension/Syncope:** Dopaminergic therapy in Parkinson's Disease patients has been associated with orthostatic hypotension. Entacapone enhances levodopa bioavailability and, therefore, might be expected to increase the occurrence of orthostatic hypotension. In Comtan (entacapone) clinical trials, however, no differences from placebo were seen for measured orthostasis or symptoms of orthostasis. Orthostatic hypotension was documented at least once in 2.7% and 3.0% of the patients treated with 200 mg Comtan and placebo, respectively. A total of 4.3% and 4.0% of the patients treated with 200 mg Comtan and placebo, respectively, reported orthostatic symptoms at some time during their treatment and also had at least one episode of orthostatic hypotension documented (however, the episode of orthostatic symptoms itself was not accompanied by vital sign measurements). Neither baseline treatment with dopamine agonists or selegiline, nor the presence of orthostasis at baseline, increased the risk of orthostatic hypotension in patients treated with Comtan compared to patients on placebo. In the large controlled trials, approximately 1.2% and 0.8% of 200 mg entacapone and placebo patients, respectively, reported at least one episode of syncope. Reports of syncope were generally more frequent in patients in both treatment groups who had an episode of documented hypotension (although the episodes of syncope, obtained by history, were themselves not documented with vital sign measurement). **Diarrhea:** In clinical trials, diarrhea developed in 60 of 603 (10.0%) and 16 of 400 (4.0%) of patients treated with 200 mg Comtan and placebo, respectively. In patients treated with Comtan, diarrhea was generally mild to moderate in severity (8.6%) but was regarded as severe in 1.3%. Diarrhea resulted in withdrawal in 10 of 603 (1.7%) patients, 7 (1.2%) with mild and moderate diarrhea and 3 (0.5%) with severe diarrhea. Diarrhea generally resolved after discontinuation of Comtan. Two patients with diarrhea were hospitalized. Typically, diarrhea presents within 4-12 weeks after entacapone is started, but it may appear as early as the first week and as late as many months after the initiation of treatment. **Hallucinations:** Dopaminergic therapy in Parkinson's Disease patients has been associated with hallucinations. In clinical trials, hallucinations developed in approximately 4.0% of patients treated with 200 mg Comtan or placebo. Hallucinations led to drug discontinuation and premature withdrawal from clinical trials in 0.8% and 0% of patients treated with 200 mg Comtan and placebo, respectively. Hallucinations led to hospitalization in 1.0% and 0.3% of patients in the 200 mg Comtan and placebo groups, respectively. **Dyskinesias:** Comtan may potentiate the dopaminergic side effects of levodopa and may cause and/or exacerbate pre-existing dyskinesia. Although decreasing the dose of levodopa may ameliorate this side effect, many patients in controlled trials continued to experience frequent dyskinesias despite a reduction in their dose of levodopa. The rates of withdrawal for dyskinesia were 1.5% and 0.8% for 200 mg Comtan and placebo, respectively. **Other Events Reported With Dopaminergic Therapy:** The events listed below are rare events known to be associated with the use of drugs that increase dopaminergic activity, although they are most often associated with the use of direct dopamine agonists. **Rhabdomyolysis:** Cases of severe rhabdomyolysis have been reported with Comtan use. The complicated nature of these cases makes it impossible to determine what role, if any, Comtan played in their pathogenesis. Severe prolonged motor activity including dyskinesia may account for rhabdomyolysis. One case, however, included fever and alteration of consciousness. It is therefore possible that the rhabdomyolysis may be a result of the syndrome described in Hyperpyrexia and Confusion (see **PRECAUTIONS, Other Events Reported With Dopaminergic Therapy**). **Hyperpyrexia and Confusion:** Cases of a symptom complex resembling the neuroleptic malignant syndrome characterized by elevated temperature, muscular rigidity, altered consciousness, and elevated CPK have been reported in association with the rapid dose reduction or withdrawal of other dopaminergic drugs. Several cases with similar signs and symptoms have been reported in association with Comtan therapy, although no information about dose manipulation is available. The complicated nature of these cases makes it difficult to determine what role, if any, Comtan may have played in their pathogenesis. No cases have been reported following the abrupt withdrawal or dose reduction of entacapone treatment during clinical studies. Prescribers should exercise caution when discontinuing entacapone treatment. When considered necessary, withdrawal should proceed slowly. If a decision is made to discontinue treatment with Comtan, recommendations include monitoring the patient closely and adjusting other dopaminergic treatments as needed. This syndrome should be considered in the differential diagnosis for any patient who develops a high fever or severe rigidity. Tapering Comtan has not been systematically evaluated. **Fibrotic Complications:** Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. These complications may resolve when the drug is discontinued, but complete resolution does not always occur. Although these adverse events are believed to be related to the ergoline structure of these compounds, whether other, non-ergot derived drugs (e.g., entacapone) that increase dopaminergic activity can cause them is unknown. It should be noted that the expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone. Four cases of pulmonary fibrosis were reported during clinical development of entacapone; three of these patients were also treated with pergolide and one with bromocriptine. The duration of treatment with entacapone ranged from 7-17 months. **Renal Toxicity:** In a 1 year toxicity study, entacapone (plasma exposure 20 times that in humans receiving the maximum recommended daily dose of 1600 mg) caused an increased incidence in male rats of nephropathy that was characterized by regenerative tubules, thickening of basement membranes, infiltration of mononuclear cells and tubular protein casts. These effects were not associated with changes in clinical chemistry parameters, and there is no established method for monitoring for the possible occurrence of these lesions in humans. Although this toxicity could represent a species-specific effect, there is not yet evidence that this is so. **Hepatic Impairment:** Patients with hepatic impairment should be treated with caution. The AUC and C_{max} of entacapone approximately doubled in patients with documented liver disease compared to controls. (See **CLINICAL PHARMACOLOGY, Pharmacokinetics of Entacapone and DOSAGE AND ADMINISTRATION**). **Information for Patients:** Patients should be instructed to take Comtan only as prescribed. Patients should be informed that hallucinations can occur. Patients should be advised that they may develop postural (orthostatic) hypotension with or without symptoms such as dizziness, nausea, syncope, and sweating. Hypotension may occur more frequently during initial therapy. Accordingly, patients should be cautioned against rising rapidly after sitting or lying down, especially if they have been doing so for prolonged periods, and especially at the initiation of treatment with Comtan. Patients should be advised that they should neither drive a car nor operate other complex machinery until they have gained sufficient experience on Comtan to gauge whether or not it affects their mental and/or motor performance adversely. Because of the possible additive sedative effects, caution should be used when patients are taking other CNS depressants in combination with Comtan. Patients should be informed that nausea may occur, especially at the initiation of treatment with Comtan. Patients should be advised of the possibility of an increase in dyskinesia. Patients should be advised that treatment with entacapone may cause a change in the color of their urine (a brownish orange discoloration) that is not clinically relevant. In controlled trials, 10% of patients treated with Comtan reported urine discoloration compared to 0% of placebo patients. Although Comtan has not been shown to be teratogenic in animals, it is always given in conjunction with levodopa/carbidopa, which is known to cause visceral and skeletal malformations in the rabbit. Accordingly, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy (see **PRECAUTIONS, Pregnancy**). Entacapone is excreted into maternal milk in rats. Because of the possibility that entacapone may be excreted into human maternal milk, patients should be advised to notify their physicians if they intend to breastfeed or are breastfeeding an infant. **Laboratory Tests:** Comtan is a chelator of iron. The impact of entacapone on the body's iron stores is unknown; however, a tendency towards decreasing serum iron concentrations was noted in clinical trials. In a controlled clinical study serum ferritin levels (as marker of iron deficiency and subclinical anemia) were not changed with entacapone compared to placebo after one year of treatment and there was no

difference in rates of anemia or decreased hemoglobin levels. **Special Populations:** Patients with hepatic impairment should be treated with caution (see **INDICATIONS, DOSAGE AND ADMINISTRATION**). **Drug Interactions:** *In vitro* studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 µM; an oral 200 mg dose achieves a highest level of approximately 5 µM in people); these enzymes would therefore not be expected to be inhibited in clinical use. **Protein Binding:** Entacapone is highly protein bound (98%). *In vitro* studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenyltolazone, and diazepam. **Drugs Metabolized by Catechol-O-methyltransferase (COMT):** See **WARNINGS, Hormone Levels:** Levodopa is known to depress prolactin secretion and increase growth hormone levels. Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects. **Effect of Entacapone on the Metabolism of Other Drugs:** See **WARNINGS** regarding concomitant use of Comtan and non-selective MAO inhibitors. No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29). More than 600 Parkinson's Disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor. As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone. These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa decarboxylase inhibitor. **Carcinogenesis:** Two-year carcinogenicity studies of entacapone were conducted in mice and rats. Rats were treated once daily by oral gavage with entacapone doses of 20, 90, or 400 mg/kg. An increased incidence of renal tubular adenomas and carcinomas was found in male rats treated with the highest dose of entacapone. Plasma exposures (AUC) associated with this dose were approximately 20 times higher than estimated plasma exposures of humans receiving the maximum recommended daily dose of entacapone (MRDD = 1600 mg). Mice were treated once daily by oral gavage with doses of 20, 100 or 600 mg/kg of entacapone (0.03, 0.3, and 2 times the MRDD for humans on a mg/m² basis). Because of a high incidence of premature mortality in mice receiving the highest dose of entacapone, the mouse study is not an adequate assessment of carcinogenicity. Although no treatment related tumors were observed in animals receiving the lower doses, the carcinogenic potential of entacapone has not been fully evaluated. The carcinogenic potential of entacapone administered in combination with levodopa/carbidopa has not been evaluated. **Mutagenesis:** Entacapone was mutagenic and clastogenic in the *in vitro* mouse lymphoma/thymidine kinase assay in the presence and absence of metabolic activation, and was clastogenic in cultured human lymphocytes in the presence of metabolic activation. Entacapone, either alone or in combination with levodopa/carbidopa, was not clastogenic in the *in vivo* mouse micronucleus test or mutagenic in the bacterial reverse mutation assay (Ames test). **Impairment of Fertility:** Entacapone did not impair fertility or general reproductive performance in rats treated with up to 700 mg/kg/day (plasma AUCs 28 times those in humans receiving the MRDD). Delayed mating, but no fertility impairment, was evident in female rats treated with 700 mg/kg/day of entacapone. **Pregnancy:** **Pregnancy Category C.** In embryofetal development studies, entacapone was administered to pregnant animals throughout organogenesis at doses of up to 1000 mg/kg/day in rats and 300 mg/kg/day in rabbits. Increased incidences of fetal variations were evident in litters from rats treated with the highest dose, in the absence of overt signs of maternal toxicity. The maternal plasma drug exposure (AUC) associated with this dose was approximately 34 times the estimated plasma exposure in humans receiving the maximum recommended daily dose (MRDD) of 1600 mg. Increased frequencies of abortions and late/fetal resorptions and decreased fetal weights were observed in the litters of rabbits treated with maternotoxic doses of 100 mg/kg/day (plasma AUCs 0.4 times those in humans receiving the MRDD) or greater. There was no evidence of teratogenicity in these studies. However, when entacapone was administered to female rats prior to mating and during early gestation, an increased incidence of fetal eye anomalies (macrophthalmia, microphthalmia, anophthalmia) was observed in the litters of dams treated with doses of 160 mg/kg/day (plasma AUCs 7 times those in humans receiving the MRDD) or greater, in the absence of maternotoxicity. Administration of up to 700 mg/kg/day (plasma AUCs 28 times those in humans receiving the MRDD) to female rats during the latter part of gestation and throughout lactation, produced no evidence of developmental impairment in the offspring. Entacapone is always given concomitantly with levodopa/carbidopa, which is known to cause visceral and skeletal malformations in rabbits. The teratogenic potential of entacapone in combination with levodopa/carbidopa was not assessed in animals. There is no experience from clinical studies regarding the use of Comtan in pregnant women. Therefore, Comtan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing Women:** In animal studies, entacapone was excreted into maternal rat milk. It is not known whether entacapone is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when entacapone is administered to a nursing woman. **Pediatric Use:** There is no identified potential use of entacapone in pediatric patients. **ADVERSE REACTIONS:** During the pre-marketing development of entacapone, 1450 patients with Parkinson's Disease were treated with entacapone. Included were patients with fluctuating symptoms, as well as those with stable responses to levodopa therapy. All patients received concomitant treatment with levodopa preparations, however, and were similar in other clinical aspects. The most commonly observed adverse events (>5%) in the double-blind, placebo-controlled trials (N=1003) associated with the use of Comtan (entacapone) and not seen at an equivalent frequency among the placebo-treated patients were: dyskinesia/hyperkinesia, nausea, urine discoloration, diarrhea, and abdominal pain. Approximately 14% of the 603 patients given entacapone in the double-blind, placebo-controlled trials discontinued treatment due to adverse events compared to 9% of the 400 patients who received placebo. The most frequent causes of discontinuation in decreasing order are: psychiatric reasons (2% vs. 1%), diarrhea (2% vs. 0%), dyskinesia/hyperkinesia (2% vs. 1%), nausea (2% vs. 1%), abdominal pain (1% vs. 0%), and aggravation of Parkinson's Disease symptoms (1% vs. 1%). **Adverse Event Incidence in Controlled Clinical Studies:** Table 4 lists treatment emergent adverse events that occurred in at least 1% of patients treated with entacapone participating in the double-blind, placebo-controlled studies and that were numerically more common in the entacapone group, compared to placebo. In these studies, either entacapone or placebo was added to levodopa/carbidopa (or levodopa/benserazide).

Table 4: Summary of Patients with Adverse Events after Start of Trial Drug Administration At least 1% in Comtan® (entacapone) group and > Placebo

SYSTEM ORGAN CLASS	Comtan (n = 603)	Placebo (n = 400)	SYSTEM ORGAN CLASS	Comtan (n = 603)	Placebo (n = 400)
Preferred term	% of patients	% of patients	Preferred term	% of patients	% of patients
SKIN AND APPENDAGES DISORDERS			GASTROINTESTINAL SYSTEM DISORDERS		
Sweating increased	2	1	Vomiting	4	1
MUSCULOSKELETAL SYSTEM DISORDERS			Mouth dry	3	0
Back pain	2	1	Dyspepsia	2	1
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISORDERS			Flatulence	2	0
Dyskinesia	25	15	Gastrointestinal disorders nos	1	0
Hyperkinesia	10	5	RESPIRATORY SYSTEM DISORDERS		
Hypokinesia	9	8	Dyspnea	3	1
Dizziness	8	6	PLATELET, BLEEDING & CLOTTING DISORDERS		
SPECIAL SENSES, OTHER DISORDERS			Purpura	2	1
Taste perversion	1	0	URINARY SYSTEM DISORDERS		
PSYCHIATRIC DISORDERS			Urine discoloration	10	0
Anxiety	2	1	BODY AS A WHOLE - GENERAL DISORDERS		
Somnolence	2	0	Back pain	4	2
Agitation	1	0	Fatigue	6	4
GASTROINTESTINAL SYSTEM DISORDERS			Asthenea	2	1
Nausea	14	8	RESISTANCE MECHANISM DISORDERS		
Diarrhea	10	4	Infection bacterial	1	0
Abdominal pain	8	4			
Constipation	6	4			

The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures do, however, provide the prescriber with some basis for estimating the relative contribution of drug and non-drug factors to the adverse events observed in the population studied. **Effects of gender and age on adverse reactions:** No differences were noted in the rate of adverse events attributable to entacapone by age or gender. **DRUG ABUSE AND DEPENDENCE:** Comtan (entacapone) is not a controlled substance. Animal studies to evaluate the drug abuse and potential dependence have not been conducted. Although clinical trials have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed. Store at 25°C (77°F) excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.]

Comtan (entacapone) tablets are manufactured by Orion Corporation, Orion Pharma (Espoo, Finland) and marketed by Novartis Pharmaceuticals Corporation (East Hanover, N.J. 07936, U.S.A.).

